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South African medical schemes spend billions of Rands each year on medical care 
costs for their beneficiaries near their end of life. Hospi-centric benefit design, fee-for-
service reimbursement arrangements and fragmented, silo-based delivery of care result 
in high, often unnecessary spending near the end of life. Factors including an ageing 
population, increasing incidence rates of cancer and other non-communicable diseases, 
and high levels of multi-morbidity among beneficiaries near their end of life further 
drive end-of-life care costs. Low levels of hospice or palliative care utilisation, a high 
proportion of deaths in-hospital and chemotherapy use in the last weeks of life point 
to potentially poor quality care near the end of life. The usual care pathway for serious 
illness near the end of life acts like a funnel into private hospitals. This often entails 
resource intensive care that includes aggressive care interventions right up until death. 
The result is potentially sub-optimal care and poor healthcare outcomes for many 
scheme beneficiaries and their surviving relatives. Understanding the complex nature 
of the end of life, the different care pathways, the available insurance benefits, the 
interactions between key stakeholders and the multitude of factors that drive end-of-
life care costs are vital to setting end-of-life care reform in motion. In order to increase 
value at the end of life, i.e. to increase quality and/or to reduce costs, benefit design 
reform, alternative reimbursement strategies, effective communication and multi-
stakeholder buy-in is key.  
Keywords 
End-of-life care, trajectories of dying, medical schemes, care pathways, cost, quality, 
value, PMB’s, benefit design, non-communicable diseases, curative care, palliative 
care, hospital, hospice, care preferences, decision-making, communication, 
stakeholder conflicts  
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All over the world, medical care costs for individuals near their end of life are high 
when compared to the medical care costs for those who are not near their end of life 
(Felder, Meier and Schmitt 2000; Hogan, Lunney, Gabel and Lynn 2001; Polder, 
Barendregt and van Oers 2006; Shugarman, Decker and Bercovitz 2009). Research in 
South Africa by Ranchod, Abraham and Bloch (2015) similarly found that medical 
schemes experience relatively high claims costs for beneficiaries in their final year of 
life. In addition to the high monetary costs of end-of-life care, research has found that 
often the care received near the end of life is ineffective, overly aggressive and at odds 
with the care preferences of individuals (Solomon, O'Donnell, Jennings, Guilfoy et al. 
1993; Connors, Dawson, Desbiens, Fulkerson et al. 1995; Mack, Weeks, Wright, 
Block et al. 2010). Globally, there exists significant scope to improve care at the end 
of life and to reduce healthcare spending at the end of life (Cheung, Earle, Rangrej, 
Ho et al. 2015; Kavalieratos, Corbelli, Zhang, Dionne-Odom et al. 2016).   
This research project evaluates the profile of end-of-life care in the South 
African medical scheme environment. The profile of end-of-life care entails the 
various modes or philosophies of care near the end of life, the design and delivery of 
this care in the medical schemes environment and the complex decision-making and 
interaction processes between the key stakeholders. This project also identifies factors 
that are associated with the relatively high claim costs experienced by South African 
medical schemes in respect of scheme beneficiaries near their end of life. Knowledge 
of these factors and of how their complex interactions may affect medical scheme 
claim costs may provide the opportunity for medical schemes to improve risk 
management, to optimise benefit design and end-of-life care delivery, and to reduce 
medical scheme claim costs whilst improving the quality of care and of life for 
beneficiaries near their end of life. This research project aims to enable the overall 
value derived from end-of-life care to be maximised for the key stakeholders. The 
value of care near the end of life is maximised when the “best outcomes are achieved 
at the lowest cost” (Porter 2010).  
In order to contextualise this research, it is worthwhile to define the ‘end of life’ 
and ‘end-of-life care’, respectively. These concepts are considered in Section 2. The 
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various modes or philosophies of end-of-life care, their respective characteristics and 
definitions, their evolution over time, as well as the various settings of care are also 
considered in this section. Quality is one of the key components of value. The quality 
of care provided and the measurement thereof are also considered briefly in this 
section.   
The other key component of value is cost. In Section 3 the medical scheme 
environment in South Africa is considered in more detail and the direct costs of 
providing end-of-life care to medical scheme beneficiaries is evaluated. Medical 
schemes, as the primary funding vehicle of private healthcare insurance in South 
Africa (Erasmus, Ranchod, Abraham, Carvounes et al. 2016) and the claims submitted 
for decedent beneficiaries over their last 24 months of life will be the key focus of this 
research project. These data are retrospective administrative claims data with limited 
clinical information. The claims data are analysed in order to identify the observable 
factors that are associated with the relatively high medical care costs for beneficiaries 
near their end of life. 
Significant research has been done, globally, on the personal preferences and 
decisions of those at or near their end of life (Lynn and Adamson 2003; Swerissen, 
Duckett and Farmer 2014). The factors affecting decision-making and the complexities 
surrounding differing stakeholder needs are considered in Section 4.  
Section 5 describes the data used for purposes of this research project, notes the 
limitations of the data and outlines the methodology followed to analyse the data and 
identify the factors associated with end-of-life care costs for South African medical 
schemes. The methodology followed to measure indicators of the quality of care based 
only on administrative data are also outlined here.    
Section 6 contains the results of the data analyses performed to understand the 
characteristics of medical scheme beneficiaries who die and the factors associated with 
their medical scheme claim costs near their end of life. The key results and findings 
are discussed and interpreted in Section 7.  
Finally, having evaluated the end of life, the available care options or pathways, 
their evolution, their relative and respective costs, the quality of care and quality of 
life (and death) that beneficiaries experience, Section 8 concludes on the findings of 
this research project and identifies opportunities for further future research. 
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The scope of this research project is limited to identifying and analysing the 
factors that are associated with end-of-life care costs for South African medical 
schemes based on a comprehensive literature review and the analysis of a sample of 
decedent beneficiaries’ characteristics and retrospective claim costs over their last 24 
months of life. This research project is a first attempt at untangling the complexities 
and nuances surrounding end-of-life care in the South African medical schemes 
environment. It sets the scene for important further research and highlights gaps in the 
current design and delivery of end-of-life care benefits to medical scheme 
beneficiaries.  
The factors affecting decision-making processes of stakeholders and the quality 
and appropriateness of care provided are often not directly available or observable 
from the administrative data. Without surveying scheme beneficiaries (and healthcare 
providers) near the end of life, it is impossible to elicit individuals’ exact preferences, 
or their thought- and decision-making processes. In South Africa, such research in the 
medical schemes environment has not been conducted and international findings from 
the literature review, are overlaid on the South African medical schemes environment, 
where applicable. A further limitation is that this research utilises only private sector 
(medical scheme) data, and further research is required to extrapolate the findings to 
the entire South African population and to the envisaged National Health Insurance 
framework given the vast differences between the private and public sector healthcare 
systems currently operating in South Africa. 
The results of this project are a novel addition to research on end-of-life care in 
the private healthcare sector of South Africa. The impact of various illness trajectories, 
co-morbidities and hospital admissions on the healthcare costs at the end of life and 
the respective cost patterns of beneficiaries on their end-of-life journeys have to date 
not yet been studied in South Africa. The results of this research project can be used 
in scheme benefit design considerations, health policy formulation and as a basis for 
further research on the provision of end-of-life care in South Africa. As such, the 
results of this research holds importance for medical schemes and their beneficiaries, 
for healthcare providers in eliciting preferences and making treatment 
recommendations, institutions of learning in the design of their curricula, as well as 
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for the government in designing and delivering end-of-life care under the envisioned 




2 The ‘End of Life’, ‘End-of-Life care’ and the 
evolution of these concepts 
Death, the end of life and end-of-life care have long been topics of heated discussion, 
both formally in research literature, health care policy formulation and public debate, 
and informally, in conversation, music, poetry, etc. A significant amount of research 
exists surrounding the end of life and the medical care received during this final stage 
of life, some of which is aimed at identifying and defining the ‘end of life’ and the 
various modes or philosophies of end-of-life care (George 2002). 
This section summarises these key concepts, defines these terms as they are used 
throughout this research project, and considers their evolution over time. This section 
also highlights the importance of quality considerations near the end of life and 
difficulties with measuring the quality of care. 
 
2.1 Death and dying 
It is important to consider what is meant by ‘death’ to be able to identify the end-of-
life (or ‘dying’) period that precedes it. The end-of-life period, i.e. the period 
commencing at the point at which a person enters the dying state that eventually 
culminates in their death is not always straightforward to determine. Significant 
differences exist in the literature as to the exact definitions of commonly used end-of-
life terminology (Hui, Nooruddin, Didwaniya, Dev et al. 2014).  
 George (2002) states that in most end-of-life research, researchers fail to define 
exactly or consistently what is meant by dying or the process of dying. At first, this 
might appear surprising and counter-intuitive given that it frequently is this very 
process being considered. However, given some thought it becomes clear that dying is 
a complex process and for each person the exact point of entering the dying state and 
the length of time spent in the dying state will be different, and depends on a myriad 
of factors. Each person in the dying state will have a unique set of demographic, 
clinical and socio-economic factors affecting their end of life trajectory (Gomes and 
Higginson 2006).  
12 
 
Some controversy and uncertainty exists even in defining the death event – the 
exact point at which a person transitions from being alive to dead, and the particular 
criteria that need to be met in order to ascertain that a death has, in fact, occurred 
(Youngner and Arnold 2001). Traditionally, the irreversible loss of cardiopulmonary 
function (i.e. when a person’s heart stops beating and they stop breathing, 
permanently) was used to define the death event (Lizza 2006). More recently, 
however, due to the advent of technological interventions such as mechanical 
ventilation and life support (which can artificially sustain cardiopulmonary function), 
the definition has been expanded to be either the traditional definition or that of brain 
death (i.e. brain function ceasing permanently) (Lizza 2006).  
It is clear that having multiple definitions for the same phenomenon, where one 
definition may not strictly imply the other, controversy, confusion and lack of 
consensus will abound (Youngner and Arnold 2001). However, the semantics 
surrounding the exact point and definition of the death event are not the focus of this 
research given the retrospective nature of the administrative data to be analysed. 
Frequently, in administrative data, death is captured as the date of cessation of cover    
and as such, for this research project, the exact point of death and the definition thereof 
is of less importance than the actual date of death. However, it is worth considering to 
gain a better understanding of the overall complexity surrounding the end of life. 
Of greater importance and relevance to this research is the period preceding the 
actual death event – the period we define as the ‘end-of-life’ or as ‘dying’ - the period 
during which persons receive end-of-life care. Determining the inception of this period 
is important for a number of reasons including knowing which care interventions to 
administer and for measuring the quality and appropriateness of the care that was (or 
is being) administered (Earle and Ayanian 2006). Depending on the exact purpose 
either a prospective or a retrospective approach to defining the end of life can be taken 
(Earle and Ayanian 2006). For deciding on the goals of care and the specific care 
interventions that are appropriate, for deciding on the communication strategies with 
patients and their families, optimising quality of care, etc. a prospective determination 
of having entered the dying state is required – i.e. before the person has died. To this 
end, clinical information and the treating doctor’s judgment to estimate survival times 
or to conclude that someone is busy dying, i.e. using prognosis, are key. For purposes 
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of retrospectively analysing the quality of care that was administered and reviewing 
the experience and factors contributing thereto, a more arbitrary time-based definition 
for the end of life and ‘dying’ can be used. Alternatively, clinical information then 
available may be used to retrospectively determine when a particular individual may 
have come to be in the dying state (Bach, Schrag and Begg 2004). It can thus be seen 
that defining the end-of-life period is important and that there are significant 
implications depending on how this is defined. Neither approach are without their 
problems and criticisms (Earle and Ayanian 2006). For purposes of this research, using 
retrospective data, the end-of-life period, per se, will not be identified, but scheme 
beneficiaries’ experience over various periods prior to death (up to 24 months) are 
investigated.      
Some research has been performed to try generalise the definition or length of 
the end-of-life period. However, there is no real consensus on both the length of this 
end-of-life period, or the inception point of this period, with some research referring 
to the end of life as a period measured in years and others as a period measured in 
hours or days at most (Hui et al. 2014). Another term, ‘active(ly) dying’, is used to 
more definitively describe the very last few hours or days of life (Hui et al. 2014).  
In the US, there has been some consensus surrounding an operational definition 
of the end of life, especially for insurance benefit (particularly hospice care benefits) 
purposes and as a broad guide to health care providers when recommending treatment 
options (Lamont 2005; Hui et al. 2014). These definitions typically require the patient 
to be diagnosed with a life-limiting, progressive illness, which is expected to result in 
their death within months (often six months for insurance purposes) (Hui et al. 2014). 
This definition is suitable and easily used retrospectively, but it is vague and has been 
criticised for not providing health care providers with effective, unambiguous tools to 
use prospectively in care planning and communication, and in making care and 
treatment recommendations, often resulting in inappropriate interventions and care at 
or near the end of life (Ellershaw, Neuberger and Ward 2003; Lamont 2005). A further 
significant problem with the time-based definition and eligibility criteria for hospice 
care in the US is the requirement to forego life-sustaining treatments, frequently 
resulting in late or no hospice enrolment (Campion, Kelley and Morrison 2015). 
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 In order to use the operational definition of the ‘end of life’ prospectively for 
effective and appropriate planning and decision-making, a highly accurate prognosis 
and a good estimate of survival time and survival probability are required (Head, 
Ritchie and Smoot 2005). For prospective determination, it is later shown that trying 
to assign a particular period is problematic and that there are more effective ways of 
determining that the end of life may be near when weighing up care alternatives 
(Highet, Crawford, Murray and Boyd 2014) 
 
2.2 Prospective determination of the end-of-life period – challenges and 
potential solutions 
Broad consensus exists that care in the end-of-life period should be different to the 
care in the period(s) preceding it (Lamont 2005). Glare, Virik, Jones, Hudson et al. 
(2003) emphasise the importance of prognosis in ensuring that patients receive 
appropriate disease-directed treatment prior to them being in their end-of-life period 
and to avoid unnecessary delays in referral to receiving hospice care once disease-
directed care proves to be ineffective. However, a significant amount of research exists 
on the difficulties associated with accurate prognostication and the estimation of 
survival times (Ellershaw, Neuberger and Ward 2003; Lamont 2005; Lau, Cloutier-
Fisher, Kuziemsky and Black 2007). This results in delays to patients receiving both 
palliative and hospice care as opposed to only intensive, aggressive disease-directed 
care aimed at only cure (which may be indicative of poor quality care near the end of 
life) resulting in suboptimal outcomes (Earle, Park, Lai, Weeks et al. 2003). 
Many factors affect the level of certainty that accompanies any prognosis, e.g. 
new/experimental treatments, variability in past survival times or in efficacy of 
treatments, optimistic bias on both the part of the health care provider and the patient, 
specific patient characteristics, e.g. age, sex, diagnosis, current level of functional 
ability and the manifestation of symptoms and co-morbidities, etc. (Lamont and 
Christakis 1999). Functional ability, as used here, refers to the relative level of an 
individual’s ability to perform independently basic activities of daily living such as 
eating, being physically mobile, dressing themselves, etc.  (Lamont 2005). Various 
measures of functional ability exist, e.g. the linear Karnofsky Performance Status 
(KPS) where a score of ‘0’ means being dead and ‘100’ means being fully functional, 
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or the Eastern Co-operative Oncology Group (ECOG) six-point scale with ‘0’ being 
fully functional and ‘5’ being dead (Blagden, Charman, Sharples, Magee et al. 2003). 
Given the complexities surrounding accurate prognostication outlined above, 
Ellershaw, Neuberger and Ward (2003) have extended the vague insurance definition, 
outlined earlier, to include a number of additional clinical signs and symptoms to 
simplify identifying when someone suffering from cancer might be dying. The 
justification for this is to give healthcare providers more clarity regarding the care 
considerations that may be appropriate for their patients, i.e. treatments alternative to 
or complementary to those aimed purely at curing their patients’ diseases. These signs 
and symptoms include considering the gradual shift to becoming bedbound, losing 
consciousness more frequently or being semi-comatose, a loss of appetite, weight loss 
and struggling to eat or take oral medications. For people suffering from progressive 
heart failure Ellershaw, Neuberger and Ward (2003) also include some additional signs 
and symptoms as indicators that death may be imminent.  These include: heart failure 
admissions being more serious than in the past, no identifiable or reversible cause for 
the heart failure, the patient is already receiving the optimum level of medication, renal 
function is deteriorating and changes to drugs don’t have the desired effects within two 
or three days. Similarly, for other seriously ill patients not suffering from cancer or 
progressive heart failure, various clinical signs and symptoms can also be considered 
to help identify approaching or imminent death and when a shift in care goals should 
be considered.  These are contained in the ‘Supportive and Palliative Care Indicators 
Tool’ (SPICTTM). These signs and symptoms include: unplanned hospital 
admission(s), low functional status, dependence on others for care, significant recent 
weight loss, a high symptom burden despite ongoing treatment, and the 
communication of a desire to receive palliative care (SPICT 2018). The SPICTTM tool 
was developed in 2010 by a collaborative team from NHS Lothian and The University 
of Edinburgh (SPICT 2018).  
Echoing Ellershaw, Neuberger and Ward (2003), Lamont (2005), found that 
clinical symptoms are powerful predictors of impending death, in addition to the 
patient’s current functional status and their health provider’s estimate of survival time. 
It is shown that considering these common predictors of survival time together, 
improves the accuracy of prognoses significantly regardless of the individuals’ 
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primary diagnosis (Lamont 2005). These, used in conjunction, remove some of the 
subjective bias the health care provider may have, but improves on the rigid, objective 
estimate based only on performance status statistics (Lamont 2005).  
When ranking the predictive power of these predictors independently, a person’s 
functional status is the strongest of these predictors, and the health care provider’s 
estimate of survival time is the weakest, as they tend to over-estimate survival times 
systematically. However, the higher a person’s current functional status, the weaker 
the prediction of survival time (Chow, Harth, Hruby, Finkelstein et al. 2001). A KPS 
score of less than 50 has been found to indicate a survival time of less than 8 weeks 
(Lamont 2005). Regularly measuring the KPS and considering the patient’s clinical 
indicators and the doctor’s estimate of survival time, the prediction of death should 
become more accurate, especially with increasing imminence of death, which can 
allow for better communication, planning and administering of end-of-life care 
(Lamont 2005).  
Given the difficulties identified with exact prognostication, it is encouraging that 
recent literature suggests that this may be of less importance than merely identifying 
whether a patient is exposed to a significant enough risk of death so as to evaluate or 
re-evaluate goals of care as well as the ensuing treatment options (Highet et al. 2014). 
Hence combining clinical indicators, performance status, the doctor’s estimated 
survival time and the guidelines in the SPICTTM tool, conversations about care 
pathways and goals of care can be initiated timely, thus avoiding late or non-referral 
to palliative care and hospice services, and interventions not aimed specifically at cure 
can be incorporated into patient care early on to maximise stakeholder value (Lamont 
2005; Highet et al. 2014). Unnecessary hospitalisations and ineffective curative 
interventions can thus be minimised and care can be aligned with patients’ 
expectations and preferences.  
2.3 Retrospective analyses  
Bach, Schrag and Begg (2004) argue that arbitrarily choosing a time period to consider 
and the selection of the population of decedents introduces bias into retrospective 
analyses of the end of life. Teno and Mor (2005) acknowledge these shortcomings, but 
highlight the problems associated with prospective approaches, e.g. accurate 
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prognostication, hence arguing the importance of and value in using both methods, 
respectively. For certain purposes and in certain circumstances, a retrospective 
approach will be advantageous, e.g. for considering the experience and costs incurred 
by decedents using administrative data. Administrative claims data is retrospective in 
nature with limited clinical and prognostic information (Iezzoni 1997).   
Allocating decedents to trajectories of dying and analysing their experience is 
one example of a retrospective analysis, given a chosen end-of-life time period. 
“Trajectories of dying” are a broad, systematic classifications of a sample of decedents 
according to their resource utilisation and given their respective diagnoses/illnesses 
(Lunney, Lynn, Foley, Lipson et al. 2003). It will be useful to look at the various 
trajectories of dying and to determine how treatment varies (or should vary) by the 
respective trajectories of dying. Each trajectory of dying exhibits a unique pattern of 
individuals’ physical function declining over time, their likely resource utilisation and 
which treatment(s) may be optimal at different stages within their respective 
trajectories of dying (Lunney et al. 2003).  
Looking retrospectively at deaths that have occurred in a sample of Medicare 
(the federal social health insurance system in the US predominantly covering citizens 
aged 65 and older) beneficiaries, Lunney, Lynn and Hogan (2002)  identifies four main 
trajectories of dying. 92 per cent of the deaths in the observed sample could be 
attributed to one of these four trajectories (Lunney, Lynn and Hogan 2002), and hence 
provides a robust framework into which we can classify and analyse the claims and 
death data analysed in this research project.  
These trajectories are: 1) “Sudden death” (roughly 7 per cent of the deaths in the 
sample), characterised by a high level of functional ability right up until death with 
death occurring suddenly, or at most over a number of days. 2) “Terminal illness” 
(cancer diagnosis only, accounted for roughly 22 per cent of the deaths in the sample), 
characterised by a high level of function ability, declining rapidly over a few weeks to 
a few months prior to death. 3) “Organ failure” (mainly deaths due to congestive heart 
failure and chronic obstructive pulmonary disease, accounted for 16 per cent of the 
deaths in the sample), characterised by a gradual decline in functional ability, often 
over a number of years, accentuated by drastic dips in functional ability and subsequent 
recoveries until an exacerbation without a subsequent recovery (death) occurs. Any 
18 
 
one of these exacerbations are potentially fatal, but significant uncertainty exists. Over 
time and with declining functional capacity, the likelihood of the next ‘event’ or 
exacerbation of the condition being the fatal one, increases (Murray, Kendall, Boyd 
and Sheikh 2005). It can be seen from the nature of the “Organ failure” trajectory that 
trying to prospectively determine the end-of-life period and/or when death will occur 
presents significant challenges, emphasising the need for concurrent curative and 
palliative care to optimise patient outcomes and the quality of care. 4) “General frailty” 
(covering diagnoses such as dementia, stroke, Parkinson’s, pneumonia, etc. accounted 
for 47 per cent of the deaths in the Medicare sample). “General frailty” is characterised 
by a very gradual decline in functional ability, often over many years, starting from a 
low base, with the patient suffering multiple co-morbidities such as chronic conditions, 
but no specific terminal illness or definite organ failure is present, i.e. general old age 
and its associated decline in functional ability over time. 
As illustrated by these main trajectories of dying it is clear that the end-of-life 
period differs significantly by trajectory, and even within trajectories (Lunney, Lynn 
and Hogan 2002). The circumstances surrounding each death within each trajectory 
are unique, be they clinical, personal, setting and mode of care, psychosocial, etc. and 
as a result the exact end-of-life period and end-of-life care needs for each dying person 
will be inherently unique (Murray et al. 2005).   
Lunney, Lynn and Hogan (2002) used a sequential profiling system to classify 
deaths using the unique diagnosis code which accounted for the most Medicare claims 
in the twelve months preceding death for each individual decedent. “Sudden deaths” 
were identified first (decedents who had less than USD$2000 worth of Medicare 
claims during the twelve months prior to death), then deaths due to terminal illness, 
i.e. “Cancer” diagnoses, were identified, then deaths due to “Organ failure” and finally, 
deaths due to “General frailty” were identified. Deaths where the main diagnosis codes 
are for conditions that infrequently cause death, the decedent is grouped as “Other” – 
roughly eight per cent of the deaths in their sample.     
In another study looking at a sample of deaths in Canada focusing on the medical 
care costs associated with each trajectory, Fassbender, Fainsinger, Carson and Finegan 
(2009) used cluster analysis and the use of expert opinions to classify the deaths in 
their sample to corresponding trajectories of dying. Their classification of deaths 
19 
 
resulted in similar proportions of deaths in each trajectory when compared to the study 
by Lunney, Lynn and Hogan (2002).   
Next we look at defining ‘end-of-life care’. 
2.4 End-of-life care 
End-of-life care, simply put, is the care (medical or otherwise) that a person in the 
dying state receives, whether this period has been identified and acknowledged or not, 
and regardless of the aims of this care. End-of-life care can also extend beyond the 
point of death of the patient to the families and caregivers to offer support and 
assistance with the bereavement process (Hui, De La Cruz, Mori, Parsons et al. 2013).  
The concept of ‘end-of-life care’ has seen numerous transformations over the 
last five decades, as well as the emergence of new terminologies and definitions 
(Bennett, Davies and Higginson 2010). It is easy to get bogged down in the intricate 
details and subtle distinctions between the multitude of terms that are used to describe 
‘end-of-life care’ in the literature today: terminal care; supportive care; palliative care; 
hospice care; comfort care; usual care; hospital care; curative care; etc.). For ease of 
reference, this research project focuses on two core philosophies or modes of care – 
curative care on one end of the spectrum and palliative care on the other. This is to 
avoid any confusion that could result from having similar, yet distinct terminologies 
and definitions (as is used throughout the literature).  
Curative care, as a care philosophy, is characterised by disease-directed 
treatments focused on curing the underlying illness, attempting to undo part or all of 
the damage caused by the condition or to prevent the condition from worsening and 
further threatening an individual’s normal function (WHO 2011). It often involves 
aggressive and invasive procedures and/or treatments and comes with a very high price 
tag (Connors et al. 1995; Felder, Meier and Schmitt 2000). Multiple terms exist in the 
literature for ‘curative care’ or versions thereof (acute care, intensive care, disease-
directed care, usual care, hospital care, etc.), but for purposes of this research paper 
the term ‘curative care’ will be used to refer to any form of care aimed at curing or 
preventing the worsening of conditions/illnesses. The most common disease-directed 
care relates to care and/or interventions in a hospital setting (Gott, Ingleton, Bennett 
and Gardiner 2011). It is important to note that palliative care can also be (and is 
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frequently) administered in a hospital setting, but that significant challenges exist in 
initiating palliative care and the transition from a curative to a palliative care approach 
in-hospital (Campion, Kelley and Morrison 2015).  
Palliative care, (and more recently, the term supportive care1) on the other end 
of the spectrum, represents a multi-disciplinary care philosophy focused not on cure 
but on providing comfort and enhancing the quality of life at any stage in the disease 
progression (Hui et al. 2013). Hospice care is a sub-component of palliative care, 
administered either at home or in a facility offering hospice services, at the very end 
of life – in the final months, weeks, days and hours of life. The goals of hospice care 
are similar to that of palliative care, but due to the operational definition and strict 
eligibility criteria used for insurance purposes in certain territories, the time period of 
hospice care tends to be very short – usually a few days to a few weeks (Billings 1998; 
Odejide 2016) 
Palliative care does not directly aim to alter the course of any disease. Rather, 
palliative care focuses on the provision of a comprehensive service to patients facing 
serious illness, including: relieving the pain and symptoms patients experience, 
psychological support and education for patients and their families about how their 
disease is likely to progress and what they can expect. Palliative care further extends 
to the bereavement process and to care for the caregivers/family members after the 
death of the patient (Billings 1998; Rome, Luminais, Bourgeois and Blais 2011). 
Palliative care involves a multi-disciplinary team consisting of doctors, nurses, 
auxiliary healthcare professionals, e.g. a physical therapist, a psychologist, and 
chaplains/social workers to deliver the wide range of medical and supportive care 
services that patients and their families and caregivers require at or near the end of life 
(Fennell, Prabhu Das, Clauser, Petrelli et al. 2010). 
The settings in or at which end-of-life care may be delivered are at one’s personal 
home, in hospital, at a care home (frail care facility/nursing home) or at an inpatient 
palliative care facility, and with approaching death there may be one or more 
transitions between these care settings (Van den Block, Deschepper, Bilsen, Van 
                                                          
1 A more modern term for palliative care stemming from the stigma that palliative care is 
synonymous with end-of-life care and/or hospice care resulting in a hesitance for patients to opt for 
palliative care and providers to recommend it (discussed later). 
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Casteren et al. 2007). Curative care is typically associated with care in hospital as the 
equipment and human resources required are not readily available at the other care 
settings, whereas palliative care is typically associated with home-based or hospice-
based care settings/services. However, the value of offering palliative care in hospital 
(even in intensive care units) and in care home settings to improve patients’ quality of 
life is increasingly being recognised and offered (Kelley and Morrison 2015).  
As can be seen from above, the two care philosophies have vastly different aims 
at the end of life. Curative care involves trying to stave off or prevent death, whereas 
palliative care acknowledges death and aims to ease the transition into it, maximising 
the quality of remaining life. As noted earlier, timeous identification of the end-of-life 
period and communication thereof (and of the available care options) to patients and 
families is important to initiate a shift in focus from cure to care and support to ensure 
that patients receive optimised care at or near their end of life (Lamont and Christakis 
1999). However, it has been argued that neither care philosophy, in isolation, may be 
completely appropriate (Kelley and Meier 2010; Dalgaard, Bergenholtz, Nielsen and 
Timm 2014). These authors analyse the benefits of early palliative care interventions 
alongside disease-directed treatment. The benefits include: improved symptom 
control, better quality of life, less intensive care near the end of life, lower levels of 
anxiety and depression and even increased survival periods (in a study performed by 
Temel, Greer, Muzikansky, Gallagher et al. (2010) on persons with advanced lung 
cancer). 
Throughout this research project, reference is made to sub-optimal care and 
outcomes. Care is deemed to be sub-optimal in cases where the aims thereof cannot 
realistically be achieved, i.e. ineffective interventions at the end of life which are aimed 
at curing or undoing the underlying illness or trauma that aren’t expected to be 
successful (Mobley, Rady, Verheijde, Patel et al. 2007). Even when curative 
interventions are clinically appropriate, care may still be sub-optimal where other 
dimensions of care (other than those focused on the disease itself) are not holistically 
considered and addressed (Steinhauser, Christakis, Clipp, McNeilly et al. 2000). These 
include the spiritual, mental, social and support dimensions of care. Hence, sub-
optimal care refers to care at the end of life which is overly aggressive, misdirected 
and/or financially unjustifiable; care that does not align with the goals and needs of 
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the patient and/or their loved ones; or care that fails to offer the infrastructure, support 
and environment needed to facilitate a good death (Emanuel and Emanuel 1998; 
Wenger and Rosenfeld 2001). At the end of life, care that is optimal is care focused 
on, inter alia, pain relief and symptom control, comfort, affirming or strengthening 
relationships, achieving peace with oneself and any relevant deity, and maximising the 
quality of remaining life (Steinhauser et al. 2000). 
We now look at what defines high quality end-of-life care and what care may be 
appropriate given that someone may be dying. 
2.5 End-of-life care – quality considerations 
The means by which a person arrives at their end-of-life (trauma, terminal illness, 
frailty, etc.), together with the many personal (age, sex, religion, etc.), and other factors 
(setting of care, doctors, loved ones, etc.), will influence which mode of care is optimal 
and which mode of care is actually received (which research has shown are oftentimes 
not the same) (Lunney et al. 2003; Frost, Cook, Heyland and Fowler 2011). 
A significant amount of international research exists on determining which 
philosophy of care (or combination of philosophies) may be appropriate during 
different phases of illness, being cognisant of patients’, their families’, doctors’ and 
funders’ specific, and sometimes opposing needs. These needs may be opposing due 
to the different stakeholders having different preferences, and viewing different 
factors, e.g. pain management, the fulfilment of dying wishes, the use of intensive care, 
mental awareness etc., as being more (or less) important at the end of life (Steinhauser 
et al. 2000). Differing stakeholder needs and/or perspectives may result in different 
stakeholders seeking, recommending/offering and paying for (or being willing to pay 
for) different care or treatment interventions at the end of life. It is clear that significant 
conflicts of interest or principal-agent issues may exist when it comes to stakeholder 
decision-making near the end of life. The different stakeholders, their interests and the 
factors affecting their decision-making are considered in more detail in Section 4. 
 Connors et al. (1995) report that many patients hospitalised for life-threatening 
conditions die receiving high levels of unwanted care achieving little more than 
prolonged suffering. These care interventions tend to be expensive, are often invasive, 
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and may result in extended periods spent in hospital (Smith, Coyne, Cassel, Penberthy 
et al. 2003).  
The personal circumstances and preferences/biases of the patients, their families 
and their health care providers will influence which care philosophy or combination 
of curative and palliative care is optimal, and which is actually received (Weissman 
2001). A blended approach to care will be more focused on being curative in nature, 
initially, then gradually transitioning to being more palliative as the patient’s 
circumstances change and disease progression advances, and hence the level of 
certainty over prognosis, improves. Schofield, Carey, Love, Nehill et al. (2006) 
suggest that this is likely to be the best approach to end-of-life care, regardless of 
primary diagnosis and current level of disease progression. They argue that palliative 
care should gradually be introduced with disease progression, and not be seen as a care 
intervention that is only offered from that point where the decision is made to cease 
curative care interventions.  
Frequently, even if the prognosis for a patient is terminal with little or no chance 
of recovery or for improvement, patients still receive expensive and ineffective 
curative care interventions. Possible reasons for seemingly inappropriate care near the 
end of life include: overly optimistic prognoses and subsequent non-/late-referral to 
hospice, concerns about receiving insufficient medical care in hospice, denial of 
death’s imminence and a hope of recovery. Furthermore, conflicts between patients, 
their families and their doctors, perverse financial incentives, poor communication, a 
lack of understanding of the implications of aggressive care, etc. can result in sub-
optimal care near the end of life (Wright and Katz 2007; Wright, Zhang, Ray, Mack et 
al. 2008). Implications of such aggressive care near the end of life may result in 
increased and prolonged suffering for patients with ineffective pain and symptom 
control, a reduction in overall quality of life and a worsened bereavement experience 
for the patient’s close relations (Connors et al. 1995; Wright et al. 2008). 
A prominent feature of the South African medical schemes environment is the 
legislative requirement for all schemes to cover a common set of benefits, the 
Prescribed Minimum Benefits (PMB’s), at cost without any limits or co-payments 
(Department of Health 1998). In this environment, a potential, additional reason for 
such aggressive treatment regardless of whether death’s imminence is appreciated or 
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not, may be that the treatment falls within this PMB’s package. These PMB’s tend to 
be hospi-centric and provider driven in nature (Kaplan and Ranchod 2015) without 
any readily available or easily accessible palliative care benefits/resources. This 
coupled with a general ignorance about end-of-life care options and alternatives and a 
general avoidance of talking about and planning for death paints a bleak picture about 
how beneficiaries progress on their end-of-life journeys (Kirshbaum, Purcell and Nash 
2011). PMB’s and their impact, in their current form, on treatment recommendations 
and eventual decisions will be analysed in Section 3, which covers the South African 
medical scheme environment.  
When it comes to the use of intensive care, one in five Americans die in an 
intensive care unit (ICU) of a hospital (Angus, Barnato, Linde-Zwirble, Weissfeld et 
al. 2004). The quality of life of a patient spending their final days in an ICU intuitively 
feels much lower than that of a person spending their final days in a comfortable 
setting. Being connected to whirring machines with multiple tubes protruding from 
their body in a brightly lit room surrounded by strangers can’t compete with being at 
home, with the symptoms and the pain associated with terminal conditions being 
managed and being surrounded by loved ones (Gawande 2014). However, a more 
rigorous measure than intuitive feel, with objective indicators of quality of care and 
quality of life is required to gauge whether the care that patients receive at the end of 
life is optimal. 
Measuring the quality of care and the quality of life, especially near the end of 
life, when many factors need to be considered, is a complex task. Steinhauser, 
Bosworth, Clipp, McNeilly et al. (2002) propose a quality measurement tool, ‘QUAL-
E’, comprising of five key domains, each including a number of factors considered to 
be important indicators of quality of life near the end of life. These five domains are: 
1) the completion of life, 2) preparation for death, 3) symptom and pain management, 
4) interaction with the healthcare system, i.e. knowledge of and control over the 
condition and treatment options, and 5) social support. It is important that these 
domains are considered prospectively for seriously ill patients and in communicating 
and recommending care/treatment to these patients at appropriate times so as to ensure 
that they are most likely to opt for and to receive the optimal care as the end of life 
draws near. Steinhauser et al. (2002) and Ostgathe and Voltz (2010) further identify 
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the domains of mental, social, spiritual, religious and cultural well-being at the end of 
life as being important considerations to ensure that good quality end-of-life care is 
given to individuals. Taking a multi-disciplinary approach to delivering end-of-life 
care including access to a psychologist, social worker and chaplain near the end of life 
may assist in addressing distress in each of these domains near the end of life. 
It is important to develop and test a set of objective quality measures in the 
medical schemes environment specifically around the delivery of end-of-life care to 
gauge the quality and cost of different care pathways for individual beneficiaries along 
different trajectories of dying. Earle et al. (2003) performed a comprehensive literature 
review, held focus group sessions and interviewed an expert panel to help identify 
indicators of poor quality care near the end of life. The top ranked indicators for poor 
quality of care include: chemotherapy for cancer patients in their last weeks of life (or 
starting new chemotherapy regimen near death), death in hospital, frequent hospital 
admissions, a ‘high’ number of days in hospital/ICU before death and no/late hospice 
enrolment. These indicators, barring for starting a new chemotherapy regimen are 
observable and can be measured from the retrospective administrative data used in this 
research project. It is important to note that the absence of these indicators of poor 
quality care near the end of life does not necessarily imply high quality care near the 
end of life.  
 Earle et al. (2003) also identified indicators of good quality end-of-life care, and 
these included: the availability and use of multidisciplinary care teams, continuity of 
care between providers, good communication including shared decision-making 
(between providers, patients and their families) and the use of advance directives, and 
effective pain and symptom management. These indicators are not observable from 
the administrative data, but should ideally be taken into account when performing any 
evaluation of the quality of care provided near the end of life.   
 
2.6 The evolution of end-of-life care 
Understanding the evolution of end-of-life care and the contributing factors thereto, 
and how this care is likely to evolve further, may yield further insights into 
distinguishing between care that is optimal and care that is suboptimal. Utilising this 
knowledge may assist in achieving the aim of maximising value for the key  
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stakeholders involved in end-of-life care, particularly beneficiaries near their end of 
life. The key stakeholders and their relationships are discussed in Section 4.  
 
2.7.1 Changes to life expectancy and cause(s) of death 
Over the last century and a half, death, the end of life and care at the end of life has 
seen significant shifts. Global life expectancy in the late 1800’s was barely thirty 
years2. In 2015, the global average life expectancy at birth was around 71.5 years 
(Feigin 2016) – a more than twofold increase in life expectancy.  
There has also been significant shifts in the most common causes of death. The 
most prevalent causes of death in the late 1800’s were communicable diseases 
associated with poor hygiene, poor nutrition, cramped living conditions and virtually 
no effective medical interventions/treatments. These diseases included 
pneumonia/influenza, tuberculosis and gastrointestinal infections (Quora 2017). Death 
was most prevalent in infants or children under the age of five years (Riley 2001). 
Death at advanced ages was uncommon in the late 1800’s as very few people lived 
long enough to die “old”. Today, the majority of deaths occur at advanced ages. In the 
book, Global burden of disease and risk factors, by Lopez, Mathers, Ezzati, Jamison 
et al. (2014), it is reported that more than fifty per cent of the global deaths in 2001 
were of people aged sixty and above. With the global phenomenon of ageing 
populations and decreasing age-standardised mortality rates, the proportion of deaths 
at advanced ages has been steadily on the rise (WHO 2015; Feigin 2016). Today, 
globally, most of the deaths are as a result of non-communicable diseases, with heart 
disease, cancer and respiratory disease being the top three causes of death (Feigin 
2016). In fact, non-communicable diseases such as these caused over seventy per cent 
of all deaths in 2015. 
Many of the communicable diseases responsible for the majority of deaths in the 
nineteenth century became preventable and/or treatable, and death was, on average, 
postponed to older ages. The reduced mortality attributable to communicable diseases 
                                                          
2 The Economist. (2017). A better way to care for the dying. Available: 
https://www.economist.com/news/international/21721375-how-medical-profession-starting-move-
beyond-fighting-death-easing-it-




resulted in the observed shift towards non-communicable diseases becoming more and 
more prevalent causes of death, globally. As cardiovascular disease and cancer became 
more prevalent, further assimilation and dissemination of knowledge and research led 
to a greater overall awareness of, and better management and treatment of chronic and 
serious illnesses such as these, accounting for most of the mortality improvements in 
the developed world during the second half of the twentieth century (Preston 2015). 
However, with better treatment and hence declining mortality from chronic conditions, 
plus increasingly unhealthy dietary habits and sedentary, stressful lifestyles, the 
incidence and prevalence of these non-communicable chronic conditions has been on 
the rise, globally (Jakovljevic and Milovanovic 2015). In the local, South Africa 
context, a similar shift in cause of death from communicable to non-communicable 
diseases is being observed (Joubert and Bradshaw 2006; Delobelle, Sanders, Puoane 
and Freudenberg 2016). The burden of disease in South Africa and the impact of non-
communicable diseases and lifestyles on medical scheme claims costs are considered 
in more detail in Section 3.       
 
2.7.2 Implications for end-of-life care 
Prior to the 1900’s, illness/disease typically had a rapid and unexpected onset and 
affected people of all ages, especially infants and young children. Death (or recovery) 
typically followed soon after the onset of illness, i.e. illness was typically not 
characterised by protracted periods of sickness and/or disability (Bern-Klug, Gessert 
and Forbes 2001). Back then there were no modern hospitals and doctors, or private 
and/or social medical insurance like available today, and access to any form of medical 
care often restricted by availability, affordability and distance (Shapiro and Field 
1993). The early hospitals or ‘poor houses’ were not places of medical care, like today, 
but rather places where the destitute went to seek refuge and the seriously ill and the 
mentally unstable were quarantined. At these institutions rogue surgeons could 
experiment with new and often fatal technologies, and test new theories and practices 
on people about whom no one would ask too many questions (Young and Kroth 2017). 
As a result most people preferred to be cared for in their own homes, and most families 
preferred to care for their ill loved ones, personally, with little to no formal medical 
intervention (Bern-Klug, Gessert and Forbes 2001).  
28 
 
 However, with the large epidemiologic transition in the first half of the twentieth 
century the United States and Europe (the more developed regions) saw major shifts 
from death at younger ages (due to predominantly infectious diseases) to death at older 
ages (predominantly from chronic conditions) (Tomes 1990; Quora 2017). The 
developing regions followed suit, albeit at a much slower rate and only decades later 
(Cohen 2000). The development of antimicrobial agents, vaccinations and other 
preventative and curative treatments and technologies during the twentieth century 
further reduced the spread of and numbers of deaths attributable to infectious diseases 
(Cohen 2000). As a result, changes gradually occurred to the setting(s) of care and in 
the mode(s) of care for the ill and for the dying.  
 The stigma around the care that hospitals or other institutionalised settings could 
provide started to change. These institutions became places where the sick could seek 
treatment and the expectation of the care in these institutions became that of cure, 
instead of the expectation of mistreatment and of hastened death (Stevens 1989; Young 
and Kroth 2017). Standardised treatment protocols and structured training 
programmes for healthcare providers gradually became commonplace (Rothstein 
1987). Government policy and funding of healthcare became national priorities in 
many countries and health insurance came into existence (Ross 2002). Over the last 
century, and currently, hospital footprints grew significantly, and still are, more 
healthcare professionals are getting educated in an ever-increasing number of medical 
schools and as a result, more and more people have gained access to high quality 
healthcare through either state or private provision (Rothstein 1987; Stevens 1989; 
Ross 2002). This, together with other factors, including: changes in family structures, 
globalisation and the societal role of children in the care of their parents, have resulted 
in death shifting from private homes to hospital settings and then, later, to formalised 
care institutions, e.g. nursing homes (Wilson, Smith, Anderson, Northcott et al. 2002; 
Gomes and Higginson 2008; Broad, Gott, Kim, Boyd et al. 2013).  
In recent, years, there has been some reversal of this trend with the recognition 
that care aims at the end of life should be different to care aims at any other life stage, 
irrespective of age. This has led to the emergence of palliative care as a new philosophy 
of care over the last seven decades (Fallon and Smyth 2008). The emergence of 
palliative care has facilitated more deaths at home, greater hospice enrolment, national 
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end-of-life care strategies in the US, the UK and in other territories, and early 
discussions regarding care and treatment preferences (Flory, Young-Xu, Gurol, 
Levinsky et al. 2004; Gomes, Calanzani and Higginson 2012). However, this reversal 
has been slow, and globally, the current state of death and dying still leaves much to 
be desired and is far from being optimal. 
 Institutionalised or hospitalised deaths are often quoted as deaths involving 
significant amounts of pain and suffering, intensive, aggressive and often ineffective 
medical interventions and a general lack of alignment of care interventions with patient 
preferences (Singer, Martin and Kelner 1999; Teno, Clarridge, Casey, Welch et al. 
2004; Heyland, Dodek, Rocker, Groll et al. 2006).  
Palliative care can be integrated with usual hospital-based care, adding an 
additional layer of support to the patient and their loved ones (Kelley and Morrison 
2015). Palliative care can equally be extended to a home or nursing home setting, 
culminating in hospice care at or near the end of life when life-sustaining treatments 
can offer no further benefit (Quill and Abernethy 2013). It is important to note that 
hospice care is not palliative care, but rather a subset of the palliative care service 
offering.  
It has become apparent that nursing home care, as an alternative to or as a step-
down from hospital care, also did not fully meet the palliative care needs of patients 
(Meier, Lim and Carlson 2010). Common problems identified with nursing home care 
include: staffing shortages, a general lack of palliative care training, untreated pain and 
symptoms, poor communication and a high chance of hospitalisations with unwanted 
medical interventions near the end of life (Ersek and Wilson 2003; Meier, Lim and 
Carlson 2010).  
The modern hospice movement started taking shape in the mid-1960’s, and this 
and the subsequent evolution of palliative care is attributed to the work of Cicely 
Saunders (1918-2005) who undertook to study pain, its manifestation and the effective 
treatment thereof (Clark 2007). Prior to this very little was understood of pain and it 
was deemed to be an inevitable and uncontrollable aspect of disease and as a result 




Opioids were found to be very effective in treating pain, however a general 
stigma against opioid use due to fears of abuse and addiction often resulted in the 
management of pain and symptoms taking the back seat when it came to treating 
seriously ill persons and their illnesses (Clark 2007). 
With an increasing recognition of the importance of pain and the management 
thereof, and with the hospice movement gaining traction as the preferred mode of care 
for those dying of cancer, the term palliative care was born, coined in 1975 by Dr 
Balfour Mount (Clark 2007). In 1987, palliative care/medicine was recognised as a 
sub-speciality of general medicine in the UK, and in 1995, it was recognised as a stand-
alone medical speciality in the UK. New Zealand and Australia recognised palliative 
care as a speciality in 1998 and the US, more recently, in 20083 (Clark 2007). In South 
Africa, non-governmental palliative care services started in the 1980’s and in 2017 the 
National Policy Framework and Strategy for Palliative Care was approved by the 
National Health Council (Gwyther, Krause, Cupido, Stanford et al. 2018).  
Palliative care and the focus of this fledgling medical speciality on quality of 
life, patient autonomy and –choice, and its easy integration with usual curative care 
measures has resulted in it rapidly becoming the benchmark of high quality care for 
the seriously ill, globally. However, the evolution of care at the end of life is far from 
complete (Lynch, Connor and Clark 2013). 
Significant challenges exist in delivering palliative care to all those who will 
benefit from it. On a global level, these challenges include (but are not limited to, and 
are not independent of each other): 1) low levels of palliative care development and 
health policy recognition; 2) poor integration of palliative services with usual care; 3) 
significant healthcare resource constraints (human, infrastructure, medication and 
monetary resources); and 4) an ever-growing burden of lifestyle and other diseases 
(Clark 2007; Connor and Sepulveda Bermedo 2018). In South Africa, the recent 
release of the National Policy Framework and Strategy for Palliative Care represents 
a big step forward for palliative care integration in South Africa (HPCA 2017). 
                                                          
3 At the time of publishing, the US recognition of palliative care as a standalone medical specialty 
was imminent, and has since been recognised as such 
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With the advent of death-defying new technologies and medicines, the shift of 
care at home to care in institutions occurred almost naturally and a fundamental change 
in attitudes and perceptions towards illness, mortality and medical care occurred – 
society as a whole has become death-denying (McConnell, Moules, McCaffrey and 
Bouchal 2012). The problem is systemic in nature, resulting in the world’s healthcare 
systems, especially hospitals, operating on this premise – illnesses are seen as curable 
manifestations and death as a phenomenon that need not be succumbed to, yet (Al‐
Qurainy, Collis and Feuer 2009). Medical professionals are trained to diagnose and 
treat and, at the core, fight illness. It may be seen as failure to accept that an illness is 
terminal and to refer a patient to palliative or hospice care (Gardiner, Cobb, Gott and 
Ingleton 2011). The unwillingness to admit that death is near and the only likely 
outcome highlights the existence of a stigma towards the use of palliative care and a 
perception that palliative care is synonymous with end-of-life care (Shen and Wellman 
2019). The WHO updated their definition of palliative care in 2002 in order to break 
the direct link with end-of-life care and to increase the remit of palliative care to all 
serious illnesses (Gott, Seymour, Ingleton, Gardiner et al. 2012). The stigma and 
associated problems with it, persisted, resulting in the emergence and the use of the 
term ‘supportive care’ with measured success (Dalal, Palla, Hui, Nguyen et al. 2011). 
The terminology may have changed, but the definition and scope of the services 
offered may not have, however, the new terminology does allow for an expansion of 
services offered – at least relative to the perceived level when compared to the term 
‘palliative care’ (Dalal et al. 2011; Hui et al. 2013). This research report uses the term 
‘palliative care’ throughout.    
The education of medical professionals on the end of life, end-of-life care and 
on the communication of these complex, uncomfortable topics are lacking (Gibbins, 
McCoubrie and Forbes 2011), however, great strides have been made and some basic 
supportive, palliative (and/or end-of-life) care training is incorporated in most 
undergraduate medical syllabi in the developed world (Horowitz, Gramling and Quill 
2014). In South Africa, palliative care training is provided through the South African 
Nursing Council as well as through tertiary institutions such as the University of Cape 
Town and the University of the Witwatersrand, with a number of other palliative care 
initiatives and training programmes countrywide (Harding, Bristowe, Downing, 
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Gwyther et al. 2019). That said, the wheels of change turn slowly and the general 
acceptance of and the full integration of supportive/palliative care into usual acute care 
for the seriously ill will still take a significant amount of time, especially in the 
developing world (Ddungu 2011; Lynch, Connor and Clark 2013).  
In the developed world, the pressure of ageing populations confronted with 
multiple chronic co-morbidities, and a rising number of annual deaths, healthcare 
systems are struggling to provide the level and quality of care required for those at or 
near their end of life (Gott and Ingleton 2011). South Africa, too, faces similar 
challenges in both the public and private sectors (Joubert and Bradshaw 2006; HPCA 
2017; Council for Medical Schemes 2019). Furthermore, there are limited availability 
of infrastructure and human resources to deliver palliative and end-of-life care to those 
who need it and will benefit therefrom (Aldridge, Hasselaar, Garralda, van der Eerden 
et al. 2016; Sharkey, Loring, Cowan, Riley et al. 2018).  
The availability of palliative care is limited (sometimes even non-existent) in 
significant parts of the developing world; financial and infrastructural resources are 
severely strained and education and research is minimal (Ddungu 2011; Lynch, 
Connor and Clark 2013). For these reasons it is necessary that strong emphasis be 
placed on the need for and importance of informal and community-based palliative 
and end-of-life care in developing regions to assist in meeting the needs of those at 
their end of life whilst formal resources, capacity and infrastructure aren’t yet available 
(Harding and Higginson 2005). The medicalisation of the dying process has greatly 
shifted the focus from care at home or in the community to care in institutions 
(Horsfall, Noonan and Leonard 2012). However, evidence exists of community 
capacity and the willingness and skills to care for the dying and achieving better 
outcomes and better meeting patients’ needs (Horsfall, Noonan and Leonard 2012; 
Kellehear 2013). 
In South Africa, for the entire population, at least 44 per cent of deaths occur in-
hospital (Bradshaw, Pillay-Van Wyk, Laubscher, Nojilana et al. 2010). It is further 
estimated that at least fifty per cent of those who die in South Africa could benefit 
from palliative care intervention leading up to death (HPCA 2017). South Africa is 
classified as a level 4a (preliminary integration) country when it comes to palliative 
(and hospice) care integration with mainstream medical care provision (Lynch, Connor 
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and Clark 2013). This means that South Africa has developed significant capacity for 
palliative care delivery in terms of education, training, availability of palliative care 
resources, etc. and what is left is to achieve full integration is to facilitate and ensure 
access to palliative care for those that need it.        
A further controversial, yet prominent, evolutionary element of the end of life is 
the debate around the deliberate ending of life. Assisted dying is beyond the scope of 
this research project as it is not permitted in South Africa, but given the evolution of 
thought on the topic, globally, it is worthwhile to consider briefly. It is worth noting 
that access to effective palliative care can significantly reduce the need for assisted 
dying as a result of the effective management of pain and symptoms, but lack of access 
to such palliative care and the existence of forms of suffering that cannot (yet) be 
controlled makes room for arguments about the necessity of assisted dying (Quill and 
Battin 2004). However, in territories where effective palliative care is readily available 
and utilised, less than one per cent of persons die receiving aid in dying (Quill and 
Battin 2004).  
Various forms of assisted dying exist, euthanasia (administered directly by the 
healthcare professional) or assisted suicide (indirectly administered by the healthcare 
professional) (Radbruch, Leget, Bahr, Müller-Busch et al. 2016). For both of these, 
the ending of life may be active (administering the treatment to end life), passive 
(withholding treatment to sustain life), voluntary (with the patient’s consent) or 
involuntary (without the patient’s consent). Involuntary assisted dying is illegal 
everywhere, i.e. it constitutes murder (Materstvedt, Clark, Ellershaw, Førde et al. 
2003). In some territories, euthanasia (the Netherlands, Belgium and Luxembourg) or 
assisted suicide (Oregon, Washington, Vermont, California, Montana, Colorado, 
Canada and Switzerland) is permitted, and more territories are following suit 
(Radbruch et al. 2016). Reasons for legalising assisted dying, despite the clear ethical 
and moral conundrums they pose include recognition of patient choice and autonomy 
when faced by unbearable pain and suffering caused by terminal illness (Fontalis, 
Prousali and Kulkarni 2018).  
Having considered the end of life and the various modes or philosophies of care 
near the end of life as well as their evolution, and contextualising the research project, 
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the following section outlines the South African medical schemes environment and the 




3 Demand for healthcare in the medical scheme 
environment in South Africa  
Demand for healthcare goods and services are driven by both demand-side and supply-
side factors (Schulz 2005). Demand-side factors include demographic factors such as 
ageing populations and clinical factors such as increasing burdens of disease due to 
chronic non-communicable diseases, etc. (Council for Medical Schemes 2019). 
Supply-side factors influencing demand include provider behaviour, technological 
advances, insurance coverage, the availability and access to care, etc. Stakeholders’ 
behaviour, including provider behaviour, and decision-making is considered in Section 
4. Separating out demand- and supply-side influences on claim costs are not 
straightforward and are frequently inter-linked. Below, we briefly consider the South 
African medical schemes environment and the factors in this environment that may 
contribute to the high healthcare expenditure observed and, particularly, the healthcare 
spending near the end of life.  
South Africa has dichotomous private and public healthcare systems with an 
inequitable split of resources between them. Per capita expenditure by persons in the 
private sector is tenfold that of persons in the public sector and seventy per cent of 
human resources for health work full time in the private sector (Mayosi and Benatar 
2014). Medical schemes cover around sixteen per cent of the South African population. 
The remaining 84 per cent of the population is reliant on out-of-pocket private 
healthcare expenditure, the public healthcare system or the informal healthcare system, 
i.e. traditional or spiritual healers and/or medicines, or on a combination of these 
(Caldis, McLeod and Smith 2001; Erasmus et al. 2016). Around 68 per cent of the 
population is wholly reliant on the public healthcare system (Ataguba and McIntyre 
2012). Medical scheme membership is predominantly concentrated in the top two 
income quintiles of South Africa, i.e. 71 per cent of scheme membership is from the 
highest income quintile and sixteen per cent of the membership is from the second 
highest income quintile (Ataguba and McIntyre 2012). The focus of this research 
project is on the private funding of cover for healthcare through medical schemes in 
South Africa.  
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Medical schemes are the dominant insurance vehicle for private healthcare 
expenditure (Erasmus et al. 2016). They are mutual, not-for-profit organisations, 
owned by the members and regulated by the Council for Medical Schemes (CMS) in 
accordance with the provisions as set out in the Medical Schemes Act of 1998 
(Department of Health 1998). The Medical Schemes Act in conjunction with other 
regulations as are published in the Government Gazette from time to time sets out the 
rules governing medical scheme registration, administration, management, and the 
requirements of schemes’ benefit offerings. Medical schemes operate on the basis of 
a number of social solidarity principles, namely community rating, voluntary and open 
enrolment and a prescribed universal minimum benefits package referred to as the 
Prescribed Minimum Benefits (PMB’s) (McLeod and Ramjee 2007). 
The ‘business of a medical scheme’ as set out in the Act is the provision of 
indemnity-type insurance benefits for healthcare expenditure incurred by scheme 
beneficiaries (Department of Health 1998). Based on this definition, traditional long- 
and short-term insurers may market and sell health insurance policies which do not 
offer indemnity-type benefits that encroach on the ‘business of a medical scheme’ – 
i.e. the demarcation of medical scheme business (Erasmus et al. 2016). The benefits 
of these ‘health insurance’ products are typically of stated amounts, either an overall 
lump sum (e.g. critical illness products, disability cover, etc.), a per diem amount (e.g. 
hospital cash products) or an income (income protection or long-term care cover).  
However, these health insurance products make up a relatively small proportion of the 
private healthcare funding and insurance markets (Erasmus et al. 2016) and are beyond 
the scope of this research project. 
 
3.1 Medical care costs at the end of life  
A recent study in South Africa has shown that, on a risk-adjusted basis, in the final 
year of life, medical scheme beneficiaries experience significantly higher medical 
scheme claims than in non-final years of life (Ranchod, Abraham and Bloch 2015). 
The amount claimed by the beneficiaries in their final year of life was found to be 3.3 
times higher than compared to the year prior to the year of death (Ranchod, Abraham 
and Bloch 2015). This is consistent with findings in the US where around 25 per cent 
of annual Medicare costs are as a result of spend on persons in their final year of life, 
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whereas only around 5 per cent of these Medicare beneficiaries die annually (Hogan 
et al. 2001). From the above studies, it is evident that medical costs for decedents are 
significantly higher than the corresponding costs for survivors in any given year.  
The total cost per individual beneficiary (irrespective of their proximity to death) 
will depend on the type of care and the intensity of the care that the beneficiary receives 
as well as the length of time for which the care is required. Another recent study in 
South Africa shows an increasing rate of hospitalisation together with an increasing 
average length of hospital stay, particularly for people aged 65 and above (Erasmus 
and Kean 2018).  
Some medical interventions at the end of life yield little benefit to the patient 
whilst being extremely costly (Chochinov and Janson 1998). It is thus important when 
considering efficiency and cost savings that beneficiaries do not receive unnecessary 
and unwanted medical interventions near their end of life that do not meaningfully 
extend life and/or improve the quality of life for the beneficiaries. To this end, it is 
important that medical schemes aim to facilitate access to optimal care at the end of 
life through their benefit design, reimbursement arrangements, benefit communication 
and an increased emphasis on early planning for end-of-life care. This may allow and 
incentivise medical professionals to make optimal recommendations for treatment and 
care insofar possible given the significant levels of uncertainty and rapidly changing 
circumstances of individual beneficiaries nearing their end of life. Furthermore, this 
will also allow for optimised decision-making by the beneficiaries themselves or by 
their proxies near the end of life.  
It is important to note that end-of-life care planning should not be a once-off 
exercise, but rather, a dynamic multi-stakeholder process that keeps pace with the 
patients’ ever-changing personal circumstances. The importance of end-of-life care 
planning is highlighted by Detering, Hancock, Reade and Silvester (2010) having 
shown that it results in better end-of-life care for the patients and also a better 
experience at the end of life for their surviving relatives.  
A large amount of international research exists on the financial implications that 
approaching the end of life have for patients, their close relations and for the funders 
of the end-of-life care received by patients. However, in South Africa, research 
surrounding the funding of end-of-life care and the factors associated with end-of-life 
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care decisions and costs are sparse. Below, the potential impact of particular elements 
of the unique legislative environment, the structure of the industry and medical scheme 
benefit design on claim costs for beneficiaries near their end of life are considered. 
Following this, the impact of chronic non-communicable diseases on medical 
schemes’ claims experience are briefly considered.  
 
3.2 Prescribed Minimum Benefits 
All registered medical scheme benefit options are required to provide at least the 
PMB’s, at cost at the point of delivery, to all beneficiaries should they require 
treatment for any of the legislated PMB’s. The only exceptions are PMB-exempt 
benefit options, but these are beyond the scope of this research project. The PMB’s 
include 270 diagnosis and treatment pairs (DTP’s) plus the management and treatment 
of 25 chronic conditions as well as evacuation and care in the event of an emergency 
(Department of Health 1998). This includes unlimited cover for hospitalisations, 
specialist consultations, medical tests, medication, etc. for any condition/event defined 
as a PMB. The PMB’s themselves in their design are hospi-centric (Kaplan and 
Ranchod 2015) and the increase in spending on PMB’s over time has far exceeded the 
increase in spending on non-PMB’s as well as the consumer price index (Council for 
Medical Schemes 2016, 2019). Additionally, the legislation surrounding full payment 
for PMB’s may create perverse incentives for providers to commit various forms of 
fraud, waste and abuse, e.g. performing unnecessary medical services, up-coding 
services (submitting claims for higher cost services/medication, etc. than what was 
actually provided), submitting false claims, etc. further driving up medical scheme 
claim costs (Legotlo and Mutezo 2018).  
Over and above the hospi-centric nature of PMB’s and the incentives created for 
providers given the legislative framework, schemes’ direct or even indirect 
interpretation of the PMB’s in the design of scheme benefits can have further 
unintended cost and care implications at the end of life. The PMB DTP’s are set out in 
Annexure A of the Medical Schemes Act. One particularly relevant DTP that lends 
itself to misinterpretation is defined as having diagnosis: “Imminent death regardless 
of diagnosis”, with treatment defined as “Comfort care; pain relief; hydration” 
(Department of Health 1998). This DTP is likely intended as the catch-all end-of-life 
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benefit which alludes to covering ‘alternative’ treatments to the ‘usual’ curative in-
hospital treatment, e.g. palliative- and/or hospice-related care. However, this definition 
as it currently stands is vague and lends itself to misinterpretation. It does not explicitly 
define exactly the diagnosis nor the treatment parameters within this DTP. 
Furthermore, no mention of eligibility criteria for this DTP nor the period or 
circumstances under which beneficiaries are eligible to continue receiving this 
particular treatment are specified. The vague wording and lack of information on this 
DTP may have resulted in medical schemes not offering targeted end-of-life care 
benefits or not explicitly communicating their coverage for end-of-life care benefits to 
their beneficiaries. The end-of-life DTP is not diagnosis-specific and the treatment 
responsibility is also not aimed at any specific provider or setting of care, whereas the 
other DTP’s are more clearly defined, and/or need less clarification about what best 
practice medical treatment for the particular diagnosis is. As a result, even when the 
end of life is ‘imminent’, it may happen that a better-defined, equally applicable DTP 
care pathway is pursued, irrespective of whether this may result in more expensive 
and/or suboptimal care aimed at cure even when cure is no longer possible. Even if 
explicit end-of-life care benefits are available, utilisation thereof depends on whether 
doctors/beneficiaries are aware thereof, and depends on the doctor, the beneficiary and 
the beneficiary’s relatives’ preferences for care, and on these stakeholders’ interactions 
over time in making care recommendations and treatment decisions. Stakeholder 
interactions are considered in section 4. 
Encouragingly, in recent years, some medical schemes have started offering 
specific end-of-life care benefits that involve multi-disciplinary care teams, advanced 
care planning and individually co-ordinated care plans for seriously ill beneficiaries4. 
These benefits are still in their infancy and are continually being refined based on 
emerging experience and with help and input from the Hospice and Palliative Care 
Association of South Africa5. These benefits are currently structured as once-in-a-
lifetime benefits, only accessible at the end of life, and only available to beneficiaries 
with end-stage cancer who meet strict eligibility criteria, who forego curative treatment 
                                                          
4 https://hpca.co.za/download/discovery-healths-advanced-illness-benefit/ 




and are referred by their treating doctors. The problem herewith is that palliative care 
and hospice-based services are accessed very late in the disease trajectory, if at all, and 
a significant part of the benefit of early palliative care intervention is lost (Dalgaard et 
al. 2014). However, the significant risk to medical schemes of widening benefit 
eligibility where home or nursing services are included is the risk of having to pay for 
long-term or frail care services for extended periods of time. These are typically 
specific scheme exclusions due to the ‘social’ rather than ‘medical’ nature of this care 
and the threat they pose to the financial sustainability of medical schemes. A way to 
trigger palliative intervention early in the trajectory of serious, life-limiting illness 
without the high financial risk to schemes is to incorporate consultations and advanced 
care planning benefits with a palliative specialist upon diagnosis of serious illnesses 
into scheme benefit designs.   
The CMS is currently undertaking a PMB review in which significantly more 
focus is placed on the importance of the provision of palliative care to those who need 
it. This is amongst other key PMB priorities requiring urgent attention, e.g. addressing 
the quadruple burden of disease experienced by South Africans (Council for Medical 
Schemes 2016). This should go a ways towards highlighting the need and importance 
of integrated palliative care for all beneficiaries with serious illness and facilitating 
access to this care. Implementation of the revised PMB package is expected by 2022 
(Council for Medical Schemes 2019). 
There are many factors particular to the medical scheme environment beyond 
the interpretation and application of PMB’s that further interact and impact on the high 
level of medical scheme claims costs, extending particularly to end-of-life care costs. 
These include, but are not limited to fee-for-service reimbursement mechanisms, 
limited value-based provider contracting and reactive rather than proactive managed 
care interventions aimed specifically at the end of life, and the incomplete regulatory 
framework resulting in anti-selective behaviour  (Competition Commission South 
Africa 2019). A further factor affecting the demand for medical goods and services 
(on both the demand- and the supply sides) in the medical schemes environment are 
benefit design considerations, i.e. what is covered, who is eligible for particular 
benefits, who may provide these, etc. (Kaplan and Ranchod 2015). Below, we briefly 
consider the fee-for-service environment as a driver of medical scheme claims costs 
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and the role of managed care organisations and value based contracting in managing 
demand for both the demand- and supply-side drivers of costs, and maximising the 
value of care for medical schemes and their beneficiaries. 
 
3.3 Fee-for-service reimbursement, managed care and value-based contracting 
Medical schemes in South Africa typically reimburse providers of medical goods and 
services on a fee-for-service basis (Competition Commission South Africa 2019). In 
the 2018/19 CMS Annual Report it can be seen that almost 77 per cent of hospital 
payments were made on a fee-for-service basis with the remainder being on the bases 
of alternative reimbursement models, per diem rates or fixed global fees (Council for 
Medical Schemes 2019). 
 A fee-for-service environment rewards providers of medical goods and services 
based on the volume of high-cost goods supplied and services rendered thus perversely 
incentivising providers to over-service beneficiaries and to place greater emphasis on 
the use of higher-cost goods and services in treatment (Competition Commission 
South Africa 2019). This is termed supplier-induced demand and has frequently been 
cited as a major driver in healthcare utilisation and hence healthcare costs in the 
medical schemes environment (van den Heever 2015). The impact of supplier-induced 
demand is likely to manifest at all levels of healthcare delivery where fee-for-service 
reimbursement exists and this may be especially true for the end of life given the 
concentration of scheme expenditure in hospital and on PMB’s near the end of life.    
The Health Market Inquiry into the private healthcare sector in South Africa calls 
for the establishment of a supply-side regulator and a move away from fee-for-service 
reimbursement models to reduce fragmentation and inefficiencies in the private 
healthcare sector (Competition Commission South Africa 2019).  
Medical schemes utilise services and clinical management programmes provided 
by managed care organisations to assist with managing their overall risk and to ensure 
appropriate, cost-effective care for their beneficiaries. These services and programmes 
include, but are not limited to, the use of pre-authorisation for planned hospitalisations, 
disease management programmes, high-cost case management, treatment protocol 
formulation, formulary formulation and implementation, etc. (Kaplan and Ranchod 
2014). Managed care interventions have had success in managing utilisation of 
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healthcare, preventing downstream costs and even in improving quality of care and 
care outcomes (Kongstvedt 2013). Near the end of life, value for the key stakeholders 
could be improved significantly with more proactive (early identification of 
beneficiaries and palliative care integration with curative care) rather than reactionary 
(high-cost case management) managed care interventions. This requires a shift from 
the traditional fee-for-service reimbursement arrangements to more value-based 
contracting solutions that incorporate multi-disciplinary care teams and individualised 
care plans. The increased value is realised both from a cost and quality perspective - 
medical scheme claim costs can be reduced and the quality of care, life and of death 
for beneficiaries near their end of life can be improved. The use of such multi-
disciplinary structures with appropriate incentives has shown success internationally 
in the delivery of high-quality, cost-effective end-of-life care (Luckett, Phillips, Agar, 
Virdun et al. 2014; Fendler, Swetz and Allen 2015). However, significant challenges 
exist in the regulation of healthcare providers in South Africa regarding the 
establishment of multi-disciplinary group practices (Competition Commission South 
Africa 2019). 
 
3.4 Social solidarity and anti-selection 
The social solidarity principles upon which medical schemes are based, i.e. voluntary 
and open enrolment and community rating creates an environment that opens schemes 
up to anti-selection (Ramjee and Vieyra 2014). Anti-selection occurs in an insurance 
environment when an asymmetry of information between an insurance company and 
an individual can be utilised by the individual to their advantage. Individuals typically 
have more information regarding their state of health and their health-related 
behaviour than the insurance company (Erasmus and Kean 2018). Normally this does 
not represent a significant problem to the insurance company as it can underwrite each 
individual to gauge the level of risk and decide on the level of cover and/or the level 
of premiums to compensate for the risk, or it may decline cover altogether. However, 
denying coverage and charging for individual risk is disallowed by medical scheme 
legislation in South Africa, thus encouraging rational individuals to select (legally) 
against medical schemes by opting out of medical scheme cover whilst young and 
healthy, and opting for cover at older ages or when ill (Ramjee and Vieyra 2014). 
43 
 
Schemes have limited means with which to protect against this anti-selection, e.g. 
waiting periods (twelve-month condition-specific, and three-month general waiting 
periods), age-related late-joiner penalties and the various managed care tools and 
techniques highlighted above (Hutcheson 2011). The intention of the social solidarity 
principles are to prevent the ill and elderly from being denied cover and ensuring 
affordable, equitable access to care for those that need it through age and health-related 
cross-subsidisation. The higher expected claims for sicker beneficiaries are thus 
subsidised by the contributions of healthy beneficiaries (Ramjee and Vieyra 2014). In 
an environment where cover is mandatory, these cross-subsidies are effective and 
overall contributions can, in theory, be kept affordable. However, in a voluntary 
environment, all things equal, selection will result in healthy individuals opting out of 
cover, the risk profile worsening year-on-year, and contributions increasing 
unsustainably year-on-year, as is happening in the South African medical scheme 
environment  (Ramjee and Vieyra 2014). Furthermore, the requirement to pay for 
PMB’s in full greatly affects the affordability of medical scheme cover as it sets a high 
minimum cost of offering cover (Kaplan and Ranchod 2015). Increases in the cost of 
offering PMB’s and hence contributions, effectively force beneficiaries at the lower 
end of the market out of medical schemes over time (McLeod and Ramjee 2007). 
 The public healthcare system in South Africa is plagued by a lack of 
infrastructure and human resources, outdated technology, long waiting times and 
generally poor quality of care (Mayosi and Benatar 2014). The private sector 
healthcare in South Africa delivers high quality care, but at a very high price tag 
putting out-of-pocket payment for care, especially specialised and in-patient care out 
of reach of the majority of the population  (Barber, Kumar, Roubal, Colombo et al. 
2018). The risk of catastrophic medical expenditure in the private sector and the poor 
quality of care in the public sector makes scheme membership a logical option for 
seriously ill persons with the means to pay the monthly contributions. This may be 
worthwhile even after applying late-joiner penalties (a penalty that remains in force 
for life) and waiting periods (expiring after three and/or twelve months, depending on 
the specific type of waiting period(s) applied). In exchange for known contributions, 
beneficiaries have access to unlimited cover for PMB’s and significant cover for 
specialist care in private hospitals. It is clear that significant scope for anti-selection 
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exists in this voluntary environment with limited means of protecting against it. This 
anti-selective behaviour may be exacerbated near the end of life when the costs of 
managing chronic conditions, unplanned hospitalisations, emergencies, etc. become 
untenable for individuals and/or their families and medical scheme cover is taken up.  
  
3.5 Chronic non-communicable diseases as a driver of healthcare demand 
Globally, chronic, non-communicable diseases are increasingly affecting populations 
and the healthcare systems. The incidence and prevalence of these diseases are on the 
rise and so are the costs managing and treating these conditions (World Health 
Organization 2011). Developing countries are experiencing an epidemiological 
transition whereby the leading causes of death are shifting from communicable to non-
communicable diseases (Kaplan, Spittel and David 2015). The situation in South 
Africa is no different – 43 per cent of all deaths are caused by non-communicable 
diseases (Pillay-van Wyk, Msemburi, Laubscher, Dorrington et al. 2016). The 
developed world experienced this transition decades ago. 
Today, most people die at advanced ages – global life expectancy at birth has 
surpassed 71 years (Wang, Naghavi, Allen, Barber et al. 2016). Age-standardised 
death rates at all ages have significantly reduced, globally, due to improvements in 
medical technology, care interventions and pharmaceuticals which have significantly 
reduced the numbers of deaths due to communicable, maternal and neonatal, and 
nutritional disorders (Moraga 2017). Non-communicable diseases account for more 
than 72 per cent of deaths, globally (Moraga 2017). Furthermore, age is highly 
correlated with the level of chronicity (Shlisky, Bloom, Beaudreault, Tucker et al. 
2017).  
The most common non-communicable diseases are cardiovascular disease, 
cancer, chronic respiratory disease and diabetes (Habib and Saha 2010). Near the end 
of life, complications resulting from chronic conditions (potentially exacerbated by the 
existence of multiple chronic conditions in some individuals) and treating these 
conditions may result in more frequent hospitalisations, longer hospital stays and more 
bouts of intensive care during these hospitalisations (Palladino, Tayu Lee, Ashworth, 
Triassi et al. 2016). 
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In the medical schemes environment, the PMB’s include full payment (subject 
to certain rules, e.g. using a designated service provider, etc.) of a defined list of 
chronic conditions (the Chronic Disease List or CDL). More comprehensive options 
may include cover for additional specified chronic conditions. Schemes generally 
require beneficiaries to inform the scheme and provide proof of the chronic condition 
in order to qualify for these PMBs. This is known as chronic ‘registration’ or 
‘authorisation’ with the scheme. Certain chronic condition registration is also 
accompanied by enrolment on a chronic condition management programme, e.g. 
HIV/AIDS and cancer. This is to ensure that the beneficiary manages their condition 
well by taking medication timeously, going for regular tests, check-ups, etc. and to 
avoid exacerbated medical costs and further complications downstream. The 
administration and management of these programmes falls under the scope of the 
scheme’s managed care arrangements. Chronicity and the impact of chronic conditions 
on end-of-life care costs are considered in more detail later in this research report. 
In the next section, the key stakeholders, their interactions and their thought- and 




4 Stakeholders, decisions and conflicts near the end of 
life 
When it comes to the end of life, no two people have the same backgrounds, 
characteristics and preferences, and no two people make decisions in exactly the same 
way. The following is a high-level exploration of the behavioural and other factors 
contributing to the complexity surrounding decision-making in end-of-life situations, 
focusing on the unique aspects in the South African medical scheme environment and 
the key stakeholders (and their respective needs) therein. The factors considered here 
are not exhaustive. Neither is the discussion around the multiple layers of interaction 
between stakeholders in the continuum of care and disease progression over time. 
Local as well as international literature on conflicts between stakeholders and 
decision-making are considered below.  
Numerous stakeholders play instrumental roles in end-of-life care decision-
making, the provision of care and the funding thereof. It frequently happens that these 
stakeholders have opposing interests or conflicting needs resulting in an additional 
layer of complexity surrounding end-of-life care decision-making and care 
provisioning (Weissman 2001; Frost et al. 2011). The complex interaction between 
stakeholders may a go a ways toward explaining the stakeholders’ observed behaviour 
and their decision-making in the face of serious, life-limiting illnesses.  
 
4.1 Key stakeholders 
Figure 4.1, below, illustrates the key end-of-life care stakeholders in the end-of-life 
care universe, and depicts the various interactions between them, e.g. communication, 







Figure 4.1 – The End-of-Life care universe 
 
 
Beneficiaries are scheme members and/or the registered dependents of the scheme 
members entitled to receive scheme benefits in accordance with the benefit rules of 
the particular medical scheme. They sit at the top of the pyramid within the end-of-life 
care universe depicted in Figure 4.1, as they are the benefactors of the care and those 
for whom the quality of care, life and death are to be optimised.  
In the centre of the pyramid is the medical scheme as the funder of the end-of-
life care given the competitive and legislative environment in which medical schemes 
in South Africa operate. The role of medical scheme service providers, e.g. 
administrators and managed care organisations were considered briefly in Section 3. 
These service providers are not considered as separate stakeholders in this section and 
are considered together with medical schemes.  
The base of the pyramid consists of the providers (and settings) of end-of-life 
care and the relatives/friends of the beneficiary that support the beneficiary near their 
end of life. The support they provide may be emotional, financial and/or in a caregiving 
capacity. Within this end-of-life universe, the greater society or community within 
which beneficiaries find themselves and the prevailing culture and attitudes of the 
persons within these communities also influences the type and intensity of care as well 
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as the care decisions and transitions between settings of care near their end of life. For 
example, in poorer or more rural communities where formal care resources like 
specialists and private hospitals are more limited, there may be a greater proliferation 
of informal or community-based care programmes or initiatives than in more urban or 
better-resourced communities. Similarly for smaller, more close-knit communities, 
greater emphasis may be placed on community involvement in care for the seriously 
ill (Byock, Norris, Curtis and Patrick 2001).    
All stakeholders are inter-connected (to a more or lesser extent depending on 
each individual beneficiary’s circumstances) in the provision of and the decisions 
made surrounding the end-of-life care the beneficiary receives. 
 
4.2 Preferences, communication, benefits and decisions 
There are many factors that impact on a beneficiaries’ choice (or lack of choice) 
regarding the care they receive at the end of their life including: demographic factors 
such as age, sex, race and geographic location, state of mind, cognition, degree of 
physical impairment, religion, doctors’ recommendations, family preferences, etc. 
(Frost et al. 2011). Financial factors, insurance and level of education/awareness will 
also have an influence on the decision-making near the end of life. Frost et al. (2011) 
argue that decision-making at the end of life is “contentious”. This is partly because of 
the complex interaction between stakeholders and the factors they consider important 
at the end of life (Steinhauser et al. 2000). Another contributing factor is the significant 
amount of uncertainty that accompany the end of life and how perspectives change 
with level of awareness and with changes in circumstances over time (Lau et al. 2007). 
Uncertainty may also translate into hope and unrealistic expectations regarding the 
effect of curative interventions, given technological advances and a tendency (by both 
providers and beneficiaries) to err on the side of optimism with prognoses and 
estimates of future survival times (Lamont 2005).  
Effective communication about care preferences and illness trajectories is a 
useful first step to reducing the level of conflict between the key stakeholders, to 
reduce uncertainty and to improve decision-making near the end of life. Effective 
communication helps to address societal ignorance and fights any stigma associated 
with the end of life and has been shown to shorten the length of hospital stays, to 
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significantly reduce end-of-life care costs, to increase patients’ quality of life near their 
end of life and helps to facilitate an improved family bereavement experience (Wright 
et al. 2008; Curtis, Treece, Nielsen, Gold et al. 2016; Keeley 2017). Identifying that 
communication gaps and inefficiencies in the delivery of end-of-life care exists, is 
straightforward; however, addressing them poses an entirely different set of 
challenges. Some challenges surrounding effective end-of-life care communication are 
outlined below.   
A beneficiary’s religious or cultural orientation may preclude conversations 
about death or make such conversations inappropriate (You, Downar, Fowler, 
Lamontagne et al. 2015). Beneficiaries may refuse to accept poor prognoses and as a 
result not engage in end-of-life care discussions or care planning with providers and/or 
family members. A doctor or specialist may avoid the topic in order to maintain hope 
or may, him- or herself, be uncomfortable/inexperienced with such communication. 
Equally family members may avoid the conversation with the beneficiary or fail to 
convey to providers the treatment preferences of a loved one when they are unable to 
do so themselves (You et al. 2015).   
Advanced care planning has been effective in encouraging discussions around 
care goals and documenting care preferences, helping to address some of the 
communication gaps identified in end-of-life care decision-making (Emanuel, von 
Gunten and Ferris 2000). However, research has shown that documenting preferences 
does not necessarily result in them being adhered to (Prendergast 2001). Significant 
problems with advanced directives are that they are once-off in nature and are often 
forgotten or misplaced after the initial directive is drawn up (Perkins 2007). Another 
problem with advanced directives is the significant, and often unanticipated, changes 
in circumstances between the time of drawing up the advanced directive and the time 
when it is meant to be acted upon, and the resulting (often drastic) change in personal 
preferences (Fagerlin, Ditto, Hawkins, Schneider et al. 2002). Researchers use 
prospect theory to explain this phenomenon and its impact on decision-making – as 
prospects change, preferences change (Winter and Parker 2007). The theory reads as 
follows: when a person is in good health, the distinction between life in poor health 
and death is small, and the preference is an expressed wish to avoid intensive, life 
prolonging interventions that will cause further pain and suffering. Conversely, when 
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a person is in poor health, the distinction between further life in poor health, and death, 
is greater, meaning that life-prolonging treatment may be more acceptable and even 
desirable (Winter and Parker 2007). It is thus recommended that advanced care 
planning should be an ongoing process of engagement that focuses on preparing 
patients and their families for making difficult decisions and eliciting care goals so  
that at that time when a crisis occurs and important, difficult decisions need to be made 
they can be made in good time (Perkins 2007; Sudore and Fried 2010). It is clear that 
effective communication and ongoing engagement between key stakeholders is 
paramount to end-of-life care decisions. However, communication is only one aspect 
of conflict and decision-making in the end-of-life conundrum. Another significant 
consideration is the actual scheme benefits to which the scheme beneficiaries are 
entitled. 
There is a proliferation of medical schemes and individual benefit options within 
medical schemes. The design of these are complex, with beneficiaries who don’t 
understand their benefits and/or are unaware of their benefit entitlements (Kaplan and 
Ranchod 2014). This lack of awareness and understanding disempowers beneficiaries 
in the decision-making process (Competition Commission South Africa 2019). It is 
possible that beneficiaries are unaware of which care alternatives or complements 
exist, and which of these may be optimal near their end of life given their unique 
circumstances and the uncertain way in which their end-of-life period will unfold.  
4.3 Third-party payer dynamics 
Scheme beneficiaries themselves don’t pay directly for the medical goods and services 
they consume (other than for out-of-pocket payments, co-payments or for medical care 
that is excluded from scheme cover) and are thus not incentivised to consider the cost 
of such treatment, nor to seek the most cost-effective services – this is referred to as 
the third-party-payer problem (Edmeston and Francis 2012). This, together with a lack 
of detailed medical knowledge on the part of the beneficiaries results in further 
disempowerment of scheme beneficiaries when it comes to medical care decisions 
whereby they assume a more passive role in making treatment decisions (Say, Murtagh 
and Thomson 2006; Longtin, Sax, Leape, Sheridan et al. 2010). Passive decision-
making means expressing a preference to not be directly involved in making care and 
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treatment decisions and accepting the doctor’s treatment recommendations (Robinson 
and Thomson 2001). Passive decision-making by beneficiaries may result in them 
receiving higher cost medical care and treatment that does not necessarily improve 
health outcomes, and at the end of life, potentially resulting in worse outcomes (Adams 
and Drake 2006; Oshima Lee and Emanuel 2013). This highlights the importance of 
shared and empowered decision-making at all levels of care, but particularly at the end 
of life where an understanding of care preferences and goals and the quality of life 
should supersede merely keeping someone alive.     
The proliferation of scheme options and complex benefit designs also presents 
challenges for providers - it is impossible for all doctors to know exactly which 
benefits are provided by which schemes and options and which beneficiaries are 
entitled to which benefits, how much of these benefits and when beneficiaries are 
entitled to them. The PMB’s (the base package that all schemes and all options need 
to cover in full) and their impact on claims were touched on in the previous section. 
Cover for intensive medical treatment for serious conditions and emergencies 
requiring hospitalisation (which are frequent near the end of life), most often fall 
within the legislated PMB’s. Providers may be more likely to admit beneficiaries to 
hospital (resulting in intensive and expensive treatment), knowing that this care is 
covered as a PMB and will be fully paid for by the scheme. This is further exacerbated 
by the fee-for-service reimbursement mechanism and provider incentives to 
potentially over-service beneficiaries (considered in the previous section) 
(Competition Commission South Africa 2019). The extent to which providers 
deliberately over-service beneficiaries and unnecessarily admit them to hospital is 
unclear. There is however some consensus that this is widespread and driven to an 
extent by the regulation surrounding the payment of PMB’s (Ramjee, Abraham, 
Kaplan, Taylor et al. 2013; Erasmus and Kean 2018; Legotlo and Mutezo 2018).    
For the reasons above, amongst others, intensive treatment in-hospital near the 
end of life may be sought despite being sub-optimal and despite the beneficiary having 
access to and cover for other complementary or palliative care benefits that may be 
more, or at least, equally, suited to their personal circumstances. 
The concept and interpretation of quality can further affect beneficiary decision-
making. A common misconception exists that more expensive healthcare means higher 
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quality healthcare or conversely, that lower cost care means substandard care 
(Weisbrod 1991; Hibbard, Greene, Sofaer, Firminger et al. 2012). The concept of 
diminishing returns (that may even become negative) can be borrowed from economic 
theory. This concept means that the more of something one receives, the lower the 
marginal utility that they derive from each additional unit thereof (Greene and Baron 
2001), and that there may be a tipping point after which the ‘benefits’ of additional 
units actually decrease the overall utility, i.e. causes harm (Chochinov and Janson 
1998; Greene and Baron 2001). This may be especially true for complex goods or 
services such as healthcare interventions near the end of life where quality (and utility) 
are often not directly observable and cost is erroneously used by some as a proxy for 
quality, irrespective of whether the care is appropriate or achieves better outcomes 
(Hibbard et al. 2012). Near the end of life, ineffective care is one such example where 
additional spending adds no additional utility or benefit, but may very well cause harm 
(Kompanje, Piers and Benoit 2013).  Beneficiaries (and even providers) may 
incorrectly assume that the more expensive or intensive the care, the better the value 
and the higher the quality thereof is. This may not be true given that more 
intensive/aggressive care near the end of life potentially results in reduced quality of 
life and poorer outcomes for patients and their families (Connors et al. 1995). It has 
also been shown that increased spending does not necessarily result in better healthcare 
outcomes or even in extended survival times (Fisher, Wennberg, Stukel, Gottlieb et al. 
2003). 
Beneficiaries may also be of the conviction that they are entitled to more 
expensive care (if given alternatives) at any given time they become ill if they had 
been contributing to the medical scheme for years during which they were healthy and 
not claiming any benefits. When choosing between care pathways at the end of life (or 
at any time), these beneficiaries may place a higher personal value on the more 
intensive, more expensive care without fully understanding the implications of their 
end-of-life care preferences and eventual decisions. The extent to which this 
rationalisation or entitlement may exist for beneficiaries in the medical schemes 
environment, and its effect on claims costs is unknown and not easily quantifiable 
without observing and surveying beneficiaries and care providers directly.  
53 
 
4.4 Agency issues and conflicts of interest 
The existence of agency issues in healthcare presents clear conflicts of interest, 
especially in end-of-life care decision-making. These conflicts potentially arise 
between any of the care provider(s), the beneficiaries, the close relations and/or the 
medical schemes. The existence of agency issues and other conflicts of interest may 
result in beneficiaries eventually receiving care that is sub-optimal in some respect 
near their end of life, resulting in a combination of unnecessary pain, suffering, 
feelings of anger and frustration, depression, etc. and receiving care that is 
contradictory to their preferences, stated or otherwise (Weissman 2001).   
At the end of life, a beneficiary may not be physically or cognitively able to 
make decisions when alternative care pathways need to be considered. The proxy 
decision-makers for the beneficiary may have different considerations and/or needs to 
those of the beneficiary when making end-of-life care decisions on their behalf (Parks, 
Winter, Santana, Parker et al. 2011). Making end-of-life care decisions for loved ones 
carries a significant emotional burden (Braun, Beyth, Ford and McCullough 2008) and 
frequently a bias exists towards favouring interventions aimed at cure, especially when 
there is unresolved family conflict surrounding the choice of care interventions (Parks 
et al. 2011). 
Doctors may also in some circumstances recommend treatments knowing that 
these may not be fully appropriate as found in an investigation by Solomon et al. 
(1993). This investigation also found that doctors often felt that the treatments they 
were offering their patients were excessive. Reasons for this overtreatment of patients 
may be because of the doctor not knowing what the patients’ preferences for treatments 
are, a fear of under-servicing patients or of being uncertain about what is ethical or 
what the law requires, etc. (Solomon et al. 1993). Weissman (2001) additionally puts 
forth that doctors may recommend overly aggressive treatment because they are wary 
of destroying hope for the dying patient and their loved ones. Doctors themselves may 
harbour strong religious or cultural convictions resulting in a stigma against foregoing 
curative care instead of rather opting for more palliative measures (Wilkinson and 
Truog 2013). Furthermore, doctors may fear being ostracised by their peers by 
recommending less aggressive treatment (Weissman 2001). Another reason for 
offering intensive interventions near the end of life may be that there are significant 
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legal risks involved in withholding or not authorising certain treatments, and/or 
reputational risk in being seen to withhold certain curative measures, even at the end 
of life (Meisel, Snyder, Quill and Panel 2000). The inherent uncertainty near the end 
of life, technological or experimental interventions and individual convictions 
potentially cause providers to err on the side of caution – favouring intensive, life-
prolonging or curative care interventions near the end of life. 
Finally, another factor driving decisions and highlighting the existence of agency 
issues in the provider-patient relationship is the existence of a profit motive for the 
provider. An economic conflict of interest exists in the fee-for-service environment 
whereby the doctor or specialist may directly benefit from the care they recommend 
and administer as opposed to referring the beneficiary to a different care provider 
(Gray 1997). Unfortunately, this may result in a provider purposely administering 
inappropriate, ineffective care near a beneficiary’s end of life. There also exists 
conflicts of interest between the providers of care and the medical schemes as third 
party funders of the care. The use of managed care techniques and treatment protocols 
by medical schemes may be seen by providers are a direct undermining of the trust 
between them and their patients (Gray 1997). Rapidly rising medical costs and 
frequently reported poor care outcomes, however, have necessitated the development 
and use of managed techniques as a means to try and contain costs and improve patient 
outcomes (Kongstvedt 2013). 
It is clear that significant conflicts of interest exist - some apparent, some more 
sinister and some more subtle. It is the confluence of this multitude of factors, the 
complex interactions between stakeholders and the significant information 
asymmetries and uncertainty, which may result in these conflicts of interest. The 
literature suggests that decision-making near the end of life by patients, their family 
members and their doctors are often, in hindsight, inappropriate resulting in patients 
often receiving sub-optimal care near their end of life (Frost et al. 2011). Inappropriate 
decision-making is often driven by a failure to recognise, understand or acknowledge 
death’s imminence, cultural values and beliefs, desperation and hope, fear of acting 
immorally or legal repercussions, etc. (Weissman 2001). Medical schemes and their 
managed care service providers can play a significant role in facilitating effective 
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communication, aligning stakeholder incentives and removing some of the contention 




5 Data and methodology 
5.1 Credibility and representivity of the data 
The data analyses performed for purposes of this research project comprises of 
retrospective analyses of a sample of decedent medical scheme beneficiaries’ medical 
scheme claims incurred during their last 24 months of life. The analyses also considers 
these decedents’ demographic characteristics to further evaluate the observable factors 
that impact on their overall end-of-life care claims costs. 
The sample contains a total of 24 980 medical scheme beneficiaries that died in 
the calendar years 2016 and 2017, representing around 12 500 deaths per respective 
calendar year under investigation. The decedents represent about 0.5 per cent of the 
total number of beneficiaries exposed to the risk of death per calendar year from the 
subset of the overall medical schemes’ population to which the decedents belonged at 
their time of death. This means that there were a total of around 2.7 million exposed 
beneficiaries per calendar year in the population to which these decedents belonged. 
The greater population to which the decent beneficiaries in our sample belong 
represents around thirty percent of the total medical schemes industry in South Africa, 
i.e. thirty per cent of the roughly 8.9 million medical scheme beneficiaries in South 
Africa (Council for Medical Schemes 2019). Given the proportion of the medical 
schemes industry covered by the sample, the analyses and results are expected to be 
representative of the experience of the greater medical schemes industry in South 
Africa. This should be interpreted with caution as some of the smaller medical schemes 
in the industry may have demographic profiles and claims experience that differs 
significantly from that of the sample analysed. Furthermore, differences in benefit 
designs, scheme and option sizes, geographic concentrations, etc. between schemes 
and options may result in different overall experience when compared with that of the 
sample under investigation.  
No explicit adjustments are made for different benefit designs between schemes 
and between different benefit options within schemes. Different benefits designs 
between schemes and options are expected to have an impact on individual 
beneficiaries’ total claims costs. However, given the common set of PMB’s on all 
medical scheme options (Kaplan and Ranchod 2015) and the hospi-centric nature of 
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these PMB’s and specifically care at the end-of-life (Ranchod, Abraham and Bloch 
2015), the effect of different benefit designs between schemes and options are likely 
to be muted at the end of life. In addition, this research project analyses the total claims 
submitted, as opposed to the total claims paid, which will further reduce the impact of 
differing benefit designs on the overall claims experience. The difference between the 
claims submitted and the claims paid are less than ten per cent of the overall claims 
for decedent beneficiaries in the sample.  
The total claims incurred by all exposed lives in the population to which the 
decedents belonged (the 2.7 million lives) amounts to around R40 billion per annum 
during these two calendar years (Council for Medical Schemes 2019), whereas the 
overall claims for the decedent beneficiaries in the sample over their last year of life 
amounts to around R4 billion per annum (in 2017 monetary terms). This means that, 
for the population under consideration, around ten per cent of total claims incurred by 
all exposed lives are incurred by the 0.5 per cent of beneficiaries that die each year. 
Stated otherwise, this reads as follows: claims costs for beneficiaries in their final year 
of life are more than twenty times greater than for beneficiaries not in their final year 
of life, on average. Medical scheme claims costs for beneficiaries in their final year of 
life are thus significantly subsidised by the contributions of those not in their final year 
of life. The high relative level of expenditure on beneficiaries nearing their end of life 
warrants an investigation into the factors that potentially drive this observed 
experience.  
While an attempt is made in this research to be comprehensive in the 
identification and analyses of end-of-life care cost drivers, there are many forces and 
factors at play, some subtle and invisible, and others less so. It is not impossible that 
some factors may have been overlooked, or that the nuances of their interaction with 
other factors may have been incorrectly or too simplistically interpreted. Where 
deemed appropriate, recommendations are made, and areas that require further 
research or require substantiating evidence are identified. This research project is a 
first step towards unpacking and understanding the complexities, the challenges and 




Next, the data analysed are considered, followed by a description of the 
methodology employed in the analyses. 
 
5.2 Description of the data 
Full claims data for the sample of medical scheme beneficiaries that died during the 
period under investigation (calendar years 2016 and 2017) are analysed. All medical 
scheme claims submitted to the scheme for these beneficiaries during their last 24 
months of life are included in the data. The data extraction was done in July 2018. 
Given a period of greater than six months following the last death, it is reasonable to 
assume that the claims data are fully run off at the time of the data extraction. All data 
are fully de-identified and individual beneficiaries have been assigned unique 
number/character strings that link them to their individual claims, their demographic 
information, their hospital events and chronic condition authorisation data across a 
number of data sets. The claims data consists of some 26 million individual claim lines. 
The data analyses are performed using Microsoft SQL Server Management Studio (a 
database application) to summarise and group the data and to do high-level 
manipulations, and Microsoft Excel (a spreadsheet application) to perform the detailed 
analyses and to construct the figures and tables presented in this report.  
 Figure 5.1, below, illustrates the various data sets and the links between them.  




The key variables are the unique identifiers for each beneficiary and for each unique 
hospitalisation and chronic authorisation. The demographic data supplied for each 
decedent beneficiary includes their age at death, date of death, sex, postal code 
(indicating his or her area of residence), chronic registration indicator and the duration 
of their scheme membership. Further, the claims information includes the monetary 
amount (in Rands) of the claim submitted to the scheme and the monetary amount paid 
by the scheme, respectively, per claim line. An ICD-106 code as well as the specific 
‘episode of care’7 (and its description) that a claim belongs to is contained in the claims 
file, per claim line. An ‘episode of care’ is broadly defined as the set of health services 
delivered during some time period to treat a particular condition or a particular event 
requiring medical intervention (Peterson, Grosse and Dunn 2019). This may consist of 
one or more hospitalisations, follow-up visits, medication, etc. that falls within the 
scope and definition of the particular ‘episode of care’ (Jackson, Walsh and Abecassis 
2016). The claims file also included a NAPPI8 code and a procedure code together 
with descriptions of these, the practice type of the providers and an in-hospital 
indicator plus a unique in-hospital ‘event’ identifier for claims occurring during each 
hospitalisation, for each individual claim line.  
 The unique hospital ‘event’ identifiers can be cross-referenced with an ‘events’ 
data file. This file contains the details of the admission and discharge dates, the 
Diagnosis-Related Group (DRG9) description for each hospital ‘event’, the admitting 
doctor practice type and a link to the individual beneficiary’s unique identifier for each 
hospitalisation the beneficiary had during their last 24 months of life. The chronic file 
contains authorisation data for chronic conditions, including the actual chronic 
condition and the start date of each chronic authorisation for each individual decedent 
beneficiary. 
                                                          
6 International Classification of Diseases (10th revision) or ICD-10 is a coding system used to 
classify/code all diagnoses, symptoms and medical procedures.  
7 ‘Episodes of care’ are defined by statistical parameters using an ‘episode’ grouper. The details of 
and methodology followed by the ‘episode grouper’ (proprietary information) is beyond the scope of 
this research project.  
8 A NAPPI code is a unique identifier for consumables or surgical products used in delivering 
healthcare and allows for the identification of individual items billed for in a fee-for-service 
environment 
9 DRG’s or diagnosis-related groupings refers to a standardised system of hospital patient 
classification depending on diagnosis (based on ICD-10-coding). 
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Summary statistics and reasonability checks performed on the data 
First, the distribution of deaths by calendar month are considered for reasonability. 
This is illustrated in figure 5.2, below.  
 
Figure 5.2 – Distribution of deaths per calendar month 
 
 
Figure 5.2 shows that there is some variation between calendar months. On average, 
approximately 1 000 beneficiaries in the exposed population die each month in both 
calendar years. July sees the highest number of deaths and February sees the lowest 
number of deaths. The calendar year patterns do not differ significantly. 
Next, as a reasonability check on the recording of the dates of death, the 













Figure 5.3 – Distribution of deaths per day of the month 
 
It can be seen from Figure 5.3 that the number of deaths per day (across both calendar 
years) range from around 750 to around 850, with the second half of each month 
experiencing a slightly higher average number of deaths than the first half of each 
month, on average. This may be due to random variation. The 31st has a lower number 
of deaths, as expected, as some months only have thirty days. Overall, the distribution 
seems reasonable, and there is no evidence of clustering of days of death, particularly 
at the end of any particular month. Cessation of cover for reasons other than death, e.g. 
resignation from scheme membership, normally occurs at the end of any particular 
month.  
Next, the demographic characteristics of the sample of decedent beneficiaries 
are analysed to gain an understanding of the profile of the lives that have died during 
the period under consideration. Figure 5.4, below, shows the distribution of deaths by 









Figure 5.4 – Number of deaths by sex and age band at death 
  
 
The profile of the decedent beneficiaries is in line with expectations – a relatively 
higher number of neonatal deaths (age ‘0’ in Figure 5.4) than child deaths, and 
increasing numbers of deaths with increasing age, dropping off significantly at extreme 
ages given the low number of beneficiaries exposed at these ages. The split between 
males and females is also reasonable with a higher proportion of male deaths (54 per 
cent male, 46 per cent female).  
Table 5.1, below gives a breakdown of the deaths by average and median ages 
(rounded) by sex of the decedent beneficiaries.  
 
Table 5.1 – Age of decedent beneficiaries 
Average age (years) at death: 
Males  63 
Females 66 
Overall 64 





A difference of about 3.5 years in the average age at death between the two calendar 
years is observed. Similarly, the median age at death also shows this discrepancy – 68 
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years in 2016 vs 71 years in 2017. Upon further investigation it was discovered that 
there were more neonatal deaths in 2016 than in 2017, bringing both the average and 
median age at death in 2016 down; and in 2017, there were more deaths at more 
advanced ages (age eighty and above), pushing the average and median age at death 
in 2017 up. Given the size of the dataset and number of deaths in each year (around 12 
500 deaths per annum), such fluctuation can reasonably be expected to occur. The 
shape of the distribution of deaths across the two years are broadly similar and follow 
that of Figure 5.4, above. The overall average and median ages at death, across both 
calendar years were around 64 years and seventy years, respectively.  
 
5.3 Data limitations 
The data analysed in this research projects have a number of limitations. The data 
contains age-last-birthday for each decedent beneficiary and the exact ages (i.e. date 
of birth) of the beneficiaries are not available. On average, this means that the 
beneficiaries that have died are six months older than suggested by the data.  
Also, the claims data contains all the details of procedures, medications and 
consumables claimed for, but no details on the exact cause of death are available. At 
best, these have to be inferred from the episodes of care and the ICD-10 codes assigned 
to the claims data. Given the large number of episodes of care and ICD-10 codes and 
the number of combinations of these for each beneficiary (each claim line is assigned 
an episode of care/ICD-10 code), such inference are only approximate. Furthermore, 
the limited clinical information contained in the claims data means that there is no 
prognostic information (functional status, symptom burden, doctor’s prognoses, etc.) 
that can be used to evaluate definitively the appropriateness and quality of care as was 
provided. Inference needs to be made based on a number of generalised indicators of 
quality that are measurable from the data which only potentially implies good or poor 
quality care.   
The claims data contains fields for the claim amounts submitted and the claim 
amounts paid. Depending on the specific scheme and option and the benefit rules 
thereof, some claims may be rejected (or only partially paid) by the medical scheme. 
A number of reasons exist for rejecting (or only partially paying for) claims. These 
include overall cover limits having been reached, a co-payment or an exclusion 
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applying, etc. Where limits and co-payments apply, the amounts claimed will be higher 
than the amounts paid. As a proportion of total claims submitted, the paid claims are 
approximately 93 per cent. This does not materially affect the overall claim amounts 
and the conclusions drawn from the analyses. The analyses that follow uses the ‘claims 
submitted’ amounts when considering the overall and average claim amounts for the 
sample of beneficiaries. This reduces the effect that different benefit designs have on 
claim costs near the end of life, as noted earlier.   
Furthermore, the claims data only contains claims submitted by providers (or the 
beneficiaries themselves) to the medical scheme and excludes any out-of-pocket 
medical expenses incurred by the beneficiaries that have not been submitted to the 
medical scheme. These may include fees for private nursing or residential frail care 
which are typically not covered by medical schemes in South Africa. Furthermore, 
over-the-counter medications and other day-to-day benefits such as GP or dentist visits 
may also not be covered on certain plans. Out-of-pocket medical costs incurred by 
beneficiaries are beyond the scope of this research. It should, however, be borne in 
mind that scheme exclusions or limits on some benefits may drive higher utilisation of 
other scheme benefits, e.g. the in-hospital benefits. Benefit design was considered in 
some detail in Section 3.  
Hospice services in South Africa are offered on a charitable basis to provide the 
necessary end-of-life care and support to indigent individuals (HPCA 2019) and hence 
hospices frequently fail to bill medical schemes appropriately for the services they 
provide to scheme beneficiaries. This is despite some schemes offering cover for 
hospice benefits and billing structures having been put in place to reimburse hospices 
for the services they provide to medical scheme beneficiaries. The utilisation of 
hospice services by scheme beneficiaries in the sample of deaths are investigated in a 
later section, but it should be borne in mind that actual utilisation may be higher than 
what is observed from the claims data due to potential irregular billing. It is more likely 
that in-patient hospice care are billed for as opposed to hospice care home visits.  
5.4 Special cases/errors identified in the data 
Some 520 beneficiaries (around two per cent) had claims dated before their recorded 
date of joining the scheme. This is investigated and it became apparent in the analyses 
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that some scheme beneficiaries had terminated their membership within the 24-month 
period preceding their death and had then had subsequently reinstated their cover prior 
to death. This means that they did not enjoy cover for the full 24 months and had claims 
before their final entry date to the scheme, relating to their prior membership. These 
beneficiaries are considered to have entered the scheme on their final cover 
reinstatement date and all claims and exposure prior to their final join date are excluded 
from the analyses.  
 A number of beneficiaries also had claims recorded after their respective dates 
of death. These claims only amount to 0.16 per cent of the overall claims for the sample 
of decedents and are thus immaterial for purposes of these analyses. The death data 
are accurate in as far as the death dates recorded by the Department of Home Affairs 
are accurate. The medical scheme administrator uses the Department of Home Affairs 
death database to scrub the date of death for purposes of their records. This was 
performed prior to the data being extracted for purposes of this research project. A 
number of reasons may explain why there are claims recorded after the date of death, 
e.g. service dates incorrectly captured, either by accident or by intent, inexperience of 
provider in billing resulting in errors, etc. Section 7.2.1 considers the billing practices 
of hospices, in particular.  
Some dialysis claims for decedents in the 2016 calendar year were very large 
(unrealistically so) and a factor of 100 times greater than the amount paid for these 
claims. Upon investigation it appeared that the claims submitted for these procedures 
were recorded in ZAR cents and not in ZAR Rands, and the claim amounts are adjusted 
downward by a factor of 100 to correct these errors. This affected less than two per 
cent of dialysis claim lines submitted for the 2016 decedent beneficiaries and amounts 
to just over two per cent of the overall claim amounts submitted.   
The hospital ‘events’ file contained a number of anomalies, e.g. discharge dates 
after the date of death, or multiple events in periods that overlap. A possible 
explanation for the overlap in periods for different ‘events’ may be that the DRG was 
updated following the initial admission to hospital after more information became 
available. Complications or acquiring a further condition whilst in hospital, e.g. 
pneumonia, or sepsis, etc. could also constitute a new (or updated) hospital event. 
When considering number of hospitalisations and the days spent in-hospital, these 
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anomalies are allowed for by excluding all days after death and in overlapping periods, 
only counting each day once. This affected less than three per cent of all hospital 
‘events’. 
 
5.5 Data analyses methodology 
In order to consider claims incurred in different calendar years on a like-for-like basis, 
an inflation adjustment is applied. All the claim amounts submitted in the years prior 
to 2017 are adjusted to 2017 ZAR-terms using the weighted average provider tariff 
increases as published annually by the Council for Medical Schemes. The weights are 
determined by overall medical scheme spend for the various tariff categories, e.g. the 
various providers, medicines, equipment, consumables, etc. It is worth bearing in mind 
that no inflation adjustment methodology is perfect, and that tariff increases are only 
one component of overall claims cost increases from year to year. Also, the actual 
weighting of medical scheme expenditure for the sample of decedent beneficiaries are 
likely to be different to the weightings of expenditure across tariff categories used in 
determining the overall tariff increase assumptions.  
Increase in the utilisation of medical goods and services for the overall scheme 
population between calendar years is not explicitly allowed for given that the analyses 
focuses only on a sample of beneficiaries and their individual claims experience. 
Higher utilisation for individual beneficiaries is reflected in their overall claims 
experience. Hence only the actual increases in provider tariffs are adjusted for.  
 The results of the data analyses are presented in Section 6 and the significance 
and implications thereof are discussed in Section 7. The next subsections outline the 
methodology followed to perform the data analyses. 
 
5.5.1 Demographic profile and overall claims patterns of decedent beneficiaries  
The distribution of deaths in the sample of decedent beneficiaries by calendar month, 
day of the month and the distribution of age at death by gender were considered earlier 
in this section. The association of age, sex, geographic location, respectively, with 
overall claims costs are considered for all decedent beneficiaries. The geographic 
distribution of deaths (derived from the postal code details contained in the 
demographic data) are also investigated in some detail. 
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 Further, the geographic analysis considers the claims experience of beneficiaries 
given that they are classified as having lived in either ‘urban’ or ‘rural’ areas, 
respectively. A report by Statistics South Africa notes the difficulties in defining 
‘urban’ vs ‘rural’ and highlights various methodologies that may be employed, and the 
vastly different results using different definitions and approaches (StatsSA 2003). One 
approach to defining the split is based on population size and population density in 
particular areas. For purposes of these analyses, the split between ‘urban’ and ‘rural’ 
was done on a pragmatic basis using number of deaths per area as a proxy for 
population size/density. Any area (by postal code) that experienced 100 or more deaths 
during 2016 and 2017 (from the sample of decedent beneficiaries) is classified as being 
an ‘urbanised’ area and the rest (less than 100 deaths) are classified as being ‘rural’ 
areas. Further research is required to classify locations as ‘urban’ or ‘rural’ based on a 
more robust metrics, (e.g. distance to nearest metropole or private hospital, 
infrastructure in the particular area, etc.), but this is beyond the scope of this research 
project. 
Claim patterns are constructed at various proximities to death (two and four 
weeks, three, six, twelve and 24 months, respectively) to investigate how claims 
develop as death for the beneficiaries in the sample draws nearer. In Section 2, the 
problems with using time-based definitions of dying were considered as well as the 
usefulness of such definitions, especially when only retrospective data are available 
(as is the case here). 
In a later subsection, these overall claim patterns and characteristics are also 
considered for the various trajectories of dying as well as for beneficiaries dying in- or 
out-of-hospital, respectively. Only the experience for lives who were beneficiaries on 
the scheme for the full 24-month period leading up to their deaths are considered in 
the analysis of the overall claims patterns. The methodology followed and the results 
of the analyses for decedent beneficiaries with only partial exposure are given in 
Sections 5.5.3 and 6.3, respectively. 
A brief look is also taken at the distribution of claims excluding the tails of the 
distribution (the bottom and top ten, twenty, thirty and forty per cent tails of the 
distribution, respectively) to gauge the effect on average (and median) claim amounts 
of beneficiaries with higher than average claims. The trimming of the data for this 
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purpose is done on a pragmatic basis as this sufficiently highlights the effect of these 
beneficiaries on average claims, and thus the employing of more robust trimming 
techniques are beyond the scope of this research project.  
 
5.5.2 Place of death 
Death in-hospital and the factors associated therewith, and the costs of care in-hospital 
for the sample of decedent beneficiaries are considered. These are compared to the 
costs for those who died out-of-hospital. Special consideration is given to the 
utilisation of hospice care (which is considered to be an indicator of good quality care 
and an indicator of receiving palliative care near the end of life) and the association 
between hospice use and overall claims and the likelihood of eventual death in-
hospital. Consideration is given to lives having any hospice-related claims in the last 
24 months of life, as well as to lives having hospice-related claims during their last 
four weeks of life – when death is imminent. 
The number of hospitalisations and the number of days spent in-hospital for 
beneficiaries utilising hospice services are also considered and compared to the 
experience of those who had received no hospice-related care leading up to their 
deaths. 
 
5.5.3 Analysis of lives with partial exposure 
Some decedents in the sample were not scheme beneficiaries for the full 24-month 
period. They were either new joiners, or had gaps in their coverage – lapsed and 
subsequently reinstated their cover during their last 24 months of life. Their claims 
costs are analysed separately to determine whether the profile and the experience of 
these beneficiaries differed significantly from that of scheme beneficiaries who were 
on the scheme for longer than the full 24-month period under investigation. This may 
indicate whether these lives selected against the medical scheme in becoming scheme 
members/beneficiaries. 
 
5.5.4 Ageing populations, lifestyles and chronic non-communicable diseases 
The impact and cost implications of chronic non-communicable conditions and multi-
morbidity are important given the increasing incidence and prevalence thereof in 
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medical scheme risk pools (Govuzela, Thsehla and de Villiers 2018). These are briefly 
investigated from the information contained in the administrative claims and chronic 
authorisation data.  
The chronic file contains details of the chronic condition authorisations for each 
decedent beneficiary in the sample. In the analyses these conditions are grouped into 
main chronic illness groups, predominantly driven by the bodily systems or organs 
they affect, e.g. the heart, the lungs, the endocrine system, etc. ‘Cancer10’ is a special 
group that covers all cancer authorisations for all bodily systems and organs. 
‘Hypertension’ and ‘hyperlipidaemia’, which aren’t diseases as such, but conditions 
that are major risk factors for the development of chronic heart diseases are included 
in the ‘chronic heart disease’ category. In South Africa, the legislated CDL includes 
full payment at the point of service for the treatment and management of hypertension 
and hyperlipidaemia. It is thus sensible to consider these as chronic conditions/diseases 
(of the heart) for purposes of this part of the analyses. 
 Less prevalent diagnosis groups included those for chronic liver illness, chronic 
skin conditions, haematological conditions (excluding cancer related to the blood or 
blood-forming organs), immunological conditions (excluding HIV) and chronic 
prostate conditions. Together these groups affect only six per cent of the total sample 
and are grouped together in a group called ‘OTHER chronic conditions’.  
Certain diseases of the central nervous system and musculoskeletal systems 
provided some difficulty in grouping them into their respective groups since a disease 
of the nervous system often manifests as a musculoskeletal deficiency, e.g. cerebral 
palsy or muscle dystrophy. However, the overall prevalence of these two groups of 
conditions, combined, total only five per cent of the overall prevalence of chronic 
conditions. The bulk of these conditions being musculoskeletal conditions, i.e. the 
various forms of arthritis. Given the relatively low prevalence of these conditions, the 
impact of grouping these as either musculoskeletal disorders or nervous system 
disorders has no material impact on the results of the investigation. The majority of 
                                                          
10 In the data, for the sample of decedent beneficiaries, “Cancer” is recorded as a chronic condition, 
and is treated as such for the analyses in this subsection. This is despite some cancers being 
curable/treatable. In the next subsection, where “cancer” is deemed to be the most likely cause of 
death, it is considered as one of the main trajectories of dying. 
70 
 
these ambiguous conditions are included with musculoskeletal conditions. For a 
number of other chronic illnesses similar difficulties were experienced and these are 
pragmatically grouped under a sensible category based on the bodily system or organ 
they predominantly affect, e.g. dementia is grouped as a condition affecting the brain, 
and schizophrenia is grouped as a mental health condition, etc.  
 
5.5.5 Trajectories of dying 
Following the high-level demographic and claims analyses, above, the decedent 
beneficiaries are then segmented into the main trajectories of dying to analyse their 
end-of-life care costs based on their particular trajectory of dying. Differences between 
the profiles of the lives and claim patterns given each respective trajectory are 
investigated. The methodology used by Lunney, Lynn and Hogan (2002) which 
involves a sequential analysis and allocation of a sample of Medicare decedents into 
the various trajectories of dying, is also broadly followed here. Given the nature of the 
data used in this research project (retrospective claims data of medical scheme 
beneficiaries who have died), no information on the beneficiaries’ functional status or 
the decline in functional status over time, their symptom burden or the doctor’s 
prognoses leading up to death are directly available or measurable. However, broad 
trajectories of dying (e.g. “Sudden death”, “Cancer”, “Organ failure” and “General 
frailty”) can be analysed based on the observed level of healthcare spending and based 
on the diagnoses and episodes of care respective beneficiaries experienced during their 
last year of life. These trajectories are illustrated in Figure 5.5.5.1, below, plotting 
individuals’ health or functional status against time, eventually culminating in death, 




Figure 5.5.5.1 – Trajectories of dying 
 
11 Lunney, Lynn and Hogan (2002) 
 
Lunney, Lynn and Hogan (2002) classifies those decedents having claims of less than 
$2000USD and being younger than eighty as belonging to the “Sudden death” 
trajectory. This amount was converted to 2017-ZAR-terms using the methodology 
described by Turner, Lauer, Tran, Teerawattananon et al. (2019), i.e. first converting 
to ZAR-terms at the 31 December 2002 USD/ZAR-exchange rate and then inflating it 
to 1 January 2017 using the headline South African inflation index (StatsSA 2019). 
This came to an amount of approximately R36 000. Medicare only covers persons aged 
65 and older, and medical schemes cover lives of all ages (i.e. 35 per cent of all deaths 
in the sample are beneficiaries younger than 65 years). Given this, and given that 
medical costs generally increase with age as a result of increasing chronicity (Yu, 
Ravelo, Wagner and Barnett 2004), the threshold for sudden deaths was set, 
pragmatically, at R24 000. This amounts to an average of R2 000 per month during 
the last year of life. A further reason for reducing the threshold is due to frail care and 
home nursing care being specific medical scheme exclusions, and frail beneficiaries 
who had died at older ages with relatively low average claims would then erroneously 
                                                          
11 Lunney, J.R., Lynn, J., and Hogan, C. (2002). Profiles of older medicare decedents. Journal of the 
American Geriatrics Society 50(6): 1108-1112.  
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be classified as “Sudden deaths”. ‘Sudden death’ as defined here is intended only for 
‘accidental’ and/or ‘unanticipated’ deaths of beneficiaries that had a low level of 
medical scheme claims during their last year of life. 
Given that the exact cause of death for decedent beneficiaries are not available 
from the claims data, akin to the study on which this methodology is based, a similar 
approach is followed whereby the assigned episodes of care and ICD-10 codes are 
analysed to determine the most costly episode/ICD-10 combination for each 
beneficiary. The most likely cause of death is inferred from this and the beneficiary is 
allocated to the appropriate trajectory of dying based hereon. Following this 
methodology (based only on most costly episode/ICD-10 combinations) may result in 
some beneficiaries being incorrectly classified into the respective trajectories of dying. 
However, on average, this approach results in a reasonable allocation of beneficiaries 
to particular trajectories of dying. Appendix 1 contains an extract of the episodes of 
care and ICD-10 combinations used to classify beneficiaries into the particular 
trajectories of dying. 
After decedent beneficiaries are allocated to the “Sudden death” trajectory as per 
the above methodology, the “Cancer” trajectory allocation is performed. If the most 
costly episode of care/ICD-10 combination is cancer-related, then the beneficiary is 
assigned to the “Cancer” trajectory. 
Next, beneficiaries are assigned to the “Organ failure” trajectory. Beneficiaries 
falling into this trajectory had dominant episodes of care and accompanying ICD-10 
coding related to specifically either of heart, respiratory, renal or hepatic (liver) failure. 
For the final trajectory, “General frailty”, Lunney, Lynn and Hogan (2002) 
allocates those with the following diagnoses: stroke, Alzheimer’s disease, dementia, 
pneumonia, Parkinson’s disease, incontinence, dehydration, delirium, hip fractures, 
syncope and cellulitis. Similar episodes of care and diagnoses were used for this 
sample of decedents, including more generalised heart, respiratory, and other organ 
diseases, i.e. not specific ‘failure’ of these organs, as well as mental health conditions. 
Furthermore, lives younger than fifty were removed and included in the “Other” group 
as they are unlikely to be generally ‘frail’. 
The remainder of the beneficiaries are grouped into the “Other” group. These are 
beneficiaries younger than fifty who aren’t grouped into any of the “Sudden death”, 
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“Cancer” or “Organ failure” groups, those for whom no episode of care/ICD-10 code 
are assigned or where the dominant episode of care/ICD-10 combinations are unlikely 
causes of death, e.g. conditions related to ears, eyes, skin, teeth, etc. The “Other” group 
also contains episodes related to pregnancy and childbirth, claims from trauma-related 
episodes as well as those related to acute infections. Given the different set of lives 
considered in the Medicare study, there would not have been any pregnancy and 
childbirth-related deaths in their dataset (i.e. only lives aged 65 and above are covered 
by Medicare). 
 
5.5.6 Decedent beneficiaries with high end-of-life care costs 
The demographic profile and claims experience of the highest claiming lives (in terms 
of overall claim amount over the last 24 months of life) are considered. These are the 
lives that predominantly drive the high overall average claims costs observed near the 
end of life for medical schemes. Their demographic profile, trajectories of dying, place 
of death and overall claims profiles are considered in some detail to understand the 
drivers of their high observed costs when compared to the experience of the overall 
sample of decedent beneficiaries. 
 
5.5.7 Measuring the quality of care near the end of life 
Potential indicators of the quality of care near the end of life that can be measured from 
the administrative claims data are briefly evaluated and measured. The measurable 
indicators are: death in-hospital, the number of days spent in-hospital, receiving 
chemotherapy near the end of life and the utilisation of hospice care services near the 
end of life.   
Details surrounding hospitalisations over the course of the last 24 months of life 
for the sample of scheme beneficiaries are contained in the ‘Events’ file. Each event 
of duration longer than one day (i.e. where the discharge date is at least one day after 
the admit date) for lives with full exposure is considered as a hospitalisation. 
Chemotherapy and/or initialising a new chemotherapy treatment regimen near 
the end of life are considered to be indicators of poor quality of care near the end of 
life (Earle et al. 2003). The last two weeks and four weeks of life, respectively, are 
considered here as being ‘near’ the end of life. The claims data contain the service date 
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for all claim lines and this date is used to determine the length of time between the last 
time chemotherapy was administered and the date of death. The claims data contains 
a field that gives the procedure codes and their descriptions. The dates associated with 
procedure codes for the administering of infusional or non-infusional chemotherapy 
(i.e. the daily global fee for the administering of chemotherapy) are compared to the 
date of death for individual beneficiaries.  
Next, hospice utilisation near the end of life is considered. Dates of hospice-
related claims are compared to the date of death to determine the proximity of hospice 
utilisation to death. It is important to note that ad hoc billing processes of hospices may 
result in billing errors or even non-billing for hospice services utilised by scheme 
beneficiaries. Potential billing errors made by providers can be seen when considering 
the number of beneficiaries that have service dates for claims recorded after their date 
of death (ninety of the 1 219 (or 7.4 per cent) beneficiaries that had utilised some billed 
hospice services). To be pragmatic, it is assumed that all hospice claims after death 
occurred on the date of death. Knowing that there may be errors in the hospice claims 
data impedes on determining exactly how long prior to death these beneficiaries had 
enrolled for hospice care, and up until which point they received hospice care. 
However, interesting insights can still be gleaned from the analyses of hospice 
enrolment and the utilisation of hospice services. 
The literature frequently refers to seven days as being an indicator for late 
hospice enrolment and that three months prior to death is a desirable benchmark for 
enrolment (Diamond, Russell, Kryza-Lacombe, Bowles et al. 2015; Wang, Knight, 
Evans, Wang et al. 2017; Mulville, Widick and Makani 2019). Given the uncertainty 
about hospice billing and potential errors, looking at the last seven days of life, only, 
is spurious. However, looking at longer periods, two and four weeks, and three months, 
respectively, gives a better idea of who may have enrolled late for hospice care, or at 
least who had not enrolled more than three months before death (earlier enrolment is 
desirable). Also, note that disenrollment from hospice care can also not be measured 
from the data. Some decedent beneficiaries may have received hospice-related services 
more than three months before death, but may have opted for hospital-based care at a 
later stage, potentially stopping hospice care and not benefiting from hospice services 
75 
 
anymore. The results of the analyses into measurable indicators of quality of care near 
the end of life are discussed in Section 7.7. 
 The results of all the analyses described above are presented in Section 6, next. 
The interpretation of the results and a discussion on the practical implications of these 
results for the medical schemes industry in South Africa follows in Section 7.  




6 Data analyses and presentation of the results 
The analyses and results that follow are divided into seven main subsections, as set out 
in the methodology, above.   
 
6.1 Demographic profile and overall claims patterns of decedent beneficiaries  
High-level summary statistics of the demographic profile of the decedent beneficiaries 
were given in Section 5.5. Next, the overall claims patterns of the decedent 
beneficiaries are considered 
 All claim amounts in this research project are stated in 2017 ZAR-terms having 
been adjusted by the weighted average medical scheme tariff increases as reported by 
the Council of Medical Schemes. The overall claims analyses for lives with full 
exposure are presented in this subsection. Of the 24 980 deaths, 21 457 (or 86 per cent) 
were scheme beneficiaries for the full 24-month period. However, given that the 
number of lives with less than full exposure is significant – fourteen per cent of 
decedents (3 523 lives) – their claims are analysed separately in Section 6.3. The 
reason for this is to investigate whether there are any apparent signs of anti-selection 
given that voluntary and open enrolment, and community rating are legislated. 
Furthermore, medical schemes may only perform limited underwriting on new joiners 
to their schemes. Neonates (died aged 28 days or younger) accounted for 1.1 per cent 
(284 lives) of all decedents and child decedents aged younger than two years, 
excluding neonates, accounted for a further 1.6 per cent (404 lives) of all decedents.  
Figure 6.1.1, below, shows the average claim amount over the last 24 months of 













Figure 6.1.1 – Average claims over the last 24m of life given age band at death 
 
 
From Figure 6.1.1, it can be seen that claims costs over the last 24 months of life peak 
for beneficiaries between the ages of 55 and 75, before rapidly decreasing at more 
advanced ages. Note that all neonates and children under two years are excluded as 
they did not contribute full exposure during the period. The overall average claims 
over the last 24 months of life for those with full exposure is approximately R480 000 
(in 2017 ZAR-terms). 
 The distribution of claims by age band at proximities to death shorter than the 
full 24-month period (i.e. at two and four weeks, and three, six and twelve months to 
death, respectively), exhibit a similar pattern to that observed in Figure 6.1.1. The 
analyses performed in the next subsection (Section 6.1.1) considers the cumulative 
claims for decedent beneficiaries at these proximities to death. 
Table 6.1.1, below, illustrates the overall claims costs for males vs females at 









Table 6.1.1 – Average cost by proximity to death – split by sex 
 
Average male cost (R) – 
per beneficiary 
Average female cost (R) – 
per beneficiary 
2w                      89 000                           80 000  
4w                    137 000                         122 000  
3m                    232 000                         209 000  
6m                    292 000                         272 000  
12m                    375 000                         351 000 
24m                    494 000                         464 000 
 
It can be seen that males, on average, experience higher claims than females at all 
proximities to death. To confirm this, the null hypotheses that average claims for males 
are equal to that of females are tested at the various proximities to death. The null 
hypotheses are rejected unequivocally with all p-values ~0. Z-tests were used given 
the sample sizes of greater than thirty and ratios of variances between 0.5 and two (i.e. 
making it reasonable to assume equal sample variances).  
Table 6.1.2, below, shows the standard deviations and lower- and upper bounds 
of the 95 per cent confidence intervals using a Student’s t-distribution at the various 
proximities to death for males and females, respectively. 
 
Table 6.1.2 – Standard deviation and confidence interval bounds: Males vs Females 




















2w  146 000  87 000       92 000  123 000  78 000         83 000  
4w 220 000       133 000  141 000  190 000  118 000  126 000  
3m 367 000  225 000       239 000  325 000       203 000       216 000 
6m 435 000        284 000       300 000  421 000       263 000       280 000  
12m   530 000      366 000       385 000   505 000      341 000       360 000  
24m   637 000      482 000       505 000  609 000      452 000      476 000  
 
Given the different age profiles of male and female decedent beneficiaries, it is 
worthwhile to consider the average claims cost for males and females in their 






Figure 6.1.2 – Average claims over the last 24 months given sex and age band at death 
 
     
It is interesting to observe the overall claim patterns over the last 24 months for males 
and females in their respective age bands. Except for the age band 0-4 (which had low 
numbers of deaths for both males and females), females, on average, experience 
consistently higher claims than males up until age 65. From age 65, onwards, except 
for the band 100-104 (again, very low numbers of deaths), males experience 
consistently, albeit less pronounced, higher claims than females. At all proximities to 
death, a similar pattern is observed. To confirm this, statistically, null hypotheses that 
claims are equal for males and females younger, and older than 65 years, respectively, 
are tested at the various proximities to death. Except for lives younger than 65 during 
their last two weeks of life (rejected at two per cent-level), the null hypotheses are 
unequivocally rejected at the one per cent level. Thus, females experience higher 
medical scheme claims than males at the various proximities to death if they are 
younger than 65 years old and conversely, males experience higher medical scheme 
claims than females after the age of 65.  
Table 6.1.3, below, shows the standard deviations and lower- and upper bounds 
of the 95 per cent confidence intervals using a Student’s t-distribution at the various 





Table 6.1.3 - Standard deviation and confidence interval bounds: Males vs Females (younger 
and older than 65, respectively 




















2w 160 000         87 000      96 000   146 000      94 000  104 000  
4w  242 000     130 000        144 000   228 000       142 000       158 000  
3m  415 000       219 000       244 000   385 000       243 000       270 000  
6m  503 000       282 000      312 000  491 000       319 000      354 000 
12m  623 000       360 000       398 000  611 000    425 000  468 000 
24m  728 000     463 000    507 000  800 000       567 000       623 000  
  Male (>=65) - Count: 7 243 Female (>=65) - Count: 6 852 
2w  138 000       85 000       91 000   109 000       69 000         74 000  
4w 206 000      132 000       142 000 168 000    105 000      113 000  
3m 336 000     225 000    240 000   290 000    181 000     195 000  
6m 390 000       280 000       298 000   381 000     233 000     251 000  
12m 467 000    363 000     384 000   441 000       297 000       317 000  
24m 577 000       485 000     512 000   486 000      393 000      416 000  
 
Next, the geographic distribution of all decedent beneficiaries in the sample are 
considered (including those with partial exposure). Figure 6.1.3 illustrates the 
proportion of overall deaths across the nine provinces of South Africa.  
 




Figure 6.1.3 shows that deaths are concentrated predominantly in provinces with large 
urban areas, i.e. Gauteng (Johannesburg and Pretoria), Western Cape (Cape Town) and 
Kwazulu-Natal (Durban). 
Almost half of the deaths occurred in Gauteng, and, on average, the Gauteng 
decedent beneficiaries experienced the highest average claims over the last 24 months 
of life. The Northern Cape experienced the lowest number of deaths as well as the 
lowest average claim costs per decedent beneficiary.  Figure 6.1.4 illustrates a more 
granular distribution of deaths across the country in the form of a heat map based on 
the postal codes recorded for individual decedent beneficiaries in the sample. 
 
Figure 6.1.4 – Location of death heat map 
 
 
The heat map above clearly shows the concentration of deaths in the more urbanised 
areas of the provinces with the largest number of deaths (red blotches), e.g. 
Johannesburg, Cape Town and Durban, and the low concentration of deaths in more 
rural areas (areas with no blotches or scattered blue spots), particularly in the Northern 
Cape Province.  
Table 6.1.4 highlights a pragmatic split between ‘urban’ and ‘rural’ areas and 





Table 6.1.4 – Urban vs rural split 
 Count Average claims cost (R) – 
per beneficiary 
Standard deviation (R) 
– per beneficiary 
Urban 17 215 489 000 648 000 
Rural 7 725 410 000 551 000 
Total 24 980 464 000 626 000 
 
An area is considered ‘urban’ here if it experienced 100 or more deaths. This is a 
pragmatic distinction between ‘urban’ and ‘rural’, used only to illustrate the difference 
in average claims per decedent beneficiary based on the relative size of the area 
(measured by the number of deaths in the particular area, where an ‘area’ is represented 
by its postal code). Given the high-level split between ‘urban and ‘rural’, 
approximately 69 per cent of decedent beneficiaries resided in an urbanised area. This 
split between ‘urban’ and ‘rural’ is similar in magnitude to that found in report 
produced by Statistics South Africa (68.5 per cent) in which urbanity is defined by 
population size and population density in the particular areas (StatsSA 2003).   
The null hypothesis that average claims costs for ‘rural’ and ‘urban’ areas are 
equal is rejected for the alternative hypothesis that ‘urban’ areas experience higher 
average claims costs per decedent beneficiary with a p-value of ~0. The null hypothesis 
was tested using a standard z-test given that the sample sizes are large enough (greater 
than thirty) and the ratio of the variances lie between 0.5 and two (1.38).  
Table 6.1.5, below, shows the lower and upper 95% confidence interval bounds 
for average claims in urban and rural areas, respectively, using a Student’s t-
distribution of claim sizes. 
 





CI bound (R) 
Upper 95% 
CI bound (R) 
Urban 648 000      479 000       499 000  
Rural   551 000      397 000      422 000  
 
It can be concluded that the average overall claims are higher in the more urbanised 
areas (given the high-level distinction between what is classified as ‘urban’ and what 
is classified as ‘rural’). Beneficiaries residing in more urbanised areas also experienced 
a greater standard deviation in overall claims over their last 24 months of life. This 
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could be indicative of those residing in more urbanised areas having a greater number 
of care options (and more expensive care options) available to them near their end of 
life as compared to those residing in areas that are more ‘rural’. 
 
6.1.1 Claims by proximity to death 
Total, average and median claim amounts at various proximities to death (i.e. all the 
claims in the last x-period before death) for lives with full exposure are given in table 
6.1.1.1, below.  
 







(R) – per beneficiary 
Median claims 
(R) - per beneficiary 
2w 1 827 18% 85 000 45 000 
4w 2 793 27% 130 000 62 000 
3m 4 754 46% 222 000 111 000 
6m 6 064 59% 283 000 153 000 
12m 7 808 76% 364 000 210 000 
24m 10 297 100% 480 000 290 000 
 
As can be seen from the Table 6.1.1.1, the total claims during the last 24 months of 
life for the 21 457 beneficiaries that had full exposure amount to around R10.3bn. 46 
per cent of this is spent in the final three months of life and 27 per cent in the last four 
weeks of life. Another way to consider this is to look at the average cost of medical 
care per day given the proximity to death. This is given in Table 6.1.1.2, below.  
  
Table 6.1.1.2 Claims cost per day – Proximity to death 
Proximity 
to death 
Average cost per day 
(R) – per beneficiary 
Median cost per day 
(R) – per beneficiary 
2w                6 082                    3 204  
4w                    4 984                   2 218  
3m                    2 435                    1 224  
6m                1 553                       838  
12m                   996  576  
24m                       657  397  
 
Average claims cost per day over the last 24 months of life are around R660 per person 
per day vs during the last two weeks of life, the average cost is nearly ten times higher 
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at around R6 000 per person per day. This is across all decedent beneficiaries, at all 
ages and from all causes. At the various proximities to death, it can also be seen that 
there is a significant discrepancy between the size of the average claim costs and the 
median claim costs per day. This indicates that there is large variation in total claims 
around the mean for the decedent beneficiaries.  
 Figure 6.1.1.1 illustrates the distribution of total claims by proximity to death 
(two weeks to 24 months) by deciles of the distribution. The 5th, 95th and 99th 
percentiles are also included to give a more complete picture at the extremes of the 
distributions. 
 
Figure 6.1.1.1 – Average claims build up by proximity to death - Percentiles of distribution 
 
 
From Figure 6.1.1.1, it can be seen that, at all proximities to death, the bottom thirty 
per cent of beneficiaries claim significantly less compared to the total claims of the top 
thirty per cent of beneficiaries. The 100th percentile of the distribution has been 
excluded from the figure as the maximum claims at each proximity is very high 
(relative to even the 99th percentile) and distorts the graph significantly. The top one 
per cent of claimants claimed almost ten per cent of the overall claims for all the 
decedent beneficiaries over the last 24 months of life. The top ten per cent claimed 39 
per cent of overall claims and the top thirty per cent claimed 71 per cent of overall 
claims. The bottom fifty per cent of claimants only claimed twelve per cent of the 
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overall claims in the last 24 months of life, and the bottom ten per cent almost none 
compared to the top claimants. 
Table 6.1.1.3, below, illustrates the cumulative proportion of overall claims at 
various proximities to death, highlighting the skewed distribution of claims towards 
the high claimants at the end of life. 
 
Table 6.1.1.3 – Distribution of high and low claimers 
  
Proportion of overall claims by proximity to death: Top and bottom 
ends of distribution  
Percentile 2w 4w 3m 6m 12m 24m 
Top 1% 9% 9% 10% 10% 10% 9% 
Top 5% 29% 30% 31% 29% 27% 25% 
Top 10% 45% 46% 46% 44% 42% 39% 
Top 20% 65% 67% 65% 63% 61% 58% 
Top 30% 78% 79% 78% 76% 74% 71% 
Top 40% 87% 88% 86% 85% 83% 81% 
Top 50% 93% 93% 92% 91% 90% 88% 
Bottom 5% 0% 0% 0% 0% 0% 0% 
Bottom 10% 0% 0% 0% 0% 0% 0% 
Bottom 20% 0% 0% 0% 1% 1% 1% 
Bottom 30% 1% 1% 2% 2% 3% 3% 
Bottom 40% 3% 3% 4% 5% 6% 7% 
Bottom 50% 7% 7% 8% 9% 10% 12% 
  
From this distribution it can be seen that end-of-life medical care, on average, is very 
expensive, but that it is a reasonably small number of very high claiming decedent 
beneficiaries that drive the majority of these costs.  
Figure 6.1.1.2, below, shows the cumulative distribution of claims by decile 








Figure 6.1.1.2 – Percentage of overall claims by proximity to death – Percentiles of distribution 
 
From figure 6.1.1.2 it can be seen that the low claimants (bottom thirty per cent) have 
relatively low levels of claims near their date of death (two weeks up to even twelve 
months) with 40-55 per cent (depending on relative claim level – i.e. percentile of the 
distribution) of claims occurring between twelve and 24 months prior to death. For 
high claimants (top thirty per cent), almost twenty per cent of claims occur in the last 
two weeks of life and roughly fifty per cent in the last three months of life, with only 
fifteen to 25 per cent of their claims being between twelve and 24 months prior to 
death. 
A relatively small proportion of decedent beneficiaries drive the observed high 
level of average medical scheme claim costs near the end of life. The majority of 
decedent beneficiaries (bottom fifty per cent) claim only slightly more (twelve per cent 
of overall claims) than the top one per cent (nine per cent of overall claims) of claimers. 
The top thirty per cent of claimers are considered in further detail in this Section 6.6 
to identify the main factors associated with their claims experience, e.g. age, sex, 
trajectory of dying, number and length of hospitalisations, place of death and the 







6.1.2 Truncated distributions 
The analysis, so far, has been performed looking at the full distribution of lives with 
full exposure, thus including all outliers. Figure 6.1.2.1, below, details the average 
claims per decedent beneficiary (at the various proximities to death) for the overall 
and truncated distributions.  
 
Figure 6.1.2.1 –Distribution of average claims by proximity to death – truncated distributions 
 
 
As can be seen from Figure 6.1.2.1, excluding a step-wise increasing tail, decreases 
the average claim amount at all proximities to death. The average claim costs seem to 
stabilise at around the thirty per cent level, emphasising the importance of 
investigating and better understanding the claims experience of the top thirty per cent 
of claimers – explored in Section 6.6. The trimming is done pragmatically as this 
sufficiently highlights the impact of outliers on average claim amounts at all 
proximities to death. 
 
6.1.3 Claims by provider type 
Table 6.1.3.1 highlights the total proportion of claims for the top ten provider types at 




Table 6.1.3.1 – Claims by practice type 
Practice type (Top 10) 2w 4w 3m 6m 12m 24m 
Private hospitals 56% 57% 57% 54% 51% 48% 
Pharmacy 1% 2% 3% 5% 7% 9% 
Radiologist 5% 5% 5% 5% 5% 6% 
Clinical Pathologist 6% 6% 5% 5% 5% 5% 
Physicians 5% 5% 5% 4% 4% 4% 
Blood transfusion 6% 6% 5% 4% 4% 4% 
Clinical or Medical 
technology 4% 3% 3% 3% 3% 3% 
Radiotherapist 1% 1% 1% 2% 2% 3% 
Anaesthetist 3% 2% 2% 2% 2% 2% 
Surgeon 2% 2% 2% 2% 2% 2% 
Total  88% 88% 87% 87% 86% 85% 
 
The majority of claims costs (48-56 per cent of overall claims) over the last 24 months 
of life are the costs of private hospital care (including one per cent of overall claims in 
sub-acute facilities). Note that the claims for specifically hospital providers do not 
represent the full quantum of claims incurred by beneficiaries in-hospital. Other 
providers, e.g. specialists, bill separately for services they render to hospitalised 
beneficiaries.  
The proportion of overall claims billed by private hospitals, specifically, increases 
as death draws nearer. At 24 months, pharmacies are the next most utilised providers 
(in terms of cost) – nine per cent of total claims. The proportion of claims from 
pharmacies (relative to other practice types) decrease as death becomes imminent 
(down to one per cent during the last two weeks of life). Blood transfusion and medical 
technology (e.g. dialysis) account for around ten per cent of total claims and there is 
an increasing utilisation (in terms of cost) as death draws nearer. Pathology accounts 
for around five to six per cent of claims, slightly increasing with increasing imminence 
of death. The bulk of the remaining expenditure (around twenty per cent) are for 
various specialists, mainly radiologists, physicians, radiotherapists and anaesthetists. 
The remaining five per cent of overall claims are spread between auxiliary healthcare 
professionals and all the other provider types.    
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6.2 Place of death  
For beneficiaries in the sample with full exposure, sixty per cent died in-hospital. 
Figure 6.2.1, below, illustrates the place of death for lives with full exposure given 
their age band at death in five-year intervals. 
 
Figure 6.2.1 – Number of deaths by age band and place of death 
 
 
It can be seen from Figure 6.2.1 that as age increases (at the advanced ages), the 
proportion of deaths out-of-hospital increases – at ages 70-74 the proportion is 35 per 
cent and this steadily increases to around seventy per cent at ages 100-104 (bearing in 
mind the low exposure at these advanced ages).  
Figure 6.2.2, below, illustrates the average claims for decedent beneficiaries over 












Figure 6.2.2 – Average claims by place of death and age band 
 
 
From Figure 6.2.2 it can be seen that dying in-hospital is consistently more expensive 
than dying out-of-hospital, and that for both in- and out-of-hospital deaths, average 
claims costs increase with increasing age, and eventually decreases at more extreme 
ages (75 and above). 
Average costs over the last 24 months of life for those who died in-hospital 
amounted to around R613 000 per beneficiary whereas the costs for those that died 
out-of-hospital amounted to around R295 000 per beneficiary. This means, all else 
being equal, that beneficiaries dying in-hospital experience claims that are at least two 
times higher, on average, than the claims for beneficiaries dying out-of-hospital. Table 
6.2.1, below, shows the average cost per beneficiary dying in- and out-of-hospital, 
respectively, at the various proximities to death. 
 
Table 6.2.1– Average claims by place of death 
Proximity 
to death 
Average cost (R) – 
per beneficiary 
(died in-hospital) 






2w 136 000  18 000  7.38  66% 
4w 202 000  33 000  6.06  63% 
3m 321 000  86 000 3.73  61% 
6m 392 000  133 000 2.96  60% 
12m 485 000  197 000 2.46  60% 




From Table 6.2.1 it is interesting to note the relative costs in the last two weeks, four 
weeks and three months of life, respectively. First, those who had claims during their 
last two weeks of life experienced a greater likelihood of eventual death in hospital 
(66 per cent) as compared to someone claiming three months from death (61 per cent). 
Second, the average claims for those dying in-hospital increase significantly 
relative to the costs for the average beneficiary that died out-of-hospital as death draws 
nearer. From a multiple of two times during the last 24 months of life to a multiple of 
more than seven times during the last two weeks of life. This may mean that a 
significant number of those beneficiaries who died out-of-hospital also experienced 
relatively high claims due to intensive and/or curative interventions in-hospital at such 
a time before death was clearly imminent, i.e. when their death was three or more 
months away. Note that this effect will be somewhat muted if beneficiaries who had 
died suddenly/unexpectedly are excluded from the above.  
For the various proximities to death considered, testing the null hypotheses that 
claims costs for beneficiaries who had died in-hospital are equal to that of beneficiaries 
who had died out-of-hospital results in them being rejected for the alternative 
hypotheses that those who died out-of-hospital experienced lower overall claims. The 
p-values are ~0 at each of the proximities to death. Welch’s t-tests are used to test these 
hypotheses given the large ratios between the variances (greater than two) for those 
who died in- and out-of-hospital, respectively, at each proximity to death.  
Table 6.2.2, below, shows the standard deviation and lower- and upper bounds 
(at 95 per cent confidence) of the average claims costs given place of death at the 











Table 6.2.2 – Standard deviation and confidence intervals – Place of death 




















2w  156 000    133 000       138 000    45 000        17 000         19 000  
4w 239 000     197 000     206 000   71 000         32 000          35 000  
3m  404 000      314 000     328 000  167 000       82 000          90 000  
6m  494 000      384 000       401 000 239 000    127 000       138 000  
12m  593 000      475 000      496 000  315 000    190 000       204 000  
24m  708 000       601 000    626 000  411 000       286 000       304 000  
 
Irrespective of whether a beneficiary died in- or out-of-hospital, table 6.2.3 highlights 
the total claims for procedures/treatments that were performed in-hospital by 
proximity to death. Only lives with full 24 months exposure are considered here. 
 







2w 1 827  94% 
4w 2 793  93% 
3m 4 754  89% 
6m 6 064  85% 
12m 7 808  80% 
24m 10 297  75% 
 
As can be seen from Table 6.2.3, a significant proportion of claims result from 
treatments/procedures performed in-hospital – upwards of 75 per cent of all claims in 
the last 24 months of life. As death draws nears, the claims in-hospital as a proportion 
of total claims increase to 94 per cent of total claims in the last two weeks of life, 
irrespective of whether death occurred in- or out-of-hospital. When considering deaths 
that occurred in-hospital, 96 per cent of claims in the last two weeks of life were for 
procedures or treatments in-hospital (compared to 68 per cent for lives that died out-
of-hospital). Over the last 24 months of life, 79 per cent of total claims for lives that 
died in-hospital were for treatments and procedures in-hospital (compared to 63 per 





6.2.1 Hospice utilisation 
Hospice utilisation (in terms of overall claims cost of the sample of decedents) is 0.19 
per cent (during the last 24 months of life) and increases to 0.37 per cent of overall 
cost (during the last two weeks of life). Below the utilisation of hospice services by 
the sample of decedents are explored in further detail. 
Of the 24 980 decedent beneficiaries in the sample, a total of 1 219 (or 4.9 per 
cent) had utilised some hospice services during their last 24 months of life. Looking at 
lives with full exposure only, 1 176 (or 5.5 per cent) of the 21 457 decedent 
beneficiaries utilised hospice services. The average age at death of these beneficiaries 
is 69 years (higher than the overall average age of all decedents – 64 years), with a 
median age at death of 70 years (the same as the overall median age). Half of the 
hospice users were male. Of the beneficiaries utilising hospice services, 94 per cent 
had a registered chronic condition. Hospice utilisation for deaths occurring in 2017 
was around twenty per cent greater than for deaths occurring in 2016, but given the 
small number of beneficiaries utilising hospice services, this may just be due to random 
variation between the two calendar years, or may be due to changes in hospice billing 
practices. This may also be as a result of a trend towards more hospice utilisation by 
medical scheme beneficiaries, but a two-year period is too short to confirm this. The 
below analyses focus only on lives with full exposure over the 24-month period prior 
to death. It is important to note that the following analyses may be skewed due to non-
billing or non-submission of hospice-related claims and should be interpreted with 
caution. 
Beneficiaries that had used some hospice services in their last 24 months of life 
were less likely, overall, to die in-hospital – thirty per cent vs sixty per cent of deaths 
occurred in hospital, respectively. Furthermore, beneficiaries that had utilised some 
hospice services during their last four weeks of life were even less likely to die in 
hospital – only 25 per cent of these beneficiaries died in hospital.  
The claims experience for beneficiaries that had utilised some hospice services 
(during the last 24 months of life) are compared to those who had utilised none at all. 
The analysis focuses on the average claims experience in the last four weeks of life as 
this is where the majority of hospice claims costs are concentrated (around 52 per cent 
of all hospice-related claims). Beneficiaries who had no hospice-related claims had 
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overall average claims amounting to around R143 000 during the last four weeks of 
life. This is significantly higher (p-value of ~0; tested using a Welch’s t-test) than the 
average claims during the last four weeks of life for those beneficiaries who had 
utilised at least some hospice services in the last 24 months of life (around R80 000). 
A Welch’s t-test allows for differences in sample sizes as well as differences in sample 
variances (in this case it cannot be reasonably concluded that the sample variances are 
equal since the variance ratio between the samples is greater than two).  
Table 6.2.1.1, below, shows the standard deviation of claims during the last four 
weeks of life and the 95 per cent confidence interval for these claims using a Student’s 
t-distribution. 
 
Table 6.2.1.1 – Standard deviation and confidence interval in last 4 weeks – Hospice use vs no 











Hospice (n= 1 176)  115 000          74 000         87 000  
No hospice (n= 18 838) 215 000       140 000     146 000  
 
Next, the claims experience for those beneficiaries that had utilised some hospice 
services during the last four weeks of life are compared to those who had utilised none 
in the last four weeks of life (but had utilised some in the last 24 months of life). The 
average claim costs amounted to around R76 000 and R102 000, respectively. The null 
hypothesis that the average claims during the last four weeks of life are equal for those 
dying whilst receiving hospice care and for those dying without receiving hospice care 
is tested against the alternative hypothesis that those receiving hospice care have lower 
average claims during the last four weeks of life using a Welch’s t-test. There is a 
significant difference between sample variances (ratio greater than four). The sample 
variance for those that died without receiving hospice care during their last four weeks 
of life (but had some hospice care earlier on) is particularly large (and the sample size 
is relatively small – 192 beneficiaries) which may distort the results. However, the null 
hypothesis is still rejected in favour of the alternative hypothesis at the five per cent-
level with a p-value of 0.035.  
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Table 6.2.1.2, below, shows the standard deviation of claims during the last four 
weeks of life for those who had hospice claims during the last four weeks and those 
who had not (but had utilised some hospice in the last 24 months of life), and the 95 
per cent confidence interval for these claims using a Student’s t-distribution. 
 
Table 6.2.1.2 - Standard deviation and confidence interval – Hospice use vs no hospice use in the 











Hospice (n = 984) 92 000         70 000         82 000  
No hospice (n = 192) 191 000         74 000      129 000  
 
We can thus conclude that, with all else being equal, hospice utilisation near the end 
of life is associated with lower overall claims costs and a significantly reduced 
probability of death in-hospital. 
A further interesting observation comes from comparing the overall average 
costs in the last four weeks of life for those that died out-of-hospital, grouped based 
on whether or not there had been any billed hospice services during this time. A total 
of 735 beneficiaries died out-of-hospital having billed hospice care in the last four 
weeks of life, compared to 6 638 beneficiaries that died out-of-hospital with no billed 
hospice care in the last four weeks of life. The average cost for these beneficiaries 
amounted to around R60 000 and R30 000, respectively. The null hypothesis that these 
amounts are equal is rejected (with a p-value of ~0. using a Z-test given the sufficiently 
large sample sizes and almost identical variances – ratio of 0.985). The hypothesis is 
rejected in favour of the alternative hypothesis that those receiving hospice care, who 
died out-of-hospital, experience higher claims, on average, during their last four weeks 
of life when compared to those dying out-of-hospital that have no billed hospice 
services during their last four weeks of life.  
Table 6.2.1.3, below, shows the standard deviation of claims during the last four 
weeks of life for those who died out-of-hospital either having utilised hospice care, or 
















Hospice (n = 735) 71 000         55 000       65 000  
No hospice (n = 6638) 70 565          29 000       32 000  
   
Note that even though the average claims costs for beneficiaries utilising hospice 
services and dying out-of-hospital is significantly higher than the costs for the 
corresponding beneficiaries who had not utilised hospice services, the converse is true 
for deaths occurring in-hospital (and exceeds the relative difference in cost for out-of-
hospital deaths), i.e. around R203 000 vs R124 000, respectively. Using a Welch’s t-
test, the hypothesis that these amounts are equal is rejected with a p-value of ~0.  
 Table 6.2.1.4, below, shows the standard deviation and 95 per cent confidence 
interval (using a Student’s t-distribution) of the average claim costs for those dying in-
hospital utilising hospice services, or not, respectively.  
 











Hospice (n = 249) 124 000       108 000       140 000  
No hospice (n = 12 389) 240 000       199 000       207 000  
 
Table 6.2.1.5, below, summarises the average claims during the last four weeks of life 
according to whether the beneficiary died in- or out-of-hospital, and whether or not 
they had any billed hospice services during their last four weeks of life. 
 
Table 6.2.1.5 – Average claims last four weeks – Hospice vs no hospice in the last four weeks of 
life 
Average claims - Last 4w  
(Number of beneficiaries) 
Died receiving 
hospice care – 
per beneficiary 
Died not receiving 
hospice care – per 
beneficiary 
Overall average 
during the last 4w 
Died in-hospital R124 000 (249) R203 000 (12 389) R202 000 (12 638)  
Died out-of-hospital R60 000 (735) R30 000 (6 638) R33 000 (7 373) 
Overall average 
(Number of beneficiaries) 
R76 000  
(984) 
R143 000  
(19 027) R140 000 (20 011)* 
*20 011 is the total number of beneficiaries that had full exposure and claims >0 during the last four weeks of life 
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The number of beneficiaries not utilising hospice services in their last four weeks of 
life and dying in-hospital are much greater than the corresponding number of 
beneficiaries dying out-of-hospital, 12 389 vs 6 638 beneficiaries, respectively, and 
significantly greater than the number dying in-hospital whilst utilising hospice 
services, i.e. 249. 
The relatively high observed cost for beneficiaries who died out-of-hospital 
whilst receiving hospice care is partly explained by the cost of hospice care services – 
average cost of R12 000 per beneficiary during their last four weeks of life. A further 
part of the result may be explained by the profile of the beneficiaries utilising hospice 
services. Scheme beneficiaries utilising hospice services are predominantly those with 
cancer. More than 90 per cent of beneficiaries that had utilised hospice services over 
their last 24 months of life and had died out-of-hospital had cancer-related claims. 
Comparing the claims experience in the last four weeks of life of beneficiaries who 
died out-of-hospital that had claimed for cancer-related benefits to those that died out-
of-hospital and had no cancer-related claims yielded the following results. Average 
claim amounts amounted to around R49 000 and R24 000, respectively, with a 
variance ratio of less than two. Performing a Z-test indicates that the average claim 
costs for those diagnosed with cancer (who died out-of-hospital) is significantly higher 
during the last four weeks of life than for those without cancer – p-value ~0.  
Table 6.2.1.6, below, shows the standard deviation and 95 per cent confidence 
interval for claims during the last four weeks of life for those who died out-of-hospital 
who had cancer-related claims and for those who died out-of-hospital who did not have 
cancer-related claims during this time, respectively. 
 
Table 6.2.1.6 – Standard deviation and confidence interval – Last four weeks; Cancer-related 










Cancer claims (n = 2 752)   77 000              46 000          52 000  
No cancer claims (n = 4 621)  66 000              22 000          26 000  
 
The result of this hypothesis test means that average claims costs for those receiving 
hospice care and dying out-of-hospital is expected to be greater than the costs for those 
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dying out-of-hospital and not receiving hospice care due to these beneficiaries likely 
having been diagnosed with cancer. The claims experience of beneficiaries that had 
been diagnosed with and who are likely to have died of cancer is briefly considered in 
Section 6.5 that covers the main trajectories of dying. 
 
6.3 Analysis of lives with partial exposure 
An interesting hypothesis to test is whether, based on the profile of the lives and their 
total claims, there exists any evidence to suggest that lives that joined the scheme 
within the last 24 months of life did so with the aim of selecting against the scheme.  
Of the total 24 980 deaths recorded 3 523, or fourteen per cent, only had partial 
exposure. Of these beneficiaries, 61 per cent died in-hospital – this is similar to the 
experience of those with full exposure over the 24-month period – 60 per cent died in 
hospital. 283 decedents were neonates (younger than 28 days) and a further 404 child 
decedents died before being aged two years (and will thus necessarily have exposure 
of less than two years). Neonates and children younger than two total approximately 
twenty per cent of beneficiaries with partial exposure. Of the lives with partial 
exposure, a total of 343 decedent beneficiaries (approximately ten per cent) had no 
claims during their period of cover (compared to only 202 decedent beneficiaries 
(approximately one per cent) that were exposed for the full 24-month period having 
no claims). 
Figure 6.3.1, below, illustrates the distribution of male and females deaths by 













Figure 6.3.1 – Distribution of deaths by age band – partial exposure 
  
   
As expected, there is a relatively large number of neonatal and infant deaths. However, 
within the adult age bands there is no observable trend towards more deaths at older 
ages (as seen in the distribution of deaths of the lives with full exposure). 
This part of the analysis is performed to determine whether schemes experience 
higher claims due to the anti-selective behaviour of new joiners. Average claims are 
considered at the various proximities to death as with the analysis for lives with full 
exposure above. Table 6.3.1, below, compares the average costs for those decedent 
beneficiaries with partial exposure to the average cost for those decedent beneficiaries 
with full exposure (in both cases the lives with zero claims are also included in the 















Table 6.3.1 – Average cost comparison – full vs partial exposure 
All incl. zero 






Average costs (R) 
– per beneficiary 
Average costs (R) – 
per beneficiary 
0m 270 3 523                 106  000 - 
2w 144 3 253                 85 000                      85 000  
4w 409 3 109                  126 000                   130 000  
3m 489 2 700                 190 000                    222 000 
6m 836 2 211                  241 000                    283 000 
12m 1 375 1 375                  316 000                    364 000 
24m 0   -                   480 000 
 
Table 6.3.1 reads as follows: an exposure period of ‘2w’ means having at least two 
weeks’ exposure; ‘4w’ means having at least four weeks’ exposure, and so on. None 
of these lives were exposed for the full period and all were exposed at least for one 
day (the ‘0m’ exposure period). The average costs of the ‘0m’ exposure period is 
higher than that of the ‘2w’ period mainly due to the effect of neonatal deaths and the 
high costs associated with neonatal ICU (Richardson, Zupancic, Escobar, Ogino et al. 
2001). 
It can be seen from Table 6.3.1 that claims for decedent beneficiaries who only 
had cover for part of the period under consideration, consistently had lower claims, on 
average than beneficiaries who enjoyed cover for the full period. The null hypotheses 
that the overall average claims for decedent beneficiaries with partial exposure are 
equal to the overall average claims of those with full exposure are tested against the 
alternative hypotheses that beneficiaries with partial exposure have lower average 
claims. At two weeks and four weeks proximity to death, there is no evidence to 
suggest that average claims for lives with partial exposure is any different to that of 
lives with full exposure – p-value >0.1. At greater proximities to death, three months 
or more, statistically, claims for decedent beneficiaries with full exposure are greater 
than for lives with partial exposure who had been on the scheme for at least the 
corresponding period – p-value ~0. For these hypotheses, z-tests were used given 
sample sizes of  greater than thirty and ratios of sample variances being between 0.5 
and two in all cases (i.e. it is not unreasonable to assume equal sample variances).  
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Table 6.3.2, below, shows the standard deviation and 95 per cent confidence 
intervals for those with full and partial exposure, respectively, at the various 
proximities to death.  
 
Table 6.3.2 – Standard deviation and confidence intervals – lives with partial exposure 
  Full exposure 










2w 136 000         83 000          87 000  
4w    206 000       127 000       133 000 
3m    348 000       217 000       226 000  
6m   429 000       277 000        288 000  
12m   518 000      357 000       371 000  











2w (n = 3 253)    161 000          79 000          90 000  
4w (n = 3 109)   236 000        117 000      134 000  
3m (n = 2 700)    345 000      177 000       204 000  
6m (n = 2 211)    421 000       223 000       258 000  
12m (n = 1 375)    579 000       286 000       347 000  
 
Since ten per cent of the decedent beneficiaries with partial exposure had no claims 
(possibly due to the enforcing of waiting periods), compared to only one per cent of 
decedent beneficiaries with full exposure, average costs for only those that had claims 















Table 6.3.3 - Average cost comparison – full vs partial exposure (non-zero claimers) 
Beneficiaries 






Average costs (R) 
– per beneficiary 
Average costs (R) 
– per beneficiary 
0m 239 3 143                   120 000  - 
2w 88 2 904                      95 000                   96 000  
4w 297 2 816                   139 000                 140 000  
3m 424  2 519                   204 000                 230 000  
6m 765 2 095                   254 000                 290 000  
12m 1330 1 330                   327 000                 370 000  
24m 0                    485 000  
 
As can be seen from Table 6.3.3, excluding those with zero claims increases the 
average claim amounts (at each proximity to death) for both those with full and those 
with partial exposure. This is as expected – smaller denominator with the same 
numerator. However, claims for those with partial exposure remains consistently 
below that for lives with full exposure, on average. Similar to the above, claims in the 
last month of life for decedent beneficiaries, both those with full and those with partial 
exposure during the period, are statistically similar.  
    
6.4 Ageing populations, lifestyles and chronic non-communicable diseases 
This section considers the effect on care costs near the end of life of having one or 
more chronic conditions. The chronic registration/authorisation for the decedent 
beneficiaries under consideration show that 18 173 (or about 73 per cent) of the 
decedent beneficiaries had at least one chronic condition. This information is contained 
in the data in the form of a “chronic indicator” per decedent beneficiary. In fact, 55 per 
cent of decedent beneficiaries had more than one chronic authorisation/condition at 
the time of their death.   
 Of the sample of 24 980 deaths, irrespective of the number of co-morbidities, 49 
per cent of the decedents had been diagnosed with hypertension and 31 per cent had a 
hyperlipidaemia diagnosis before death. 57 per cent decedent beneficiaries had one or 
more chronic conditions of the heart (including hypertension and hyperlipidaemia) – 
making this the most prevalent chronic condition group for the sample of decedent 
beneficiaries. 24 per cent of the sample of decedent beneficiaries suffered from a form 
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of cancer during their last 24 months of life. 21 per cent of decedent beneficiaries 
suffered from a chronic endocrine-related illness (including sixteen per cent suffering 
from diabetes), twelve per cent had a chronic respiratory illness and eight per cent 
experienced chronic mental illness.  
 Table 6.4.1, below, summarises the various chronic condition groupings together 
with the prevalence of each, ordered from most prevalent to the least prevalent. These 
include lives with both full and partial exposure. 
 




Chronic heart condition 14 130 57% 
Cancer 6 091 24% 
Chronic endocrine condition 5 288 21% 
Chronic respiratory disorder 3 051 12% 
Chronic mental condition 1 879 8% 
OTHER chronic condition 1 449 6% 
Chronic brain condition 1 403 6% 
Chronic musculoskeletal condition 1 217 5% 
Chronic renal condition 798 3% 
HIV 714 3% 
 
Figure 6.4.1, below, benchmarks the relative cost of having a single condition in one 
of these groups relative to having no chronic conditions. This figure only contains the 
data for lives with full 24-month exposure who only had one authorised chronic 
condition in any one of the groups above. Having no chronic conditions, i.e. ‘NONE’ 













Figure 6.4.1 – Chronic condition cost relative to the benchmark            
 
 
Figure 6.4.1 highlights the relative cost as a multiple of the average claims cost of 
having no registered chronic conditions. Note that the numbers of lives having only 
one chronic condition in each respective category is relatively low – shown in Figure 
6.4.1. The results may thus be prone to statistical variation over the 24-month period 
and multiple unobserved interactions or confounding factors influencing overall 
claims may be present. Hence, these results should be interpreted with caution. Note 
that Figure 6.4.1 ignores all lives that have multiple chronic conditions. 
Note the very small numbers exposed to (only) renal and musculoskeletal 
conditions, respectively. This may result in statistical variation in the results and the 
results are thus prone to being skewed by outliers. Cancer and chronic renal conditions 
exhibit interesting patterns and levels of claims relative to the benchmark, on average. 
HIV, musculoskeletal and ‘other’ conditions exhibit a high level of claims relative to 
the benchmark and conditions related to mental health exhibit a relatively low overall 
level when compared to the benchmark.  
The following analysis considers the impact of having multiple chronic 
conditions on overall claims costs. Table 6.4.2, below, illustrates the prevalence of 
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chronic conditions and the high rate of co-morbidity experienced by the decedent 
beneficiaries in the sample leading up to death.  
 
Table 6.4.2 – Comorbidity (all decedent beneficiaries)  
#Conditions Total Total proportion 
0 6 443 26% 
1 4 722 19% 
2 3 875 16% 
3 3 462 14% 
4 2 708 11% 
5 1 790 7% 
6 1 051 4% 
7 528 2% 
8 241 1% 
9 110 0% 
10 35 0% 
11 12 0% 
12 3 0% 
    
Table 6.4.2 includes both those the decedents with full and partial exposure over the 
period (i.e. all 24 980 deaths). Conditions are counted individually, irrespective of how 
they are grouped. For example, if a beneficiary had multiple heart conditions, e.g. 
hypertension and ischaemic heart disease, these are counted separately, i.e. this 
particular beneficiary is considered to have had two chronic heart conditions. 
From Table 6.4.2, above, it can be seen that 55 per cent of all decedent 
beneficiaries experience multi-morbidity, i.e. suffering from more than one chronic 
condition, at the time of death. The proportion is reasonable given the age structure of 
the sample of decedent beneficiaries (average age of 64, median age of 70) with 35 per 
cent of lives being younger than age 65. In a US study of individuals ages 65 and older 
(average age 73), it was found that 67 per cent of individuals experienced multi-
morbidity (Jindai, Nielson, Vorderstrasse and Quiñones 2016).  
Figure 6.4.2, below, highlights the cumulative average costs for all beneficiaries 
with full 24-month exposure given the number of chronic illnesses and authorisations 




Figure 6.4.2 – Cumulative average cost given the number of chronic conditions at the various 
proximities to death 
 
 
From Figure 6.4.2, above, it can be seen that there is an upward trend in end-of-life 
medical care claims costs at all proximities to death with an increasing number of 
chronic diseases. There were very few beneficiaries that had ten or more conditions 
(fifty in total), and the impact of their total (high) average claim costs distort the graph 
and masks the upward trend (given an increasing number of chronic conditions) for 
beneficiaries with fewer chronic conditions. As such, these are not shown in Figure 
6.4.2.  
Hypotheses testing are performed to confirm, statistically, that having one (or 
more) chronic conditions results in higher claim costs than having no chronic 
conditions. Lives with full exposure are grouped as either having ‘0’, ‘1 or 2’, or ‘3+’ 
chronic conditions. This grouping results in groups of comparable size with sufficient 
statistical credibility. At the various proximities to death, the impact on claims of 
having one (or more) chronic conditions as compared to having none, resulted in 
significantly higher overall claims, on average (p-value ~0.). Z-tests were used given 
large enough sample sizes and ratios of variances between 0.5 and 2.  
Table 6.4.3, below, sets out the decedent beneficiaries’ average claims (at the 





Table 6.4.3 – Average claims cost given chronic conditions at each proximity to death 
    Average claim costs (R) – per beneficiary 
  Count (n) 2w  4w  3m  6m  12m 24m 
0 
conditions 4 041  74 000  105 000  158 000  182 000   206 000  240 000  
1 or 2 
conditions 7 849  83 000  128 000  220 000  281 000  363 000 470 000  
3+ 
conditions 9 567  92 000 143 000  250 000  326 000  431 000  589 000  
 
Table 6.4.4, below, shows the standard deviation and 95 per cent confidence intervals 
(using a Student’s t-distribution) of the average claims cost at the various proximities 
to death, given the number of chronic conditions per decedent beneficiary. 
 
Table 6.4.4 – Standard deviation and confidence intervals – chronic condition groupings 





CI band (R) 
Upper 95% 
CI band (R) 
2w            149 000          69 000          78 000  
4w          220 000          98 000       112 000  
3m    358 000      147 000       169 000  
6m            434 000       169 000       195 000  
12m         488 000       191 000       221 000  
24m         526 000       224 000       256 000  





CI band (R) 
Upper 95% 
CI band (R) 
2w            132 000          80 000         86 000  
4w            206 000        123 000       132 000  
3m  336 000       212 000       227 000  
6m       424 000      272 000       291 000  
12m   500 000       352 000       374 000  
24m          579 000       457 000       483 000  





CI band (R) 
Upper 95% 
CI band (R) 
2w         134 000         89 000         94 000  
4w         205 000      139 000       147 000  
3m         357 000     243 000       257 000  
6m         445 000       317 000       335 000  
12m          543 000       420 000       442 000  
24m           668 000       576 000       603 000  
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The Pearson correlation coefficients between total claims and the number of chronic 
conditions, and between the number of days spent-in-hospital (during the specific 
period preceding death) and the number of chronic conditions, respectively, are set out 
in Table 6.4.5 and Table 6.4.6, below.  
 
Table 6.4.5 - Correlation coefficients – Total claims and number of chronic conditions 
  2w 4w 3m 6m 12m 24m 
Pearson correlation 0.05 0.06 0.09 0.12 0.15 0.21 
 
Table 6.4.6– Correlation coefficients – Number of days spent in-hospital and number of chronic 
conditions 
Pearson's correlation 
2w 4w 3m 6m 12m 24m 
0.12 0.12 0.13 0.16 0.18 0.22 
 
By computing the Pearson correlation coefficients between total claims and the 
number of chronic conditions at the various durations from death, we can see that a 
positive correlation exists. Similarly, the Pearson correlation coefficients between the 
number of days spent in-hospital and the number of chronic conditions shows a 
positive relationship (correlation coefficient greater than zero). 
Additionally, the Pearson’s correlation coefficient between the number of 
chronic conditions and the number of hospitalisations the decedent beneficiary 
experiences in their last 24 months of life is 0.3, showing that these are also positively 
correlated. 
 
6.5 Trajectories of dying 
A broadly similar methodology to that followed by Lunney, Lynn and Hogan (2002) 
to study the profiles (or trajectories of dying) of decedent Medicare beneficiaries is 
used here. The coding methodologies and/or conventions used between different 
territories, insurers, providers, etc. may mean that there are significant differences 
between the two sets of data, and hence the results are likely not directly comparable. 
The four main trajectories of dying considered are: 1) “Sudden death”, 2) “Cancer”, 3) 
“Organ failure” and 4) “General frailty”. A 5th group, “Other”, is used to capture lives 
that cannot be sensibly or easily grouped into one of the other four trajectories. Only 
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lives with full exposure who had medical scheme claims in the last twelve months of 
life are considered here. This yielded a total of 21 105 beneficiaries. 
Beneficiaries are allocated to the “Sudden death” trajectory if their total claims 
are below R24 000 in their last year of life and if they are younger than eighty years 
old. This yielded a total of 2 125 (or ten per cent) of beneficiaries that had died 
suddenly. Given the lower claim amount threshold and greater age spread in the data 
used for purposes of this study, this appears reasonable when compared to the seven 
per cent found by Lunney, Lynn and Hogan (2002). Trauma-related deaths with 
relatively high claims (relative to the R24 000 threshold) which may have included 
emergency transport and/or care will not be reflected in the “Sudden death” trajectory. 
Next, beneficiaries in the “Cancer” trajectory are identified by looking at the 
most costly episode of care/ICD-10 combinations for each beneficiary in their claims 
data. This yielded a total of 4 112 (or nineteen per cent) of beneficiaries, which is 
comparable to the 22 per cent found by Lunney, Lynn and Hogan (2002) in the 
corresponding Medicare study. In the previous section, it was found that 24 per cent 
of decedent beneficiaries had been diagnosed with a form of cancer. It is worth noting 
that not every beneficiary diagnosed with cancer dies of cancer and that the trajectories 
of dying are based on the most costly episode of care/ICD-10 code combination for 
each beneficiary, which may not necessarily coincide with the chronic disease 
registration.  
If beneficiaries experienced heart, respiratory, hepatic (liver) or renal failure as 
their most costly episode of care/ICD-10 combination, they are allocated to the “Organ 
failure” trajectory. This yielded 3 002 (or fourteen per cent) of beneficiaries, 
comparable to the sixteen per cent found in the corresponding Medicare study.  
Next, the remaining beneficiaries meeting the clinical requirements for the 
“General frailty” trajectory are assigned to this trajectory. This included chronic 
conditions related to the above-mentioned organs (not specifically failure of these 
organs) and other conditions associated with frailty at older ages. This yielded 8 306 
(or 39 per cent) of beneficiaries, compared to the 47 per cent in the Medicare study. 
Note that the Medicare study only contained lives older than 65 years, so a reduced 
proportion of frail individuals is expected in the overall medical schemes sample of 
decedent beneficiaries.  
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The remainder of the beneficiaries are assigned to the “Other” trajectory. A total 
of 3 556 (or seventeen per cent of) beneficiaries formed this group – comparable to 
eight per cent found in the Medicare study. Given the greater age spread, the number 
of anomalous episodes of care/ICD-10 codes, and the inclusion of those younger than 
fifty within this group, this appears reasonable.  
Table 6.5.1, below, summarises the results of the analyses of the various 
trajectories of dying, including the average age, average and median claim amounts, 
sex split and the proportion that died in-hospital (captured in the data by an indicator 
of whether death occurred in- or out-of-hospital). 
 









(R) – per 
beneficiary 
Median cost 









2 125 (10%) 49 9 000 8 000 69% 16% 
Cancer 4 114 (19%) 66 515 000 399 000 53% 62% 
Organ 
failure 
3 004 (14%) 70 529 000 338 000 54% 79% 
General 
frailty 
8 306 (39%) 77 368 000 211 000 51% 65% 
Other 3 556 (17%) 62 288 000 110 000 49% 57% 
Total 21 105 68 370 000 210 000 53% 60% 
 
As can be seen from Table 6.5.1, the “Sudden death” trajectory has the lowest average 
age due to the exclusion of beneficiaries eighty years and older, and due to the low 
annual claims threshold to be included in the trajectory. Only sixteen per cent of these 
beneficiaries died in-hospital, which is not unexpected given the low overall costs and 
the predominantly accidental nature of the deaths in this trajectory. 65 per cent of 
beneficiaries assigned to the “General frailty” trajectory died in-hospital and this 
trajectory had a higher than average age profile. The “Organ failure” trajectory has a 
higher than average age profile and 79 per cent of the beneficiaries in this trajectory 
died in-hospital, relatively more than in the other trajectories.  
The “Organ failure” trajectory has the highest average costs in the last year of 
life, followed by the “Cancer” trajectory. When looking at the median costs in the last 
year of life, the “Cancer” trajectory has the highest median claim amount. As expected, 
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the “Sudden death” trajectory has very low average claims, and the “Other” trajectory 
has relatively low average and median claims as compared with the other trajectories 
of dying. 
Figure 6.5.1, below, illustrates the number of deaths for the various trajectories 
given the decedents’ age at death, in five-year intervals. 
 
Figure 6.5.1 – Number of deaths per trajectory given age band at death 
 
 
As can be seen from Figure 6.5.1, “General frailty” is the dominant trajectory of dying 
(similar to the results of the Medicare study). The number of deaths peak at 80-84 for 
the “General frailty” and “Other” trajectories. “Organ failure” peaks at 75-79 and 
“Cancer” peaks at ages 70-74. The “Sudden death” trajectory has reasonably constant 
number of deaths at all ages (slightly lower at younger ages, given the lower number 
of deaths (and exposure to the risk of death) at these ages). The number of decedent 
beneficiaries in the “Other” trajectory exhibits an odd pattern due to the inclusion of 
all lives younger than fifty who have not been assigned to any of the other main 
trajectories of dying. 
 Figure 6.5.2, below, illustrates the average claim costs (for the last twelve 
months of life) and the number of decedent beneficiaries in five-year age bands for the 












Across all trajectories, except for the “Sudden death” trajectory, the phenomenon of 
overall average claims costs decreasing at advanced ages (aged seventy and above) is 
again evident.  
There are a relatively low number of child decedents, which may result in a 
single outlier per age group distorting the overall average claims costs for children. 
Children and young adults (younger than thirty) had relatively high “Cancer” and 
“Organ failure” claims costs as compared to the experience of older decedent 
beneficiaries in these trajectories. The double-hump in the “Other” trajectory can 
clearly be seen from Figure 6.5.2. This is due to all decedent beneficiaries younger 
than fifty not grouped as “Sudden death”, “Cancer”, “Organ failure” being included in 
this trajectory. These likely include most deaths due to traumatic events/accidents that 
resulted in claims above R24 000. After age fifty, the “Other” trajectory yields a 
similar distribution of deaths by age as the “Cancer”, “Organ failure” and “General 
frailty” trajectories.  
Table 6.5.2, below, sets out the average claims by proximity to death for the 
various trajectories of dying, as well as the cumulative proportion of claims over the 
24-month period.  
 
Table 6.5.2 – Average claims cost (per beneficiary) – by proximity to death and trajectory of 
dying 
Proximity to death 




























































































As can be seen from Table 6.5.2, other than for the “Sudden death” beneficiaries, the 
beneficiaries in the “Cancer” trajectory have relatively lower claim amounts during 
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their last two weeks of life when compared to beneficiaries in the other trajectories of 
dying. Considering the proportion of overall claims, the “Cancer” trajectory has a 
notably lower proportion of claims, relative to the other trajectories, excluding 
“Sudden deaths”, at all proximities to death less than twelve months. This means that 
significantly more cancer claims are incurred twelve to 24 months prior to death as 
compared with the other trajectories of dying, which experience more claims at shorter 
proximities to death. On average, the “Organ failure” trajectory is the most costly 
during the last two weeks, four weeks, and three, six and twelve months of life. The 
last two weeks of life are particularly costly for the “Organ failure” trajectory when 
compared to the other trajectories.         
 
6.6 Decedent beneficiaries with high end-of-life care costs  
As outlined in the methodology, the profile of high cost decedent beneficiaries are 
analysed separately as it is these lives that predominantly drive the high overall claims 
costs near the end of life. In Section 6.1.1, it was determined that the top thirty per cent 
of claimers are responsible for just over seventy per cent of all decedent beneficiary 
claim costs over the last 24 months of life and nearly eighty per cent of all claims over 
the last three months of life. This section considers the claims experience and profile 
of the thirty per cent of beneficiaries (with full exposure) who experienced the highest 
average claim costs over the last 24 months of life. Figure 6.6.1, below, highlights the 
age and sex split of the top thirty per cent of claimers.  
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Figure 6.6.1 – Age and sex split – top 30 per cent of claimers 
 
 
The distribution follows a similar pattern to the overall distribution of all deaths, except 
for a relatively lower number of child and young adult deaths. During the childbearing 
years, there are more female than male deaths, and at more advanced ages, there are 
more male deaths among the top thirty per cent of claimers. 91 per cent of these 
beneficiaries had at least one registered chronic condition (compared to 73 per cent of 
all beneficiaries in the overall sample) and 77 per cent died in-hospital (compared to 
60 per cent of all beneficiaries in the overall sample). This is in-line with expectations 
that higher chronicity and death in-hospital are associated with higher claims costs, on 
average, near the end of life. 
Figure 6.6.2, below, illustrates the average claims costs per beneficiary given 





Figure 6.6.2 – Average costs – by age band and sex – top thirty per cent of claimers 
 
 
For the highest claiming thirty per cent of beneficiaries, the overall average claims 
costs do not differ significantly between males and females (at the one or five per cent-
level – p-value of 0.06) – tested using a two-tailed (i.e. sample means are unequal) z-
test (since the variance of the claims between males and females, respectively, are 
roughly equal (ratio of 0.94) and their sample sizes are sufficiently large). From Figure 
6.6.2, above, it can be seen that young females have slightly higher claims costs, on 
average, than young males and from age forty onwards, males have slightly higher 
claims costs than females, balancing out overall. Using a one-tailed z-test, at the five 
per cent-level, males are, on average, more costly than females (p-value of 0.03).  
There is a slight downward trend in average costs with increasing age, but for 
the high claimers this is not as pronounced as with the entire sample of decedent 
beneficiaries where average costs are significantly lower at extreme ages relative to 
the other ‘elderly’ ages (ages sixty to 75). Children and young adults have the highest 
average claim costs among the high claimers. The higher number of males in the top 
thirty per cent of claimers between ages 55 and 89 can also be seen from Figure 6.6.2. 
 Table 6.6.1, below, shows the standard deviation and 95 per cent confidence 
intervals (using a Student’s t-distribution) of the average claims costs for the top thirty 










CI bound (R) 
Upper 95% 
CI bound (R) 
Males (n = 3 555)          774 000       1 141 000       1 192 000  
Females (n = 2 817)          796 000       1 100 000       1 159 000  
 
Table 6.6.2, below, shows the average claims cost by proximity to death for those high 
claimers dying in- and out-of-hospital, respectively. 
 






per day (R) – 
per beneficiary 
Died in-hospital 
(R) – per 
beneficiary 
Died out-of-
hospital (R) – 
per beneficiary Multiple 
2w 167 000  11 908  206 000  36 000  5.70  
4w 281 000  10 034  342 000  79 000  4.32  
3m 521 000  5 664  602 000  257 000  2.34  
6m 676 000  3 696  752 000  429 000  1.75  
12m 878 000  2 402  943 000  663 000  1.42  
24m 1 150 000  1 574  1 198 000  994 000  1.20  
 
As with the full sample of lives, it can be seen that as death draws nearer, the average 
medical scheme claims cost per day increases rapidly. Average claims cost per day 
during the last two weeks of life is more than 7.5 times greater than average claims 
cost per day during the entire 24-month period preceding death. When death is not yet 
imminent (more than six months away), the difference in overall average claims 
between those dying in- and out-of-hospital, respectively is not as pronounced (a 
multiple of less than two). As death draws near, the costs for those dying in-hospital 
become significantly higher than for those dying out-of-hospital.  
 Next, the number of hospitalisations and the number of days spent in-hospital by 
the high claimers are considered. The average number of hospitalisations for the top 
thirty per cent of claimers during their last 24 months of life was six (compared to the 
four hospitalisation experienced by all the decedent beneficiaries, on average, in the 
sample). The average length of these hospitalisations were ten days (compared to the 




Table 6.6.3, below, shows the average number of days spent in-hospital by these 
beneficiaries given their proximity to death. 
 
Table 6.6.3 – Number of days (proportion of time, of the given proximity to death) spent in 
hospital by the top thirty per cent of claimers 
Days in-
hospital 2w (%) 4w (%) 3m (%) 6m (%) 12m (%) 24m (%) 
Overall 8 (60%)  14 (51%) 28 (30%)  37 (20%)  47 (13%) 62 (8%)  
Died IH 10 (73%)  17 (60%)  31 (33%)  39 (21%)  50 (14%)  63 (9%)  
Died OOH 2 (17%)  6 (21%)  18 (19%)  28 (15%)  40 (11%)  56 (8%)  
Multiple 
(IH/OOH) 4.24  2.85  1.72  1.41  1.25  1.13  
 
For the top thirty per cent of claimers, an average of 62 days was spent in-hospital 
during the last 24 months of life. Those that died in-hospital, spent more days in-
hospital than those that died out-of-hospital, on average, at each proximity to death. 
As a proportion of the duration and as a relative multiple of days spent in-hospital, this 
becomes more pronounced as death draws nearer. Hospitalisations and the number of 
days spent in hospital are considered in further detail in Section 6.7, below. 
Given the methodology for classifying lives by trajectory of dying, very few (ten 
beneficiaries in total) of the top thirty per cent of claimers were allocated to the sudden 
death trajectory. These are beneficiaries who experienced high claims in the year prior 
to the year of death, and low claims during their last year of life (less than R24 000).  
Table 6.6.4, below, shows the split of the top claimers by trajectory of dying. 
 
Table 6.6.4 – Trajectories of dying – Top 30 per cent 
Trajectory # beneficiaries Proportion 
Sudden Death 10 0% 
Cancer 2 142 34% 
Organ Failure 1 292 20% 
General Frailty 2 251 35% 
Other 677 11% 
Total 6 372 100% 
  
Approximately one third of the top thirty per cent of claimers were categorised into 
each of the “Cancer” and “General frailty” trajectories; twenty per cent of the top 
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claimers are categorised into the “Organ failure” trajectory and eleven per cent are 
classified as the “Other” trajectory. Relatively more of the top claimers belong to the 
“Cancer” and “Organ failure” trajectories, respectively, when compared to the 
distribution of the full sample of decedent beneficiaries by trajectory of dying (i.e. 
nineteen per cent “Cancer” and fourteen per cent “Organ failure”).  
The following section considers indicators of quality care near the end of life that 
can be measured from the administrative claims data. 
 
6.7 Measuring the quality of care near the end of life  
In addition to cost, it is important also to consider the quality component of value in 
order to achieve the aim of maximising the value of end-of-life care for the key 
stakeholders. Quality considerations were explored in Section 2, and below a number 
of quality indicators/metrics observable from the administrative data are investigated. 
These include: 1) Death in-hospital, 2) Days spent in-hospital, 3) Chemotherapy in the 
last weeks of life, and 4) Hospice utilisation near the end of life. 
 These indicators/metrics can be used to develop robust, reportable measures of 
quality care near the end of life, e.g. documenting end-of-life care discussions with 
individuals (and the frequency of these discussions as circumstances change) and the 
drawing up of advance directives, recommendations for palliative care consultations, 
patient/family surveys, etc. These metrics also provide a useful baseline for assessing 
the impact of interventions on quality of care and on care outcomes.  
 
6.7.1 Quality indicators observable from the claims data 
 
Death in hospital  
In Section 6.2, it was seen that sixty per cent of all decedent beneficiaries in the sample 
died in-hospital and that 75 per cent of all claims over the last 24 months of life for the 
decedent beneficiaries were incurred in a hospital setting. During the last two weeks 
of life, for those decedent beneficiaries that had non-zero claims, 94 per cent of these 
claims were for treatments or procedures performed in-hospital and 66 per cent of 
these beneficiaries eventually died in-hospital. Hospital utilisation near the end of life 
was considered in Section 6.2. Furthermore, in Section 6.5, it was established that the 
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“Organ failure” trajectory had the highest likelihood of death in hospital at 79 per cent, 
followed by “General frailty” (65 per cent) and “Cancer” (62 per cent).  
Days spent in hospital 
Of the 21 457 beneficiaries with full exposure, 18 098 (or 84 per cent) had at least one 
hospitalisation with at least one night spent in-hospital. Beneficiaries that had a 
hospitalisation in the last 24 months of life, on average had four hospitalisations during 
this time. The average length of stay per hospitalisation was nine days. Table 6.7.1.1, 
below, shows the average number of days spent in hospital, given the proximity to 
death for those lives who spent at least one day in hospital during that time. The 
average proportion of time, given the time to death is also shown for those that had a 
hospitalisation within that particular proximity to death. 
 
Table 6.7.1.1 – Average number of days in hospital 
Proximity to death 24m 12m 6m 3m 4w 2w 
Average # days 35  29  24  19  12  8  
% of time 5% 8% 13% 21% 44% 59% 
 
On average, the sample of decedent beneficiaries spent 35 days in hospital during their 
last 24 months of life, or five percent of the last 24 months of life. In the last year of 
life, this was, on average, 29 days (or eight per cent). As death draws nearer, the 
number of days spent in hospital as a proportion of the time until death for those that 
have a hospitalisation increase significantly. 44 per cent and 59 per cent of the last four 
weeks and two weeks of life, respectively, are spent in-hospital, on average. There is 
no significant difference between the number of days spent in hospital by males and 
females, respectively, near their end of life.  
Table 6.7.1.2, below, shows the average days by proximity to death, for lives 









Table 6.7.1.2 – Place of death and average number of days in hospital 
Proximity to death 24m 12m 6m 3m 4w 2w 
Died in-hospital       
Average number of days 38 30  25  20  13  9  
% of time 5% 8% 14% 22% 45% 61% 
Died out-of-hospital       
Average number of days 29  24  20  16  10  6  
% of time 4% 7% 11% 18% 34% 45% 
 
Those who died in-hospital spent more days, on average, in hospital at all proximities 
to death. On average, those who died in-hospital had nineteen per cent more 
hospitalisations than those who died out-of-hospital, which may partly explain the 
greater number of days spent in-hospital by those who eventually died in-hospital. 22 
per cent of decedent beneficiaries that had at least one hospitalisation of more than one 
day spent all of their last two weeks of life in-hospital. Ten per cent of decedent 
beneficiaries that had at least one hospitalisation spent all of their last four weeks of 
life in-hospital.  
 Table 6.7.1.3, below, shows the number of days spent in hospital by those that 
had utilised some billed hospice services leading up to death.  
 
Table 6.7.1.3 – Average number of days spent in-hospital 
Hospice users 24m 12m 6m 3m 4w 2w 
Utilised hospice 34  27  21  16  10  7  
% time  5% 7% 12% 18% 36% 51% 
 
Decedent beneficiaries that had utilised some hospice services near their end of life 
were shown in Section 6.2.1 to have a significantly lower probability of dying in-
hospital (and lower average claims costs) as compared to those who had not utilised 
any hospice services. From Table 6.7.1.3, it can also be seen that those beneficiaries 
who utilised some billed hospice services (and had at least one hospitalisation) also 
spent fewer days in-hospital near their end of life, on average, when compared to the 
overall sample of beneficiaries that had at least one hospitalisation during their last 24 
months of life. The average number of days spent in-hospital will be slightly lower if 




Chemotherapy in the last weeks of life 
Table 6.7.1.4, below, shows the number of beneficiaries that had chemotherapy claims 
in their last two weeks, four weeks and three months of life, respectively. 
 
Table 6.7.1.4 – Chemotherapy claims near the end of life 
Proximity to death # beneficiaries 
Proportion receiving chemo at 
the given proximity to death 
2w 615 17% 
4w 1 181 32% 
3m 2 409 65% 
3m+ 1 313 35% 
        
It can be seen from Table 6.7.1.4 that seventeen per cent of beneficiaries that had 
claims for the administering of chemotherapy, had chemotherapy administered in their 
last two weeks of life. Approximately one third of beneficiaries had chemotherapy-
related claims in their last four weeks of life and two thirds had chemotherapy-related 
claims during their last three months of life. 
 There were more males than females receiving chemotherapy over the last 24 
months of life (52 per cent vs 48 per cent of those receiving chemotherapy). Males 
were also more likely, on average, to receive chemotherapy during their last three 
months of life than females (67 percent vs 62 per cent). 66 per cent of those that had 
received chemotherapy at some point during the last 24 months of life died in-hospital.  
Table 6.7.1.5, below, shows the administering of chemotherapy to those 













Table 6.7.1.5 – Chemotherapy near the end-of-life and place of death 
Death in-hospital 2440 66% 
Proximity to death # beneficiaries 
Proportion of 
beneficiaries 
2w 516 21% 
4w 933 38% 
3m 1 698 70% 
3m+ 742 30% 
Death out-of-hospital 1 282 34% 
Proximity to death # beneficiaries 
Proportion of 
beneficiaries 
2w 99 8% 
4w 248 19% 
3m 711 55% 
3m+ 571 45% 
    
It can be seen that those beneficiaries receiving chemotherapy that died in-hospital 
were more likely to receive chemotherapy during their last two weeks and four weeks 
of life, respectively. 21 per cent of those dying in-hospital (vs eight per cent of those 
who died out-of-hospital) were receiving chemotherapy during their last two weeks of 
life. Similarly, during the last four weeks of life, 38 per cent of those who died in-
hospital (vs nineteen per cent of those who died out-of-hospital) received 
chemotherapy.  
Table 6.7.1.6, below, details the average age at death of lives who received some 
chemotherapy during the last 24 months of life. 
 
Table 6.7.1.6 – Average age at death – chemotherapy users 
 Average age #Beneficiaries 
Males 65  1 937 
Females 62  1 785 
Died in-hospital 62  2 440 
Died out-of-hospital 66  1 282 
Overall 64  3 722 
 
Males receiving chemotherapy are, on average, older than females receiving 
chemotherapy. Those who received chemotherapy that died in-hospital tended to be 




No/late hospice enrolment 
In a Section 6.2.1 it was found that less than five per cent of decedent beneficiaries 
had utilised any hospice services prior to them dying. Hospice users were mainly 
beneficiaries suffering from cancer and they experienced a reduced likelihood of death 
in-hospital – thirty per cent vs sixty per cent, overall. Further details on the analyses 
performed and the results of these analysis can be found in Section 6.2.1. Below, the 
timing of hospice enrolment is considered by looking at the first recorded date for 
hospice-related claims in the claims data. This results in an average hospice enrolment 
of 3.5 months (or 106 days) before death.  
Table 6.7.1.7, below, shows the number of hospice enrolees given their 
proximity to death.  
 
Table 6.7.1.7 – Hospice enrolment by proximity to death 
Enrolled in hospice Count Proportion 
Last 7 days of life 269 22% 
Last 2w of life 391 32% 
Last 4w of life 547 45% 
More than 4w from death 681 56% 
More than 3m from death 363 30% 
 
56 per cent of decedent beneficiaries that had utilised hospice-related services started 
utilising these services more than four weeks before death and thirty per cent of these 
beneficiaries started utilising hospice services more than three months before death. 
22 per cent of beneficiaries utilising hospice services had less than seven days of 
hospice care before death. 32 per cent of those utilising hospice enrolled during their 




7 Discussion of results   
The end of life and end-of-life care are complex, multi-dimensional and, surprisingly, 
poorly understood concepts. In the dynamic world of technological advances, drug and 
treatment innovation and an increasing capacity to deliver care, the ability of medicine, 
as well as the perceptions regarding this ability, are continually changing. With this, 
end-of-life care is also constantly evolving and continually being adapted to the 
changing medical landscape. This research project aimed to identify the multitude of 
contributory factors that are associated with end-of-life care in the South African 
medical schemes environment, and theorises the interaction between these factors and 
their effect on the observed claims cost near the end of life. The results of the data 
analyses performed in the previous section are interpreted and their implications 
discussed, below. 
7.1 Demographic profile and overall claims patterns of decedent  beneficiaries 
For the sample of decedent beneficiaries, the majority of deaths occur between the 
ages of sixty and ninety years with a median age at death of seventy years. This is 
consistent with expectations given that medical scheme membership is concentrated 
in top income quintile of South Africa (McIntyre 2010). This subset of the population 
have health outcomes, life expectancies and a disease burdens comparable to that of 
economically developed nations. The sample contained more male deaths than female 
deaths and, on average, males experienced greater medical scheme claims near their 
end of life, overall. At advanced ages (eighty years and older) there are more female 
deaths. This may be due to the longer life expectancy of females (and hence number 
of females alive at these advanced ages compared to the number of males alive at these 
ages) (Barford, Dorling, Smith and Shaw 2006). However, this cannot be said with 
certainty as distribution of the overall population of beneficiaries exposed to the risk 
of dying at advanced ages is unknown.   
More deaths are recorded in the winter months – July and August. The most at-
risk members of the exposed population (the very old and/or the very sick) tend to be 
more vulnerable during the colder winter months (influenza season) as opposed to 
during the summer months (Wilkinson, Pattenden, Armstrong, Fletcher et al. 2004). 
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Similarly, January and February (summer) have lower numbers of deaths, on average, 
bearing in mind that February is also the shortest month of the year. 
The claims costs analyses performed only considers the actual medical scheme 
claims submitted for the decedent beneficiaries. It should be borne in mind that there 
may be other costs not reflected in these amounts – both financial, quantifiable costs 
and other non-financial or indirect costs (Tseng and Hicks 2016). Financial costs 
include, for example, direct out-of-pocket healthcare expenditure, the cost of home 
modifications, loss of employment and income, etc. Non-financial costs include, for 
example, productive time lost due to illness/injury, healthy life years lost, family 
members needing to provide care and having a reduced capacity to work, the emotional 
impact of anxiety and depression caused by ill health, both for the patient and their 
families, etc. 
 86 per cent of decedent beneficiaries in the sample had been on the scheme for 
the full 24-month period preceding their deaths, and experienced average medical 
scheme claims of R480 000 (in 2017 ZAR-terms) per beneficiary during this period. 
 The results show that average medical care costs over the last 24 months of life 
increase with increasing age, up until around age 75, and then decreases sharply, on 
average, at more advanced ages. This is consistent with findings in the literature 
(Levinsky, Yu, Ash, Moskowitz et al. 2001; Hoover, Crystal, Kumar, Sambamoorthi 
et al. 2002; Ranchod, Abraham and Bloch 2015). Decedent beneficiaries at more 
advanced ages may have been healthier throughout their lives, i.e. not having had 
chronic conditions, resulting in them being healthier at more advanced ages, requiring 
less medical care and experiencing fewer hospitalisations, overall (Yang, Norton and 
Stearns 2003). Also, at more advanced ages, there may be greater rationing of medical 
goods and services, either by providers, the medical schemes, or both (Levinsky et al. 
2001). Beneficiaries may themselves also choose to forego invasive and aggressive 
care at more advanced ages, resulting in a lower level of average cumulative claims 
observed for these decedent beneficiaries.  
For middle-aged to elderly decedent beneficiaries (ages forty to eighty), the high 
prevalence of and ongoing management of chronic conditions, together with frequent 
hospitalisation, especially towards the very end of life, may explain the high level of 
cumulative claims (on average) that these beneficiaries experience during their last 24 
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months of life. Advances in medical care have resulted in seriously ill persons being 
able to live longer, albeit with significantly higher levels of disability and higher 
medical care costs before their eventual deaths (Cutler 2007).  
The overall claims experience between males and females at different ages 
yielded some interesting results. At ages younger than 65 years, females experienced 
higher average claims than males with the relationship switching at ages greater than 
65 years. This may be due to the high cost of pregnancy-related complications that 
result in death and the higher incidence of terminal breast and cervical cancers at 
relatively young ages for females compared to the relative incidence rates of terminal 
cancers for males at young ages (Mustard, Kaufert, Kozyrskyj and Mayer 1998; Cook, 
Dawsey, Freedman, Inskip et al. 2009). Also, young males are more at risk of 
unexpected or accidental deaths than young females (Stiglets 2001; Patton, Coffey, 
Sawyer, Viner et al. 2009). Furthermore, at middle ages, males may experience more 
sudden deaths, e.g. death from myocardial infarction (heart attacks) and 
cerebrovascular accidents (strokes) due to undiagnosed cardiovascular conditions 
(Regitz‐Zagrosek 2012). Where accidents result in sudden death or where an 
underlying cardiovascular condition has gone undiagnosed and untreated, these would 
typically not be associated with high medical care costs, and hence lower claims, on 
average. It should be noted that most deaths (males and females) are concentrated 
between the ages of 65 and ninety. The higher concentration of lives at the older ages, 
with males experiencing higher average claims costs at these ages result in the higher 
overall average claims costs for males, at all proximities to death. 
 The geographic distribution of decedent beneficiaries shows that there are more 
deaths in urbanised areas. The more rural areas, e.g. the Northern Cape, have a much 
lower concentration of deaths. This is not unexpected as the geographic distribution of 
the underlying population from which the decedents are drawn is more concentrated 
in urbanised areas (Council for Medical Schemes 2019). Interestingly, the more rural 
areas, e.g. the Northern Cape, experience significantly lower average claims costs near 
the end of life than the more urbanised areas, e.g. Gauteng. This may be due to the 
rural areas having a lower concentration of private hospitals than the more urbanised 
areas. This may result in hospitals in more rural provinces being less easily accessible 
and reduces utilisation of hospital and other expensive medical services near the end 
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of life for beneficiaries residing in these areas. The Gauteng province is the most 
urbanised and has the highest average claims costs per decedent beneficiary, possibly 
due to beneficiaries having easier access to more expensive care in private hospitals.  
 
7.1.1 Claims by proximity to death 
Medical scheme claims costs near the end of life increase significantly as death draws 
nearer. Average medical scheme claims for these beneficiaries during their last year of 
life amounted to R364 000 (in 2017 ZAR-terms) per beneficiary, i.e. three times higher 
than in the year preceding their year of death. Almost fifty per cent of the claims costs 
incurred by beneficiaries during their last 24 months of life are incurred during their 
last three months of life, and 25 per cent of overall claims are incurred in the last month 
of life. Similar results have been found in international literature (Yang, Norton and 
Stearns 2003). 
 There is a large difference between the mean and median claims for the decedent 
beneficiaries at all proximities to death. This is expected as on the one hand, some 
would have died suddenly, or unexpectedly, with little or no interaction with the 
healthcare system and hence no (or very few) claims. Others would have died 
following a relatively brief illness whilst some would have foregone intensive medical 
interventions or hospitalisations in the period preceding their death, all resulting in 
relatively low claims for these particular beneficiaries. On the other hand, some may 
have died following long or multiple hospitalisations with bouts of intensive care 
and/or other expensive treatments potentially with a number of complications during 
these hospitalisations requiring further expensive/intensive intervention. The 
relatively low number of very costly cases pushes the overall average claims cost 
upward and the large number of relatively low cost cases pulls the median claims cost 
downward. 
 Considering the claims cost during the last year of life compared to the claims 
cost during the twelve months preceding the last year of life shows similar results to 
the study performed by Ranchod, Abraham and Bloch (2015) which was based on an 
independent set of lives, covering a different time period as well as the experience of 
different medical schemes. In their research they found that the costs in the last year 
of life was 3.3 times higher than in the year preceding the year of death. Having 
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excluded neonate deaths and all lives with partial exposure, the experience of the lives 
under consideration in this research project shows threefold increase in costs in the last 
year of life as compared to the year prior to the year of death. Not excluding neonates 
or lives with partial exposure without any claim/exposure adjustments, this multiple 
increases to 3.4 times. However, this incorrectly places too much weight on the costs 
incurred in the last year due to neonates and other lives with partial exposure having 
no (or significantly less) claims in the year prior to the year of death. 
 Claims acceleration with death drawing nearer is not unexpected given that 
beneficiaries are likely to be seriously ill near their end of life and require heroic efforts 
(costly and resource-intensive) to prevent them from dying.   
 This acceleration can clearly be seen when looking at the daily average claims 
amount for decedent beneficiaries. This increases from about R660 per beneficiary per 
day during the last 24 months of life to around R6 000 per beneficiary per day during 
the last two weeks of life. 
 
7.1.2 Truncated distributions 
In Section 6.1.2, it is shown that the average claim amounts are significantly higher 
than the median claim amounts. This indicates that the distribution of end-of-life care 
costs are skewed towards the decedent beneficiaries having higher than average claims 
costs at the end of life,  which prompted an investigation into the distribution of claims 
excluding the tail ends of the distribution – i.e. both the top and bottom claimers.  
The effect of excluding the tails is most notable at the ten per cent level 
(excluding the highest and lowest claiming ten per cent of beneficiaries) further 
highlighting the effect of the relatively small number of decedent beneficiaries with 
very high claims near their end of life on the overall end-of-life claim costs for medical 
schemes.  
The experience stabilises at around the thirty per cent level, which prompted the 
analyses into the profile and experience of the top thirty per cent of claimers. These 
beneficiaries mainly drive the high average claim costs experienced by medical 
schemes for beneficiaries near their end of life. For these high cost cases the majority 
of medical claim costs are concentrated in the last three months of life (around fifty 
per cent). These beneficiaries may be receiving intensive, aggressive, yet ineffective 
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curative interventions near their end of life and they may have palliative and other 
needs that are not being met. This should be interpreted with caution as no data are 
available on beneficiaries with similar clinical profiles who survive because of these 
curative interventions, i.e. who would have died without them.  
The bottom fifty per cent of the sample of decedent beneficiaries claim only 
twelve per cent of the overall claim costs of the sample. The top one per cent of 
claimers claim nearly ten per cent of overall claims and the top ten per cent claims 
nearly forty per cent of the overall claims of the entire sample of decedent 
beneficiaries. 
 
7.1.3 Claims by provider type 
The bulk of medical scheme claims costs for decedent beneficiaries near their end of 
life are the costs of private hospital care (around fifty per cent of overall claims in the 
last 24 months of life are billed by private hospitals themselves). Around 75 per cent 
of total claims for the decedent beneficiaries in the last 24 months of life result from 
procedures performed or care received in a hospital setting. This means around 25 per 
cent of overall claims are billed by specialists, auxiliary healthcare providers and 
pharmacies for beneficiaries who are receiving treatment and care in-hospital, over 
and above the fifty per cent of overall claims billed by the hospitals themselves. The 
total proportion of costs incurred by beneficiaries for and in private hospitals increase 
as death draws nearer indicating an increased likelihood of hospitalisation as death 
draws nearer. The other main provider types driving claims near the end of life are 
pharmacies and specialists. 
 
7.2 Place of death 
60 per cent of the sample of decedent beneficiaries died in-hospital. Comparing the 
overall claims experience of those dying in- vs out-of-hospital, it is seen that those 
dying in-hospital, irrespective of the number and length of hospitalisations during their 
last 24 months of life, experience consistently higher claim costs over their last 24 
months of life. These analyses do not aim to attribute causality – the beneficiaries 
dying in-hospital may have been much sicker than those dying out-of-hospital, 
requiring significantly more, and more specialised medical care, driving their observed 
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higher claims costs. The ratio of claims cost for those dying in-hospital compared to 
those dying out-of-hospital increases from two during the last 24 months of life, to 
seven during the last two weeks of life.   
In addition, irrespective of death occurring in- or out-of-hospital, the overall 
average claim costs for beneficiaries aged 75 years and older, still decrease with 
increasing age – a reversal of the trend seen with increasing ages below the age of 75 
years. This may further suggest that there is either conscious choice by the 
beneficiaries, their families or the medical care providers to ration the use of intensive, 
aggressive care at advanced ages. At the teenage/young adult ages, the difference 
between average costs for those that died in-hospital vs those that died out-of-hospital 
is the greatest. This is likely due to the sudden or accidental nature of out-of-hospital 
deaths at young ages and hence, a low level of medical care utilisation and cost. 
Irrespective of whether a beneficiary dies in- or out-of-hospital, the majority of 
treatments/procedures near the end of life are performed in a hospital setting (75 per 
cent of overall claims costs). This means that as death nears, it becomes almost 
inevitable for beneficiaries to become hospitalised at some point leading up to their 
death. For those dying in-hospital, the overall proportion of claims at all proximities 
to death for treatments/procedures performed in a hospital setting is significantly 
higher than for those dying out-of-hospital (79 vs 63 per cent during the last 24 months 
of life, and 96 vs 68 per cent during the last two weeks of life). It is expected that the 
claims cost for those beneficiaries that die in-hospital will be greater than for those 
beneficiaries that died out-of-hospital due to the nature of hospital-based care being 
more resource-intensive and more specialised. With increasing age after age 75, the 
proportion of deaths occurring out-of-hospital increases. 
By comparing the age profiles, the total proportion and the acceleration of claims 
in-hospital between those dying in- and out-of-hospital, respectively, it appears that 
dying out-of-hospital (or foregoing further curative interventions or hospitalisation) 
may have been a conscious choice for some beneficiaries. This does not mean that they 
had foregone all forms of care, but these beneficiaries may have obtained alternative 
care, e.g. home nursing or hospice care that is not covered by their medical scheme 
(and hence are not claimed for).  
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Dying in-hospital may be contrary to the wishes of the dying beneficiary, 
potentially resulting from the beneficiary not having any alternative funded care 
options, e.g. nursing or hospice care, at such a time when their condition deteriorates 
and they are in need of care. The result potentially being that people die in-hospital 
receiving more intensive and more expensive care than may be warranted or effective 
given their condition, as well as potentially being contrary to their preferences. This is 
based on conjecture and on the research surrounding patients’ expressed preferences 
for not dying in a hospital setting contained in the literature. From the data analysed, 
beneficiaries’ preferences for setting(s) of care near the end of life and preferences for 
place of death, cannot be confirmed. 
 
7.2.1 Hospice utilisation 
Hospices in South Africa operate on a charitable basis serving indigent individuals12  
and as a result, the billing for hospice services utilised by medical scheme beneficiaries 
has often been on an ad hoc rather than on a structured basis. This may also result in 
billing errors and inconsistencies between different hospices. Hospice billing of 
medical schemes for the services utilised by their beneficiaries have improved over 
time and this may partly explain why utilisation in 2017 is greater than in 2016 (an 
increase in utilisation of twenty per cent is observed). Furthermore, in 2017, 
significantly fewer beneficiaries had hospice-related claims recorded after their date 
of death as compared to 2016. This may potentially indicate improved and more 
established billing processes followed by hospices with fewer errors. It should be noted 
that actual hospice utilisation by decedent beneficiaries may be higher than indicated 
by the claims data due to direct out-of-pocket payment and/or due to non-billing of 
these services rendered by individual hospices to medical scheme beneficiaries. 
‘Utilisation’, below, refers only to the utilisation of billed hospice services.  
Hospice service utilisation (that were specifically billed for by the hospices) for 
the sample of decedent beneficiaries is low (less than five per cent of decedent 
beneficiaries). 94 per cent of beneficiaries utilising hospice services had been 
                                                          




diagnosed with a chronic condition (compared to 73 per cent in the overall sample of 
decedent beneficiaries). More than ninety per cent of beneficiaries that had utilised 
some hospice services had previously been diagnosed with a form of cancer. The 
average age of hospice users is 69 years and the sex split is roughly equal.  
Beneficiaries that had utilised some hospice services had a significantly lower 
probability of death in-hospital – only thirty per cent of beneficiaries that had utilised 
hospice services eventually died in-hospital (compared to sixty per cent of the overall 
sample of decedent beneficiaries). Those who had utilised hospice services also 
experienced significantly reduced overall medical scheme claims near their end of life, 
on average (R76 000 vs R143 000 during the last four weeks of life, in 2017 ZAR-
terms). The lower overall claims cost for beneficiaries who died whilst actively 
receiving hospice care services may be due to lower rates of hospitalisation as found 
in a study by Obermeyer, Makar, Abujaber, Dominici et al. (2014) on Medicare 
beneficiaries with poor-prognosis cancer utilising hospice services. These results are 
similar to the findings of Emanuel, Ash, Yu, Gazelle et al. (2002) who studied the 
effects of hospice utilisation on end-of-life care costs and the place of death for a 
sample of  decedent Medicare beneficiaries. 
 Beneficiaries that had utilised some hospice services and died out-of-hospital 
experienced significantly higher costs than the beneficiaries dying out-of-hospital and 
utilising no hospice care during their last four weeks of life (R60 000 vs R30 000 
during the last four weeks of life) . This is partly because of the cost of hospice care 
and because of hospice care mainly being utilised by beneficiaries with cancer. 
Beneficiaries with cancer experience significantly higher medical scheme claims, on 
average, during the last four weeks of life when compared to beneficiaries that do not 
have cancer (R49 000 vs R24 000 for deaths occurring out-of-hospital; having cancer 
vs not having cancer, respectively). The reason for observing such a high number of 
beneficiaries with cancer utilising hospice services may be due to scheme benefits, 
such as ‘alternatives to hospitalisation’ or ‘compassionate care’ benefits, that 






7.3 Analysis of lives with partial exposure 
Given the stringent regulations surrounding voluntary and open enrolment (schemes 
are not allowed to decline membership based on age, state of health, etc.) and 
community rating (no differential pricing based on age, state of health, etc.), an 
environment is created in which individuals can select against medical schemes 
(McLeod and Ramjee 2007). The problem is two-fold – young, healthy individuals opt 
out of purchasing cover (these lives would have served to improve the overall risk 
profile of the scheme). On the other hand, older, sicker individuals take up medical 
scheme cover at a point where they either require care or believe their risk of requiring 
care in the near future is significant enough to justify paying for cover (these lives 
serve to worsen the overall risk profile of the scheme). Medical schemes have a limited 
range of underwriting tools available with which to protect themselves against such 
anti-selection. A three-month general waiting period and a twelve-month condition-
specific waiting period may be applied, subject to certain rules depending on whether 
the beneficiary had prior, recent and uninterrupted medical scheme coverage 
(Department of Health 1998). The three-month period may be applied to any claims 
submitted and the twelve-month period may be applied to specific conditions for which 
medical advice was sought over the preceding twelve-month period. 
Fourteen per cent of beneficiaries were new joiners (or members that had cover, 
lapsed and subsequently re-joined) to the scheme within the 24-month period 
preceding their death. Compared to the overall sample of beneficiaries, a similar 
proportion of beneficiaries with partial exposure died in-hospital, i.e. around 60 per 
cent. The age distribution of the decedent beneficiaries with partial exposure is, 
however, different to that of beneficiaries that had been exposed for the full 24-month 
period preceding their deaths. This may be indicative of anti-selective behaviour, i.e. 
persons only opting for cover once becoming ill and requiring (expensive) care, 
irrespective of their age. This should be interpreted with caution given the low numbers 
of deaths in each age band with partial exposure (around 400 per age band). This may 
simply be due to statistical variation and is merely suggestive of the existence of anti-
selection by new joiners near their end of life.  
Ten per cent of beneficiaries with partial exposure had zero claims whereas only 
one per cent of beneficiaries with full exposure had zero claims. This may be due to 
136 
 
the effect of the waiting periods being enforced on new joiners. Considering the claim 
amounts for the lives with partial exposure, there is no conclusive evidence of any anti-
selection near their end of life. However, this does not mean that no such anti-selection 
exists. The application of the general three-month and twelve-month condition-
specific waiting periods may mask the effect of any anti-selective behaviour that may 
exist, i.e. new joiners may not be submitting claims, knowing that these won’t be paid 
for by the scheme.  
In the last month of life, claims for partially exposed decedent beneficiaries are 
not statistically different to those of the fully exposed beneficiaries (R126 000 vs R130 
000). A possible reason for this may be that by this time most waiting periods may 
have elapsed, or that the scheme may be waiving the waiting periods in cases of 
emergencies at the end of life (ex-gratia payments).  
  
7.4 Ageing populations, lifestyles and chronic non-communicable diseases 
Research has shown that the burden of chronic non-communicable diseases are on the 
rise, but that the risk of becoming chronically ill can be significantly reduced by 
lifestyle and behavioural changes, e.g. increased physical activity, healthy diets, 
mental wellbeing, stopping smoking and responsible alcohol consumption (Habib and 
Saha 2010; World Health Organization 2011). Chronic non-communicable diseases 
significantly impacts medical scheme claim costs over the lifetime of their 
beneficiaries diagnosed with these conditions. This is especially true for the PMB 
chronic disease list (CDL) conditions that require full payment for the diagnosis, 
treatment and ongoing management of the conditions without any limits or co-
payments (Department of Health 1998).  
Given the average age of death of greater than sixty years (and median age at 
death of seventy years), the incidence of chronic conditions is not surprising. Around 
73 per cent of decedent beneficiaries have at least one chronic condition). This is in 
line with findings by Joubert and Bradshaw (2006) on the incidence of chronic 
conditions, and the high proportion of deaths as a result of chronic conditions for lives 
aged sixty years and older in South Africa. Increasing chronic prevalence at older ages 
is well-documented in the literature (Hung, Ross, Boockvar and Siu 2011). A total of 
55 per cent of decedent beneficiaries in the sample experienced multi-morbidity, i.e. 
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having two or more chronic conditions simultaneously. The most prevalent chronic 
conditions were heart conditions (57 per cent of decedent beneficiaries), cancer (24 
per cent of decedent beneficiaries), diabetes (sixteen per cent of decedent 
beneficiaries), chronic respiratory conditions (twelve per cent of decedent 
beneficiaries) and mental health conditions (eight per cent of beneficiaries). 
 When considering beneficiaries with only one chronic condition, it is interesting 
to note the high cancer costs at the various proximities to death relative to the 
benchmark cost (i.e. relative to the cost for those who have no registered/authorised 
chronic conditions) three months or more from their date of death. This may be 
explained by the high cost of cancer treatment and anti-cancer drugs and the relatively 
long period preceding death over which the cancer treatment is given. Similarly for 
those suffering from a chronic renal condition (possibly requiring regular and costly 
dialysis), the average costs are significantly higher than the benchmark at all durations, 
and especially high in the year preceding the year of death. HIV, musculoskeletal and 
‘OTHER’ conditions also have relatively high costs compared to the benchmark cost, 
whereas the remaining groups do not demonstrate quite such a pronounced deviation 
from the benchmark. 
 It is further shown that having more chronic conditions is associated with higher 
claims costs near the end of life at all proximities to death, increasing, on average, with 
each additional chronic condition. When death is imminent, i.e. during the final month, 
the trend is less pronounced than with durations further from death. This is not 
surprising given the knowledge that these beneficiaries are very close to death, i.e. the 
costs in the acute dying phase drown out the effect of multi-morbidity on costs during 
this phase.  
 For decedent beneficiaries with a large number of chronic conditions, the trend 
of higher claim costs is more pronounced when death is further away (twelve to 24 
months) indicating that they had relatively high medical scheme claims costs in the 
year preceding their year of death. This is not surprising given that these beneficiaries 
would have required more frequent care interventions and ongoing management of 
their (multiple) conditions, and may have had more hospitalisations in the year 
preceding their year of death than beneficiaries with fewer or no chronic conditions. 
These beneficiaries are also less likely to have died suddenly given their significant 
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level of interaction with the healthcare system and the (often) progressive nature of 
chronic illnesses. 
 A positive correlation exists between the number of chronic conditions and the 
overall medical scheme claims costs near the end of life as well as with the number of 
hospitalisations and number of days spent in-hospital, respectively. So, in addition to 
having higher costs, on average, this means that beneficiaries with more registered 
chronic conditions also have a relatively higher number of hospitalisations and spend 
relatively more days in-hospital, on average, than those with fewer chronic conditions.  
 A myriad of other factors, e.g. lifestyle factors, accidents, severity of chronic 
condition(s), chronic medication adherence, personal care preferences, etc. influences 
the ultimate medical claims costs and hospitalisations experienced by each individual 
decedent beneficiary. The analyses into the association of chronic conditions with 
overall claims costs considered only the number of chronic conditions and not at the 
relative severity of specific conditions between and within groups of conditions. For 
example, a chronic condition of the eye is expected to result in fewer hospital 
admissions and in lower claims on an ongoing basis to manage than an invasive cancer 
that affects multiple bodily systems and organs, requiring expensive medication, 
ongoing treatment and frequent hospital admissions. Furthermore, the actual effect of 
the chronic condition on the overall claims cost may be further masked by varying 
degrees of severity within chronic disease groupings. As an example consider the 
cancer grouping – within this group there will be ‘stage IV13’ cancers and ‘stage I’ 
cancers. The expectation is that for a ‘stage IV’ cancer, the beneficiary is likely to be 
sicker, require more medication, be hospitalised more frequently and more aggressive 
treatment for the cancer will be administered as opposed to a beneficiary with a ‘stage 
I’ cancer in relatively good health requiring mainly outpatient treatment. The low level 
of correlation between overall claim costs and having an additional chronic condition 
(as observed) may simply be because of the way in which the chronic conditions are 
grouped and their relative severity within these groups.  
                                                          
13 Cancer ‘staging’ is a standard method of categorising cancers by their relative severity and their 
extent and location of spreading throughout the body.  
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However, as shown earlier, there is significant evidence to conclude that having 
one or more chronic conditions results in increased costs and more hospitalisations 
near the end of life. This makes chronicity an important factor associated with medical 
care costs near the end of life.  
 
7.5 Trajectories of dying 
The sample of decedent beneficiaries are sequentially grouped into the main 
trajectories of dying. This analysis yielded the following results: ten per cent of 
decedent beneficiaries are classified as “Sudden deaths”; nineteen per cent as “Cancer” 
deaths; fourteen per cent as “Organ failure” deaths, and 39 per cent of decedent 
beneficiaries are classified as deaths due to “General frailty”. Seventeen per cent of 
decedent beneficiaries could not be grouped into one of the main trajectories of dying, 
and are classified as the “Other” trajectory. The “Cancer” and “Organ failure” 
trajectories are the most costly and warrant further investigation into the effective 
management and treatment of beneficiaries falling into these trajectories. 
As expected, the “Sudden death” trajectory has a very low average cost (R9 000) 
during the last year of life and a very low proportion of deaths occurring in hospital 
(sixteen per cent), as well as a relatively low average age of decedent beneficiaries (49 
years). It also has relatively more male deaths (69 per cent) than the other trajectories 
(around fifty per cent) which may be due to younger males tending to be more risk-
seeking (Stiglets 2001). The “General frailty” and “Other” trajectories have relatively 
more females than average (51 and 49 per cent, respectively, vs 47 per cent). This may 
be due to the higher average age for the “General frailty” trajectory and the higher 
number of females at advanced ages in the sample of decedents, and the inclusion of 
childbirth and pregnancy-related deaths in the “Other” trajectory. The “General 
frailty” trajectory has the highest average age (77 years) since all beneficiaries younger 
than fifty are excluded from this trajectory, and the conditions that make up this 
trajectory are predominantly those that manifest at older ages. The “Organ failure” 
trajectory has a higher than average age (seventy years) which is not unexpected given 
the long-term, progressive nature of “Organ failure”. The relatively high proportion of 
hospital deaths (79 per cent) for this trajectory is also not surprising given the intensive 
hospital treatment required in the event of an organ failure event, e.g. mechanical 
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ventilation, dialysis, resuscitation, intensive care unit stays, etc. (Groeger and Aurora 
2001; Murray et al. 2005). The “Organ failure” trajectory has the highest average costs 
during the last year of life (R529 000), followed by the “Cancer” trajectory 
(R515 000), whereas the “Cancer” trajectory has the highest median claims cost during 
the last year of life (R399 000). This means that there are a larger number of relatively 
high cost beneficiaries in the “Organ failure” group, as compared to the “Cancer” 
group, i.e. removing the outliers, results in the “Cancer” trajectory being the most 
expensive trajectory, on average, during the last year of life. Given the highly uncertain 
nature of the health exacerbations and care requirements for beneficiaries in the 
“Organ failure” trajectory, this result is not surprising. During the last year of life the 
“Other” trajectory has relatively low average claims (R288 000), average age (62 
years) and proportion of deaths in-hospital (57 per cent) as compared to the “Cancer” 
(R515 000, 66 years, 62 per cent), “Organ failure” (R529 000, 70 years, 79 per cent) 
and “General frailty” (R368 000, 77 years, 65 per cent) trajectories.  
 When considering proximities nearer to death (i.e. periods shorter than the last 
twelve months of life), the “Organ failure” trajectory still has the highest average claim 
costs, especially pronounced in the last two weeks of life. This is likely because of the 
intensive interventions used to try reverse episodes of organ failure. This may explain 
the high proportion of hospital deaths observed for beneficiaries in the “Organ failure” 
trajectory. On the other hand, beneficiaries in the “Cancer” trajectory experience a 
relatively low proportion of their overall claims during their last two weeks of life (ten 
per cent), when compared to the “Organ failure” (twenty per cent), “General frailty” 
(21 per cent) and “Other” (21 per cent) trajectories. This may be due to the relatively 
higher use (and lower relative cost) of hospice care near the end of life for beneficiaries 
with terminal cancer and the foregoing of intensive anti-cancer therapies as the end of 
life becomes imminent.   
 
7.6 Decedent beneficiaries with high end-of-life care costs  
The top thirty per cent of claimers are identified in Section 6.6 to be the beneficiaries 
mainly driving the high average claims costs observed near the end of life and their 
profile and experience are analysed separately. These top claimers skew the overall 
claims experience – observed when comparing mean and median claims of the sample 
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of decedent beneficiaries. The high claimers have a significantly higher chronic 
prevalence (91 per cent vs 73 per cent) and a significantly greater proportion of these 
beneficiaries died in-hospital (77 per cent vs sixty per cent) as compared to overall 
sample of decedent beneficiaries. The top claimers spent significantly more time in-
hospital than the overall sample of decedent beneficiaries during their last 24 months 
of life (62 days vs 35 days, on average) and experienced a higher number of 
hospitalisations, on average (six vs four hospitalisations). The overall claims for males 
and females were not significantly different for the top claiming decedent 
beneficiaries. The sex split of the high claimers is 56 per cent male and 44 per cent 
female, having a slightly higher proportion of males than the overall sample of 
decedent beneficiaries (54 per cent). A slight downward trend is observed in average 
claims costs with increasing age at the more advanced ages, but this is not as marked 
as with the overall sample of decedent beneficiaries. 
Comparing the experience of the high claimers (the top thirty per cent of 
claimers) who died in-hospital to those high claimers that died out of hospital, we see 
that costs are, again, consistently higher, on average, for those that died in-hospital, at 
all proximities to death. The difference between overall claims for those dying in- and 
out-of-hospital, respectively, is less pronounced at further durations from death 
(multiple of 1.2 times for in-hospital at 24 months), growing more pronounced as death 
draws nearer (multiple of 5.7 times for in-hospital at two weeks). This may be an 
indication that those who died out-of-hospital (but are still high claimers – top thirty 
per cent) may have foregone further life-sustaining/curative treatments or 
interventions near their end of life following a period or periods of intensive treatment 
before death was imminent or was known to be imminent.  
Around one third of the top thirty per cent of claimers are grouped into each of 
the “Cancer” and “General frailty” trajectories and a further twenty per cent are 
grouped in each of the “Organ failure” and “Other” trajectories. A greater proportion 
of the top claiming decedent beneficiaries belong to the “Cancer” and “Organ failure” 
trajectories as compared with the overall investigation in Sections 6.6 and 6.7, 
considering all decedent beneficiaries with full exposure. This is due to the relatively 
higher treatment cost of cancer and the intensive in-hospital nature of care for the 
various types of organ failure. Together, these two trajectories comprise more than half 
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of the high-cost cases and thus provides the greatest opportunity for interventions 
focused on improving the quality of care provided and reducing any unnecessary 
spending and hospitalisations near the end of life.  
 
7.7 Measuring the quality of care near the end of life 
A number of indicators of the quality of care near the end of life are measured from 
the data. These are: 1) Death in-hospital, 2) Days spent in-hospital, 3) Chemotherapy 
in the last weeks of life, and 4) Hospice utilisation near the end of life. This list is not 
an exhaustive list of quality of care indicators that can be measured. Emergency room 
visits are an important metric for measuring the quality of care a beneficiary receives 
as it indicates how well the beneficiary’s condition is managed outside of a hospital 
setting. Repeat visits may indicate poor quality of care (Pines, Mullins, Cooper, Feng 
et al. 2013). The data, however, does not allow for the accurate identification of 
emergency room visits.  
The results of the analyses show that a significant number of medical scheme 
beneficiaries die in-hospital (sixty per cent overall) and that these beneficiaries spend 
significant amounts of time in-hospital (an average of 35 days during the last 24 
months of life, on average). Trajectories of dying, i.e. “Organ failure” and “General 
frailty” have a significantly higher rate of deaths in-hospital (79 per cent and 65 per 
cent, respectively). Significant time spent in hospital near the end of life may be an 
indicator of poor quality care near the end of life and is also associated with a higher 
probability of eventual death in-hospital (Iezzoni 1997). The top five ‘episodes of care’ 
by days spent in-hospital are, unsurprisingly, those related to critical care for 
mechanically ventilated beneficiaries, pneumonia, septicaemia (likely acquired in-
hospital following surgery), heart failure and shock, and cerebrovascular accidents 
(strokes). Renal failure, respiratory failure and chronic obstructive pulmonary disease 
(COPD) episodes of care follow thereafter. These are complicated conditions, 
requiring intensive care and treatment, and are thus associated with more hospital 
admissions and longer (more costly) hospital stays and are more prone to the 
development of complications.   
Almost a third of decedent beneficiaries diagnosed with cancer had received 
chemotherapy during their last month of life, and almost two-thirds received 
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chemotherapy during their last three months of life. This means that almost one third 
of beneficiaries receiving chemotherapy may be receiving ineffective treatment close 
to their end of life and may be experiencing sub-optimal care during this period. 
Overall, the utilisation of hospice services are very low (less than five per cent 
of decedent beneficiaries) and are predominantly accessed by beneficiaries diagnosed 
with cancer. The use of hospice-related services is associated with improved quality 
of life near the end of life and reduced end-of-life care costs (Wang et al. 2017). The 
improved quality of life is in the form of better symptom and pain management, 
management of psychological distress, care that is better aligned with patient 
preferences, a lower likelihood of dying in hospital and less use of 
intensive/aggressive, yet ineffective interventions near the end of life (Wang et al. 
2017).  
For the low proportion of beneficiaries (less than five per cent overall) that do 
enrol for hospice care, it is concerning that 22 per cent only enrol in the last week of 
life and that 45 per cent only enrol during the last four weeks of life. Thirty per cent 
of these beneficiaries enrol three or more months before death, which may indicate 
good quality care for these beneficiaries. It is encouraging to see a greater uptake for 
those dying in 2017 as compared to those dying in 2016, but a longer time period needs 
to be investigated to establish whether this represents a true trend towards greater 
hospice utilisation (and/or better billing of hospice services to medical schemes). It is 
also important to bear in mind that only hospice services that have been billed to the 
medical scheme are included here. Any out-of-pocket or non-billing of services cannot 
be estimated, and hence the results need to be interpreted with some caution.  
In order to optimise care near the end of life for individual beneficiaries, early 
initiation of palliative care and determining care preferences and goals of care, and 
subsequently refining these as individual circumstances evolve are paramount 
(Dalgaard et al. 2014; Foglia, Lowery, Sharpe, Tompkins et al. 2019). 
 
7.8 Research project limitations 
As noted in Section 5, the data used for purposes of this project are limited to 
retrospective administrative claims data for beneficiaries that have died. Limited 
clinical information are available from these data. Data on claims for survivors with 
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similar clinical profiles are not available for direct comparison, making it impossible 
to gauge the effectiveness of certain care interventions near the end of life. This 
problem is exacerbated by not having any information on beneficiaries’ prognoses 
(prospective information) at that time the specific care interventions are administered. 
 The exact cause of death for individual beneficiaries are not known and are 
inferred from the claims data based on their episodes of care and the accompanying 
ICD-10 coding. This presents the opportunity for the incorrect classification of deaths 
by trajectory of dying. 
 Demand- and supply-side drivers of healthcare costs are considered in this 
research, but it should be noted that the distinction between these are often not clear. 
Demand for healthcare may shape and inform supply and equally, supply can directly 
influence the demand for healthcare, e.g. the behaviour of providers, the effects of 
medical scheme benefit design, etc. It should be borne in mind that where distinction 
is drawn, it remains open to alternative interpretation, given the nuances and intricate 
interwoven nature of the supply and demand for private healthcare in South Africa. 
 The distinction between ‘urban’ and ‘rural’ areas in the analyses is pragmatic 
and it is noted that more robust definitions and methodologies exist for making such a 
distinction between ‘urban’ and ‘rural’, but this is beyond the scope of this research 
project.  
 No research exists in the South African medical schemes environment 
surrounding the care preferences, the intricate interaction between the key stakeholders 
and the eventual decisions of stakeholders regarding medical care at the end of life. 
International research overlaid on the South African medical schemes environment is 
used as a basis for conjecture as to how these might play out in this environment.  
 This research focuses only on South African medical schemes, and the 
experience and characteristics of this sub-population may not be directly relatable to 
the overall South African population and the bigger picture surrounding end-of-life 





This research project considers the various factors that are associated with end-of-life 
care claim costs for South African medical schemes. At the macro-, or structural level, 
it is evident that the fee-for-service reimbursement mechanism, the hospi-centric PMB 
legislation and the resultant medical scheme benefit designs, and the existence of a 3rd 
party payer creates incentives for care and treatment in-hospital and potentially for 
over-servicing beneficiaries. This may partly explain the high proportion of 
beneficiaries observed to die in-hospital. For decedent beneficiaries, hospital-based 
costs account for almost 75 per cent of overall medical scheme claims costs over the 
last 24 months of life, and eighty per cent over the last twelve months of life. At the 
micro-level, individual care and treatment preferences, religious beliefs, cultural 
traditions, expectations of society and those of close relations, the awareness of and 
the costs of alternative care options, etc. influence end-of-life care decision-making 
and directly impacts on whether a beneficiary gets admitted to and is likely to die in-
hospital.  
Illness, disability, frailty, medical care, hospitals, hospices and eventual death 
are anxiety-provoking concepts (Grumann and Spiegel 2003; Lehto and Stein 2009).  
This may result in a general avoidance of these topics, a lack of advance care planning 
and ignorance about what to expect, what care options exist, and what cover is 
available. This ignorance, together with fragmented care delivery and misaligned 
stakeholder incentives, may result in costly, aggressive, sub-optimal care for scheme 
beneficiaries near their end of life (Connors et al. 1995; Emanuel and Ferris 2000). 
None of these macro- or micro-level factors, directly observable or otherwise, 
are independent of each other. The confluence of these factors are complex and multi-
faceted given the dynamic, uncertain and unique end-of-life experience of each 
individual scheme beneficiary. There is no one-size-fits-all solution for deciding on 
the most appropriate care pathway near the end of life, and even for a particular 
beneficiary, the optimal care pathway is likely to change over time. What is optimal 
and appropriate changes depending on beneficiaries’ specific needs, care requirements 
and the complex progression of their illness, or their combination of illnesses. 
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Additionally, the impact of a multitude of external or indirect factors may also 
influence what is deemed optimal or appropriate at a particular point in time. 
The analyses of the demographic characteristics and medical scheme claims data 
for a sample of decedent scheme beneficiaries, show that factors such as age, sex, place 
of residence, number of chronic conditions, hospice use, etc. are associated with claims 
costs near the end of life. Claims during the last four weeks of life for beneficiaries 
that had utilised some hospice care services were nearly half that of beneficiaries who 
had not utilised any hospice services. The number of days spent in-hospital, and dying 
in-hospital show a positive association with the overall claims cost for decedent 
beneficiaries. Beneficiaries that died in-hospital, on average, experienced claims more 
than double that of beneficiaries who died out-of-hospital, all else being equal. This 
may be due to private hospitals being relatively more expensive care settings, but there 
may be a secondary consequence of being in hospital increasing the likelihood of more 
aggressive care interventions at the end of life (i.e. there may be a greater inclination 
towards heroic lifesaving interventions for beneficiaries who are in-hospital).  
Given the high proportion of deaths in-hospital and the number of days spent in-
hospital, the low utilisation of hospice services and the (international) literature 
indicating an overall preference for death either at home or in a hospice environment, 
it would appear that a significant number of medical scheme beneficiaries are likely 
receiving sub-optimal end-of-life care.  
On the cost front, medical schemes are experiencing ageing memberships and 
an observed increase in the incidence and cost of treating and managing chronic non-
communicable diseases with a significant proportion of beneficiaries eventually dying 
because of such chronic conditions. Medical schemes have also been facing cost 
pressures due to new technology, high demand for experimental/new treatments and 
therapies and a year-on-year increase in utilisation of healthcare services by scheme 
beneficiaries. These point to an expectation of further significant cost increases in 
future. 
A key takeaway from this research project is that in order to manage end-of-life 
care costs, and to optimise stakeholder value in end-of-life care, it is required to enable 
beneficiaries to make optimal care decisions, all else being equal. In order to achieve 
this, appropriate care options should be made available through the medical scheme 
147 
 
and beneficiaries should be fully informed about their care options. Beneficiaries 
should have an appreciation for how their illness(es) are likely to progress and how 
their physical condition may deteriorate over time, and focus should be placed on 
continually discussing care goals and preferences with their providers of medical care. 
This implies significant end-of-life care benefit reform within the current legislative 
framework to ensure seamless, cost-effective and appropriate care delivery all along 
each end-of-life pathway.        
The success of such benefit reform is highly dependent on multi-disciplinary 
stakeholder buy-in and cooperation (to ensure seamless delivery), early, effective and 
ongoing communication (to enable optimal decision-making) and innovative managed 
care solutions (to manage risk and to ensure quality outcomes are achieved). Ongoing 
monitoring, feedback and quality measurement together with incentivised alternative 
reimbursement mechanisms are vital to ensuring that the desired optimal outcomes are 
consistently achieved for beneficiaries nearing their end of life. 
This research project has evaluated end-of-life care in the South African medical 
schemes environment and has identified factors associated with the claims costs 
observed for beneficiaries near their end of life. The research aimed to illustrate the 
complexities surrounding communication, decision-making and care delivery near the 
end of life and the factors that contribute to this uncertainty. It also considered the 
profile and claims cost of medical scheme beneficiaries near their end of life to gain 
an understanding of the factors influencing the care costs near the end of life for these 
beneficiaries. Significant areas for further research, beyond the scope of this project, 
are also identified in performing this research. These are summarised below.  
 
Opportunities for further research     
Further research is required on how to elicit care goals and preferences and to facilitate 
death in the beneficiaries’ preferred setting of care, bearing in mind the scheme benefit 
design, the beneficiaries’ personal circumstances (e.g. their functional status, their 
home and family environment, their care needs, etc.) and the financial implications to 
both the schemes and their beneficiaries. This research is needed in the South African 
context in order to be relevant. This may assist in preventing unnecessary 
hospitalisations, shortening length of stay and facilitating the transfer of the 
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beneficiary to the appropriate or optimal care setting(s) near their end of life. Research 
is also required to determine the extent to which a stigma towards death exists within 
the medical scheme membership base and how the stigma affects advanced care 
discussions and planning for care near the end of life. An understanding of these 
preferences and an appreciation for the discomfort caused by confronting the idea of 
mortality can highlight the best strategies to educate scheme beneficiaries and 
healthcare providers about important care considerations near the end of life. Such an 
understanding will assist in optimising decision-making by both the beneficiaries and 
the providers in the face of serious illness. Further research into the design and delivery 
of appropriate palliative care benefits are required to ensure that beneficiaries have 
access to and are aware of such care to facilitate the early integration of palliative care 
with curative care and ensuring a smooth transition to more palliative-orientated care 
as the end of life draws near.  
Longitudinal studies on the claims experience of beneficiaries living with 
chronic non-communicable diseases will highlight the impact on claims of these 
conditions over time as opposed to only the association of these conditions with claims 
cost near the end of life. Specific attention needs to be given to the most prevalent and 
the most costly chronic conditions. Studies of this nature will also be useful in 
understanding the relative costs of different conditions and the impact of multi-
morbidity on overall costs, both at the end of life as well as over longer periods of 
time. Additional research is required to determine the impact on medical scheme claim 
costs near the end of life for the most prevalent and most severe chronic conditions, 
e.g. heart disease, cancer, chronic endocrine disorders (e.g. diabetes) and chronic 
respiratory diseases. Further research is also required to develop more effective 
strategies to lower the incidence and prevalence of chronic, non-communicable 
diseases in medical schemes’ risk pools. This is particularly true for preventable, 
lifestyle-related chronic conditions.  
More in-depth analyses of the various trajectories of dying, adapted to the South 
African medical schemes environment (as opposed to the Medicare environment 
which predominantly covers lives older than 65 years and based on an entirely 
different set of insurance and benefit rules) with a more robust identification and 
attribution of cause of death are required. These studies may prove useful in 
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determining which care pathways are optimal for beneficiaries given their trajectory 
of dying. The type and timing of optimal care interventions may well differ between 
the various trajectories of dying. Significant research and development of guidelines 
and care interventions have been undertaken for the “Cancer” trajectory, globally (as 
well as in South Africa), but not for the other trajectories of dying where beneficiaries 
may also have significant unmet palliative and other care needs near the end of life. 
There is significant scope for further research in this area.  
 Research in South Africa around the drivers of the sustained utilisation and cost 
increases are sparse – especially at the end of life. This project aimed to untangle 
components of the complex private healthcare funding system in South Africa to 
identify both demand-side and supply-side cost drivers with a focus on the cost drivers 
that are observable from historic claims data. Some supply-side drivers, e.g. supplier-
induced demand, structural and system inefficiencies, e.g. 3rd-party payer dynamics, 
fee-for-service reimbursement arrangements, full payment for PMB’s, etc. were 
considered on a theoretical basis. The interaction between these factors and the various 
stakeholders were also considered on a theoretical basis. Further research is required 
to quantify the impact of and to measure the multi-dimensional link between the supply 
and demand for healthcare and between the factors identified in this research, and their 
effect on medical scheme claims cost and the increases in these costs over time. A 
strong evidence base is required to enact policy and regulatory change towards a more 
efficient, more sustainable private healthcare funding system in South Africa.   
 Community- or home-based care and the development of such care initiatives in 
communities (both urban and rural) have shown to improve end-of-life care outcomes 
for patients and their families and to build social capital (Horsfall, Noonan and 
Leonard 2012). The existence of such informal community-based care and the social 
structures through which such care are delivered in South Africa needs further 
research. There is some evidence from the data that the care received by beneficiaries 
in ‘rural’ areas and smaller towns are different to the care received by those in more 
urbanised areas – evidenced by significantly different medical scheme claims cost near 
the end of life between these areas. It may be that the lack of specialist care and limited 
quaternary care in more rural areas have necessitated the development of more 
informal care networks and alternative care pathways for the dying. The composition 
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of these community- or home-based care networks (where they exist), their efficacy in 
delivering end-of-life care and the quality of care provided needs further investigation. 
 Hospice service utilisation near the end of life is associated with better quality 
care and lower costs of care. More research is required on the hospice utilisation 
patterns of medical scheme beneficiaries and the billing practices of hospices to get an 
accurate picture of the use of hospice care by medical scheme beneficiaries and the 
impact thereof on medical scheme claim costs near the end of life. Where a trade-off 
between hospice and hospital care exist, further research is required to identify the 
factors that impact on decision-making surrounding this trade-off and to understand 
which beneficiaries opt for hospice care and why. This may assist with facilitating a 
transition from hospital- to hospice- or home-based care for a greater proportion of 
beneficiaries, potentially more in line with their care preferences and resulting in an 
improved quality of life and of care, and a reduction in end-of-life care costs for a 
greater number of medical scheme beneficiaries.        
Brief consideration is also given to the importance of measuring (and rewarding) 
quality care to optimise care outcomes. Evidence of poor quality care near the end of 
life are investigated by considering a number of measurable quality indicators that can 
be gleaned from the claims data. Further research is required to identify more 
indicators and to develop fair, objective measures of quality end-of-life care that are 
applicable to the South African medical scheme environment. The measures developed 
should be simple, pragmatic and used consistently across providers, settings and levels 
of care, as is appropriate. They should encourage both the providers and the 
beneficiaries to engage in an iterative approach of analysing and eliciting goals of care, 
treatment preferences, care settings of choice, etc. The quality measures should not be 
static and should be linked to appropriate provider incentives to help achieve optimised 
care outcomes for beneficiaries near their end of life.  
The retrospective analysis of indicators (both of good and poor quality end-of-
life care) can be used in engagement with providers to highlight gaps and areas for 
improvement in the delivery of end-of-life care. It is important to note that there is no 
one-size-fits-all approach to measuring the quality of care near the end of life, and 
different illness trajectories or stages within trajectories will call for different modes 
of care and hence different metrics for measuring the quality of care and the care 
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outcomes. These need to be developed, tested and refined over time to ensure optimal 
outcomes given differing stakeholder needs and preferences and constrained financial-
, human- and infrastructural resources for healthcare.  
Looking ahead, the role of medical schemes (and the private healthcare sector as 
a whole) is unclear in South Africa. The country is moving towards universal 
healthcare coverage for its population, and there are currently significant debate, 
policy reform and development around introducing the National Health Insurance 
(NHI) framework in South Africa. Questions still exist as to what exactly the NHI will 
cover, how it will be implemented and governed, and whether it will be successful in 
achieving the aims of universal health coverage in South Africa (Passchier 2017). 
Valuable lessons can be learnt from the experience of South Africa’s private healthcare 
sector, i.e. medical schemes, in the design and delivery of the optimal benefits, 
including end-of-life care benefits. As more clarity around NHI unfolds, research into 
delivering high quality, cost-effective end-of-life care at the population level will be 
required. The characteristics of the overall population is different to the profile of the 
lives that currently have medical scheme cover and the factors affecting their medical 
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Appendix 1 
This appendix sets out an extract of the episode of care/ICD-10 code mappings to allocating the sample of decedent beneficiaries to the various 
trajectories of dying. The most costly episode of care/ICD-10 combination per beneficiary over their last twelve months of life is assumed to be 
the primary diagnosis or condition driving their particular trajectory of dying. The allocation is performed sequentially to allocate each beneficiary 
to one trajectory only. The “Other” trajectory contains all lives that could not be sensibly grouped in one of the four main trajectories of dying. 
These included beneficiaries for whom no episode of care/ICD-10 codes were assigned, pregnancy-related deaths, trauma-related deaths, episode 
of care/ICD-10 combinations unlikely to have resulted in death, and those younger than fifty who are thus unlikely to be frail, in general.   
Table A1 – Mapping to trajectories of dying 
Trajectory Rand limit (12m) Age range ‘Episode of care’ code ICD-10 code 
Sudden death < R24 000 < 80 All All 
Cancer  >=R24 000  Any TUM510 - Malignant neoplasm of 
hepatobiliary tract C240 - Malignant neoplasm| extrahepatic bile duct 
Cancer  >=R24 000  Any TUM200 - Malignant neoplasm of breast C509 - Malignant neoplasm| breast| unspecified 
Cancer  >=R24 000  Any TUM470 - Malignant neoplasm of 
gastrointestinal system C169 - Malignant neoplasm| stomach| unspecified 
Cancer  >=R24 000  Any TUM280 - Malignant neoplasm of male 
reproductive system C61 - Malignant neoplasm of prostate 
Cancer  >=R24 000  Any 
TUM020 - Non-Hodgkin's lymphoma 
C839 - Non-follicular (diffuse) lymphoma| 
unspecified 
Cancer >=R24 000  Any … … 
Organ failure >=R24 000  Any CAR120 - Congestive cardiac failure I500 - Congestive heart failure 
Organ failure >=R24 000  Any 
RES170 - Respiratory failure 




Organ failure >=R24 000  Any NEP040 - Chronic renal failure N189 - Chronic kidney disease| unspecified 
Organ failure >=R24 000  Any HEP080 - Liver failure K729 - Hepatic failure| unspecified 
Organ failure >=R24 000  Any … … 
General frailty >=R24 000  >= 50  CAR060 - Ischaemic heart disease I259 - Chronic ischaemic heart disease| unspecified 
General frailty >=R24 000  >= 50  
NEU010 - Ischaemic stroke 
I64 - Stroke| not specified as haemorrhage or 
infarction 
General frailty >=R24 000  >= 50  RES280 - Pneumonia J180 - Bronchopneumonia| unspecified 
General frailty >=R24 000  >= 50  NEU150 - Alzheimer's disease G309 - Alzheimers disease| unspecified 
General frailty >=R24 000  >= 50  … … 
Other >=R24 000  Any NULL NULL 
Other >=R24 000  Any TRA120 - Burn of Non-specific region T312 - Burns involving 20-29% of body surface 
Other >=R24 000  Any EAR110 - Sinusitis J340 - Abscess| furuncle and carbuncle of nose 
Other >=R24 000  Any OBS010 - Post-partum complication O721 - Other immediate postpartum haemorrhage 
Other >=R24 000  Any … … 
 
The classification is done pragmatically where it unclear to exactly which trajectory a particular episode of care/ICD-10 combination belongs. A 
more robust classification of the multitude of episode of care/ICD-10 combinations, with expert clinical input may result in more credible results 
from analysing the main trajectories of dying. However, from this high-level analysis, it is clear that treatment and cost patterns do vary considerably 
by trajectory of dying. 
